Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
02/2010 | Recent  |  14:  | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions February patent applications/inventions, industry category 02/10

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
02/25/2010 > patent applications in patent subcategories. patent applications/inventions, industry category

20100048452 - Injectable sustained-release formulation of active principles, and process for the preparation thereof: Composition for the implementation of a therapeutic method for the human or animal body, comprising a fatty phase (O) and an aqueous phase (W), in the form of an 5 emulsion of the water-in-oil (W/O) type, in which said aqueous phase (W) comprises at least one hydrosoluble active ingredient, characterized... Agent: Air Liquide Intellectual Property

20100048451 - Novel spill-resistant formulations comprising hydrocolloidal polymers: The invention relates to novel spill resistant formulations comprising two or more hydrocolloidal polymers and an effective amount of a pharmaceutically active agent. The formulations have a viscometric yield value of a semi-solid, and a pH and spill-resistant consistency allowing for easier preparation and use of the pharmaceutical composition.... Agent: Taro Pharmaceuticals U.s.a., Inc. C/o Venable LLP

20100048450 - Sumoylation control agent and uses thereof: The present invention relates to novel agents that are useful for controlling sumoylation. In particular, the present invention relates to a sumoylation control agent comprising: (i) a pharmaceutically-effective amount of a HLS-5 polypeptide, isoform thereof, functional fragment thereof, or pharmaceutical composition thereof; or (ii) a compound or composition capable of... Agent: K&l Gates LLP

20100048453 - Oxazole and thiazole ppar modulator: The invention provides compounds (I) pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families, particularly the activity of PPARδ.... Agent: Genomics Institute Of The Novartis Research Foundation

20100048454 - Antidiabetic oral insulin-biguanide combination: Pharmaceutical dosage forms, comprising insulin, a delivery agent that facilitates insulin transport in a therapeutically effective amount to the bloodstream and a biguanide, such as metformin, are disclosed for oral administration to a patient for the treatment of diabetes. Also disclosed are methods for achieving improved glucose tolerance and glycemic... Agent: Pearl Cohen Zedek Latzer, LLP

20100048455 - Formulations for therapeutic administration of thyroid stimulating hormone (tsh): This disclosure generally relates to novel formulations containing the active ingredient thyroid stimulating hormone (TSH) having modified pharmacokinetic profiles as compared to prior art formulations.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100048456 - Glycopegylation methods and proteins/peptides produced by the methods: The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.... Agent: Morgan, Lewis & Bockius LLP (sf)

20100048457 - Glycoprotein for treating chronic obstructive pulmonary diseases: Provided is a glycoprotein product extracted from limax, wherein the preparation method of the glycoprotein product comprises the following steps: adding ethanol to the dry limax powders and removing the supernatant, extracting the resulting residue with water and then adding ethanol to the water extract for precipitating. The obtained glycoprotein... Agent: Dr. Mark M. Friedman C/o Bill Polkinghorn - Discovery Dispatch

20100048458 - Tribonectins: The invention features a tribonectin and a method of tribosupplementation carried out by administering tribonectins directly to an injured or arthritic joint.... Agent: Clark & Elbing LLP

20100048459 - Lantibiotic biosynthetic gene clusters from a. garbadinensis and a. liguriae: This invention relates to characterisation of the biosynthetic gene cluster for the lantibiotic actagardine, identification of a novel variant of actagardine and its biosynthetic cluster, and methods of production and use of actagardine, a novel actagardine variant, herein referred to as actagardine B, and variants of both of these produced... Agent: Morgan Lewis & Bockius LLP

20100048461 - Methods of use of trk receptor modulators: The present invention relates to methods of treating or preventing retinal ganglion cell (RGC) death and/or glaucoma using modulators of neurotrophic receptors that comprise β-turn peptidomimetic cyclic compounds or derivatives thereof. The neurotrophic receptor modulators can be used alone, in combination and/or in conjunction with one or more other compounds,... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100048460 - Selective vpac2 receptor peptide agonists: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.... Agent: Eli Lilly & Company

20100048462 - Truncated pth peptides with a cyclic conformation: The present invention provides PTH peptides which are cyclised substitution analogues of the truncated PTH fragment PTH (1-17) and which preferably retain the desired or similar biological activity of human PTH (1-34).... Agent: Clark & Elbing LLP

20100048463 - Template-fixed peptidomimetics: The template-fixed B-hairpin peptidomimetics Cyclo(-Tyr-His-X-Cys-Ser-Ala-DPro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-DPro-Pro), disulfide bond between Cys4 and Gys11, and pharmaceutically acceptable salts thereof, with X being Ala or Tyr, have CXCR4 antagonizing properties and can be used for preventing HIV infections in healthy individuals or for slowing and halting viral progression in infected patients; or where Cancer... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100048479 - Adrenal grk2 activity as a therapeutic target for heart failure: The present invention relates to compositions and methods for the treatment of failing hearts. More specifically, the present invention provides for the inhibition of G-protein coupled receptor kinase 2 activity in the adrenal gland, which, for example, decreases catecholamine secretion and the sympathetic burden of the failing heart, thereby improving... Agent: David S. Resnick

20100048472 - Albumin fusion proteins: The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100048471 - Angiogenesis inhibitor comprising meteorin as an active ingredient: The present invention relates to an angiogenesis inhibitor comprising meteorin as an active ingredient that is highly expressed in astrocytes of the brain and retina in the late embryonic stage and after the birth of a mouse. It is in particular highly detected in astrocyte endfeet surrounding blood vessels and... Agent: Greenlee Winner And Sullivan P C

20100048469 - Antimicrobial peptides: There is provided at least one isolated antimicrobial peptide, wherein the peptide is a linear analog of hBD3 or a fragment thereof. In particular, there is provided a linear analog of hBD3 wherein the peptide has a reduced cytotoxicity to at least one cell compared to the wild type hBD3.... Agent: Heslin Rothenberg Farley & Mesiti PC

20100048464 - Bioactive peptides identified in enzymatic hydrolyzates of milk caseins and method of obtaining same: The invention relates to the production of bioactive products that are derived from milk proteins for the production of bioactive milk products derived from milk proteins, particularly caseins. The 16 inventive peptides can be obtained chemically, biotechnologically or by means of enzymatic treatment from proteins containing same and give rise... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100048482 - Compositions and methods for modulating epsilon protein kinase c-mediated cytoprotection: Compositions and methods for reducing ischemic cell damage and treating mitochondrial disorders using therapeutic agents derived from the V2 domain of epsilon protein kinase C (PKC) are described.... Agent: King & Spalding LLP

20100048466 - Compositions, reagents and kits for and methods of diagnosing, monitoring and treating hormonal imbalance: The present invention concerns ten novel variants of alternative splicing of the hormonal imbalance related genes.... Agent: Potter Anderson & Corroon LLP Attn: Janet E. Reed, Ph.d.

20100048481 - Controlled release composition: e

20100048467 - Cystine-knot fold cytokine: This invention relates to a novel protein (INSP002), herein identified as a secreted protein that is a member of the Dan family of the cystine-knot fold cytokine superfamily and to the use of this protein and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100048478 - Fn14/trail fusion proteins: Fusion proteins which act on the TWEAK and TRAIL signaling axes are provided. The proteins are useful in the treatment or amelioration of autoimmune diseases, particularly multiple sclerosis, as well as other diseases such as alloimmune diseases and cancer.... Agent: Meyer Unkovic & Scott LLP

20100048468 - Glp-1 compounds: GLP-1 compounds comprising GLP-1 analogs and methods of using the GLP-1 compounds for treating metabolic disorders, enhancing insulin expression, and promoting insulin secretion in a patient are provided.... Agent: Amgen Inc. Law Department

20100048470 - Immunotoxins for the treatment of diseases related to cmv infection: The present invention relates to the field of cytomegalovirus (CMV) infection. In particular the present invention relates to highly specific immunotoxins useful in treating diseases related to CMV infection. CMV encodes chemokine receptors that undergo constitutive internalization. Thus CMV infected cells can be targeted specifically with immunotoxins with high affinity... Agent: Dann, Dorfman, Herrell & Skillman

20100048477 - Method for prevention of platelet aggregation employing an rgd-enriched gelatine-like proteins: The invention concerns a cell support comprising an RGD-enriched gelatine that has a more even distribution of RGD sequences than occurring in a natural gelatine and with a minimum level of RGD sequences. More precise the percentage of RGD sequences related to the total number of amino acids is at... Agent: Ip Patent Docketing K&l Gates LLP

20100048475 - Method of treating dyspnea associated with acute heart failure: The disclosure pertains to methods of reducing decompensation through acute intervention including in subjects afflicted with acute decompensated heart failure. Particularly, the disclosure provides methods for treating acute cardiac decompensation by administering a pharmaceutically effective amount of relaxin.... Agent: Morrison & Foerster LLP

20100048474 - Method of treating or preventing tissue deterioration, injury or damage due to periodontal disease or disease of oral mucosa, and/or downregulating nf-kappabeta or supressing nf-kappabeta-mediated actions: A method of treatment for treating, at least partly preventing, inhibiting or reducing tissue deterioration, injury or damage due to a periodontal disease or disease of oral mucosa, or for restoring tissue adversely affected by the disease, in a subject, and/or for downregulating NF-kappaB or suppressing NF-kappaB mediated action in... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100048484 - Methods for treating diabetic wounds: The present invention relates to a method of treating chronic wounds using calreticulin. In particular, the invention relates to the treatment of chronic diabetic wounds using topical application of calreticulin to a patient in need of such treatment.... Agent: Darby & Darby P.C.

20100048473 - Modified protein polymers: In an embodiment, a number of synthetic protein triblock copolymers are provided comprising first and second end hydrophobic blocks separated by a central hydrophilic block. In particular, the synthetic proteins are elastin-mimetic proteins having improved mechanical characteristics and related methods of making the proteins with the capability of providing precise... Agent: Greenlee Winner And Sullivan P C

20100048476 - Novel use of bacteriocin derived from enterococcus faecalis sl-5: The present invention relates to novel use of bacteriocin derived from Enterococcus faecalis SL-5. More particularly, the present invention relates to a composition for preventing and treating acne comprising a polypeptide of SEQ ID NO: 1 or SEQ ID NO: 2, which is a bacteriocin derived from Enterococcus faecalis SL-5.... Agent: Lucas & Mercanti, LLP

20100048465 - Peptide mimics of melanocyte stimulating hormone: Provided are peptides having melanocyte stimulating hormone activity. Also provided are vectors encoding these peptides and transgenic cells comprising the above vectors. Additionally, methods of reducing or preventing release of an inflammatory cytokine from mammalian cells are provided, as are methods for treating a mammal suffering from, or at risk... Agent: Amster, Rothstein & Ebenstein LLP

20100048483 - Polymeric benzyl carbonate-derivatives: The present invention relates to polymeric derivatives, which can be conjugated to an amino-containing drug to improve its in vivo properties. The polymeric derivative can subsequently be released to yield the drug in its native form. Methods of preparing and using these polymeric derivatives and drug conjugates are described.... Agent: Marshall, Gerstein & Borun (baxter)

20100048480 - Production of anti-microbial peptides: The present application provides methods of producing antimicrobial peptides (AMPs) in a cell, for example by expression a fusion protein that includes small ubiquitin related modifier (SUMO) and an AMP in the cell. Also provided are nucleic acid and protein sequences of SUMO-AMP fusion proteins, and kits that include such... Agent: Klarquist Sparkman, LLP

20100048485 - Substrates of n-end rule ubiquitylation and methods for measuring the ubiquitylation of these substrate: The present invention relates to methods, compositions, compounds and kits for detecting, measuring and modulating protein ubiquitylation via the N-end rule pathway and for identifying novel substrates, enzymes and modulators of N-end rule ubiquitylation. The present invention also relates to specific substrates of N-end rule ubiquitylation as well as activated... Agent: Nixon & Vanderhye, PC

20100048486 - Use of soluble fgl2 as an immunosuppressant: Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of a soluble fgl2 protein or a nucleic acid encoding a soluble fgl2 protein. The methods are useful in preventing graft rejection, autoimmune disease, and allergies.... Agent: Bereskin And Parr LLP/s.e.n.c.r.l., S.r.l.

20100048488 - Immunomodulatory peptides: The invention relates to peptides which, in some embodiments, bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used in some embodiments, for example, in treating autoimmune diseases and inflammatory... Agent: Biogen Idec / Finnegan Henderson, LLP

20100048487 - Novel cell penetrating peptide: According to the present invention, it is possible to provide a novel cell penetrating peptide that transports proteins into cells and/or into nuclei at higher frequency than conventional cell penetrating peptides, and a pharmaceutical containing the peptide.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100048489 - Stable solid formulation of a gc-c receptor agonist polypeptide suitable for oral administration: Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”) or a pharmaceutically... Agent: Honigman Miller Schwartz & Cohn LLP

20100048490 - Binding ligand linked drug delivery conjugates of tubulysins: Described herein are compounds, pharmaceutical compositions and methods for treating pathogenic cell populations. The compounds described herein include conjugates of tubulysins and vitamin receptor binding ligands. The conjugates also include a releasable bivalent linker.... Agent: Barnes & Thornburg LLP

20100048491 - Drugs, foods or drinks with the use of algae-derived physiologically active substances: foods, drinks, cosmetics, etc. containing as the active ingredient at least one member selected from the group consisting of the above-mentioned compound, its aldehyde, its hydrate and 2-O-methylated derivatives thereof and soluble sugar compounds containing the above compound. This compound also shows, for example, an apoptosis-inducing activity, a carcinostatic activity... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100048492 - Composition for the prevention and/or treatment of diseases associated with tnf and/or il-12 overexpression: or one of its pharmaceutically acceptable salts in which R1, R2 and R3 are independently a hydrogen or an R7—CO— group where R7 is an alkyl, alkene or alkyne group, linear, branched or cyclic, comprising 2 to 24 carbon atoms; R4 is a hydrogen atom or a mannosyl group substituted... Agent: Harness, Dickey & Pierce, P.L.C

20100048493 - Method of administering oral flora-improving agent, antibacterial agent and growth promoter: It is intended to provide an oral flora-improving agent capable of forming a favorable flora in the oral cavity and a food or a drink for improving the oral flora. An oral flora-improving agent containing as an active ingredient a ganglioside and a food, a drink, or a feed for... Agent: Young & Thompson

20100048496 - Core 2 glcnac-t inhibitors:

20100048495 - Core 2 glcnac-t inhibitors iii:

20100048494 - Natural products from vinca: New and useful compounds C. roseus cultured hairy roots are provided, by Isolating flavone glycosides together with a pharmaceutically acceptable carrier This is accomplished by immersing powdered the hairy roots in methanol to produce an extract, concentrating the extract, resuspending the extract in water, extracting the compound with organic solvent,... Agent: Baker & Mckenzie LLP

20100048497 - Insecticidal active ingredient combinations (formononetins + insecticides): The present invention relates to novel active compound combinations consisting, firstly, of formononetin and, secondly, of known insecticidally active compounds, which active compound combinations are highly suitable for controlling unwanted animal pests, such as insects or acarids, or nematodes.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100048498 - Stable non-dihydrate azithromycin oral suspensions: e

20100048499 - Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane: The present invention relates to methods and kits for the treatment of breast cancer based on hormone receptor status of progesterone receptor and estrogen receptor comprising the administration of a taxane alone, in combination with at least one other and other therapeutic agents, as well as other treatment modalities useful... Agent: Morrison & Foerster LLP

20100048672 - Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications: The invention relates to compositions of transfection comprising an oligonucleotide and an amphiphilic cationic molecule of formula (I) wherein, —X is N—R1, S or O, R1 being a C1-C4 alkyl radical or an hydroxylated C3-C6 alkyl radical, R2 and R3, identical or different, represent H or a C1-C4 alkyl radical,... Agent: Nixon & Vanderhye, PC

20100048671 - Inhibition of the 44 kilodalton isoform of pim-1 kinase restores apoptosis induced by chemotherapeutic drugs in cancer cells: The present invention relates to a newly discovered 44 kD isoform of Pim-1 kinase made in human cells, and to the gene and messenger RNA for the 44 kilodalton isoform. The invention further describes methods and compounds for treating, especially prostate and hematopoietic cancer, by inhibiting expression of the 44... Agent: Ditthavong Mori & Steiner, P.C.

20100048675 - Mirna triplex formations for the downregulation of viral replication: As discovered herein, using miRNAs having high homology with both HIV-1 and a co-infecting virus such as HHV-6, HHV-7, or GVB-C, one can inhibit viral replication, more particularly HIV-1 replication using such mutually homologous miRNAs that give rise to the creation of stable triplex formations effective in the downregulation and/or... Agent: Mcnair Law Firm, P.A.

20100048676 - Non-androgen dependent roles for androgen receptor in liver cancer: Disclosed are compositions and methods for modulating AR activity, such as non-androgen dependent AR activity. Also disclosed are compositions and methods for diagnosing beast cancer and for inhibiting liver cancer growth. In addition, disclosed are methods for identifying molecules that inhibit AR in non-androgen dependent ways.... Agent: Patent Correspondence Arnall Golden Gregory LLP

20100048673 - Oligonucleotides affecting expression of phosphodiesterases: The invention relates to therapeutic antisense oligonucleotides directed against genes encoding phosphodiesterases (PDE) and the use of these antisense oligonucleotides in combination. These antisense oligonucleotides may be used as analytical tools and/or as therapeutic agents in the treatment of disease associated with reduced cellular cAMP in a patient, such as... Agent: Pepper Hamilton LLP

20100048677 - Regulation of integrin surface expression: Disclosed are methods and compositions for preventing and treating conditions associated with platelet aggregation, comprising administering a therapeutically effective amount of a composition that modifies the interaction of DNAJC10 with αIIbβ3 in a megakaryocyte, thereby altering the expression of αIIbβ3 on the surface of the megakaryocyte.... Agent: K&l Gates LLP

20100048674 - Role of mirna in t cell leukemia: The ability of miR-181a to support active signaling between Notch and pre-TCR pathways by coordinately dampening negative regulators of these pathways allows the use of miR-181a as a therapeutic target for T-ALL.... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20100048670 - Stable and long-lasting sirna expression vectors and the applications thereof: The invention relates to a siRNA expression vector that can inhibit or eliminate the expression of a target gene in a mammalian cell, said vector comprising: a bacterial cassette containing a bacterial origin of replication and a bacterial selection marker M1; a eucaryotic cell selection cassette comprising a marker M2... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100048680 - Alpha-1-antitrypsin variants and uses thereof: The subject invention is directed to novel polynucleotides and polypeptides comprising SEQ ID NOs: 1 and 2. Also provided arc fragments these polypeptides. The polynucleotides and polypeptides disclosed herein have been isolated from the liver cells (hepatocytes) of end stage liver failure patients and appear to be associated with a... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100048682 - Inhibiting dna polymerase beta to enhance efficacy of anticancer agents: The invention provides anticancer methods. In one embodiment, the inventive method involves the co-administration to cancerous cells of (a) a chemotherapeutic agent, radiation, or a combination of a chemotherapeutic agent and radiation and (b) an inhibitor of DNA polymerase beta. In another embodiment, the invention provides anticancer methods involving the... Agent: Klarquist Sparkman, LLP

20100048681 - Microrna-based methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia (aml): The present invention provides novel methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia (AML). The invention also provides methods of identifying anti-AML agents.... Agent: Macmillan Sobanski & Todd, LLC

20100048683 - Modified vaccinia virus ankara for the vaccination of neonates: The invention relates inter alia to a method for inducing a long-term protection in an animal against foreign antigens and tumor antigens comprising the step of administering to the animal at least one factor selected from type I interferons and Flt-3, and to a method for inducing a long-term increase... Agent: Law Office Of Salvatore Arrigo

20100048678 - Nucleic acids and polypeptides that are useful in controlling neuronal regeneration: The present invention relates to methods for promoting regeneration response of peripheral and central nervous systems in mammals in need of such biological effects. The methods comprise altering the activity or steady state level of specific polypeptides that control regeneration of injured or degenerated neuronal cells. Preferably the activity or... Agent: Morgan Lewis & Bockius LLP

20100048679 - Polynucleotide therapy: This invention provides methods of treating an autoimmune disease in a subject associated with one or more self-protein(s), polypeptide(s), or peptide(s) present in the subject non-physiologically comprising administering to the subject: a self-vector comprising an immunosuppressive vector backbone and a polynucleotide encoding the self-protein(s), polypeptide(s) or peptide(s) associated with the... Agent: Townsend And Townsend And Crew, LLP

20100048500 - Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections: i

20100048502 - Bhq-caged nucleotide probes photolysable by two-photon excitation: The disclosure encompasses caged compounds such as caged nucleoside phosphoesters (caged nucleotides). In an embodiment, the caged nucleotides include compounds corresponding to those described by formula (I) that may be activated by two-photon excitation, and methods of synthesis of such compounds. 8-Bromo-7-hydroxyquinoline-caged ATP was synthesized and examined for its photochemistry... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20100048501 - Phosphorylated a2a receptor agonists: A phosphorylated A2A receptor agonist providing agonist properties on the A2A receptor after dephosphorylation the phosphorylated A2A receptor agonist comprises a ribosyl moiety and a purine moiety and being phosphorylated at the 5′-position of the ribose moiety except adenosine monophosphate (AMP), adenosine diphosphate (ADP) or adenosine triphosphate (ATP), a medicament... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100048503 - Composition for treatment of pancreatic cancer: Disclosed are a pharmaceutical composition having excellent antitumor activity, and a method for treating a cancer. Specifically, excellent antitumor activity is achieved when 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or an analogous compound thereof, a pharmacologically acceptable salt thereof or a solvate thereof is used in combination with gemcitabine or erlotinib, a pharmacologically acceptable salt... Agent: Darby & Darby P.C.

20100048504 - Crystalline and amorphous forms of beta-l-deoxythymidine: Physical forms of beta-L-2′-deoxythymidine are disclosed that can be characterized by physical appearance, purity levels, Infra-Red and Raman spectroscopy, X-ray powder diffraction patterns, thermal properties, and methods of manufacture. These forms of beta-L-2′-deoxythymidine can be used in the manufacture of other forms of beta-L-2′-deoxythymidine, or in pharmaceutical compositions. Particularly preferred... Agent: Dilworth & Barrese, LLP

20100048506 - Composition for treating arthritic disorder: The present invention provides compositions and methods for treating a joint disease containing as an active ingredient thereof a monovalent metal salt of alginic acid for which the endotoxin level thereof has been lowered to an extent that does not substantially induce inflammation or fever. As a result, it is... Agent: Foley And Lardner LLP Suite 500

20100048505 - Composition having effect of treating, preventing, or improving diabetes or diabetic complication and drink comprising the same: A safe, economical, and convenient food drink having the effect of treating, preventing, or improving diabetes or diabetic complications without involving significantly changed dietary life habits is provided. A food or drink is provided for treating, preventing, or improving diabetes or diabetic complications, comprising oligosaccharides at a concentration of 0.15... Agent: Fitch Even Tabin & Flannery

20100048507 - Food/beverage and pharmaceutical composition for oral administration for improvement in acidic urine each comprising fucoidan as active ingredient: The present invention provides a food/drink or pharmaceutical composition for oral administration for improving an acidic urine, comprising fucoidan or a fucoidan-containing material as an active ingredient, characterized in that a urinal pH is persistently increased; use of fucoidan or a fucoidan-containing material for production of the food/drink or the... Agent: Bacon & Thomas, PLLC

20100048508 - Mixture and method for reducing cholesterol using hydrophobic microparticles: The present invention relates to mixtures including hydrophobic microparticles comprising a positively charged polymer (e.g. a polysaccharide such as chitosan) chemically bound to an anionic or non-ionic surfactant such as lecithin. The mixtures are useful for reducing cholesterol of an animal, for example a bird such as a chicken or... Agent: Dr. Mark M. Friedman C/o Bill Polkinghorn - Discovery Dispatch

20100048509 - Pharmaceutical composition comprising perindopril: The present invention provides a stable pharmaceutical composition comprising an inclusion complex of perindopril, a microcrystalline cellulose having a low moisture content and/or a silicified microcrystalline cellulose having a low moisture content, and optionally other pharmaceutically acceptable excipients.... Agent: Arent Fox LLP

20100048510 - Dissolution of amyloid fibrils by flavonoids and other compounds: Methods for disrupting amyloid fibrils in a subject, comprising combining an effective amount of a β-2 microglobulin fibril disrupting compound with a medium associated with the subject, are disclosed. The invention also relates to combining the β-2 microglobulin fibril disrupting compound ex vivo with the blood during dialysis treatment of... Agent: Venable LLP

20100048511 - Complex formulation for preventing or treating osteoporosis which comprises solid dispersion of vitamin d or its derivative and bisphosphonate: Provided is a solid dispersion comprising vitamin D or a derivative thereof and a cyclodextrin; a complex formulation for the prevention or treatment of osteophorosis, which includes the solid dispersion and a bisphosphonate; and a method for preparing said complex formulation. The complex formulation can maintain a constant therapeutic level... Agent: Sughrue Mion, PLLC

20100048512 - Radiation protection drug containing tocopherol or tocotrienol compound ester derivative as active ingredient: Administration of either a tocopherol represented by the general formula (1) or a tocotrienol compound ester derivative before or after exposure to radiation is effective in preventing or treating health disorders caused by the radiation exposure.... Agent: Sughrue Mion, PLLC

20100048513 - Novel inhibitors of chymase: m

20100048515 - Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders: Novel synthetic oxidized lipids and methods utilizing oxidized lipids for treating and preventing an inflammation associated with an endogenous oxidized lipid are provided.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100048514 - Use of phospholipids for wound healing: The present invention provides a phospholipid and a pharmaceutical composition comprising a phospholipid for use in the treatment of a wound by inducing hyaluronic acid secretion; and a method of treating a wound comprising the application of a phospholipid thereto.... Agent: Quarles & Brady LLP

20100048516 - Penetration enhancer for fungicides: The invention relates to the field of chemical plant protection, in particular the use of a specific compound as a penetration enhancer for agrochemical active substances selected from the group consisting of the herbicides and safeners. The compound is tributoxyethyl phosphate (TBEP).... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100048517 - Androgen modulators: The present invention is directed to a new class of 4-cycloalkoxy benzonitriles and to their use as androgen receptor modulators. Other aspects of the invention are directed to the use of these compounds to decrease excess sebum secretions and to stimulate hair growth.... Agent: Pfizer Inc

20100048518 - Pharmaceutical composition combining tenatoprazole and an anti-inflammatory agent: The invention relates to a novel pharmaceutical combination. The inventive pharmaceutical composition comprises a combination of tenatoprazole and one or more anti-inflammatory agents selected from non-steroid anti-inflammatory agents and cyclooxygenase-2 inhibitors. The invention is suitable for the treatment of painful and inflammatory manifestations.... Agent: Crowell & Moring LLP Intellectual Property Group

20100048519 - Methods of treatment for ulcerative colitis using aminosalicylate: Disclosed herein is a new treatment for ulcerative colitis in male mammalian subjects. Further disclosed are increased dosages of an aminosalicylate composition for treatment of moderate ulcerative colitis in male mammalian subjects.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20100048521 - Combination of a gluco-korticoid and beta-cyclodextrin conjugated vitamin a-derivate complex: The present invention is related to a pharmaceutical combination of a glucocorticoid and a β-cyclodextrin conjugated vitamin A derivative complex as well as a pharmaceutical composition comprising the same. The combination and the composition of the invention can be used for reducing or eliminating skin atrophy induced by treatment with... Agent: Ladas & Parry LLP

20100048522 - Method of treating otic infections with moxifloxacin compositions: Ophthalmic, otic and nasal compositions containing a new class of antibiotics (e.g., moxifloxacin) are disclosed. The compositions preferably also contain one or more anti-inflammatory agents. The compositions may be utilized to treat ophthalmic, otic and nasal conditions by topically applying the compositions to the affected tissues.... Agent: Banner & Witcoff, Ltd.

20100048520 - Rifaximin anti-rectal dysfunction preparation: The present invention relates to compositions and methods for treating rectal disorders.... Agent: Edwards Angell Palmer & Dodge LLP

20100048523 - Compounds, compositions and methods for treating hormone-dependent maladies: A composition and method of using are provided, which composition includes: at least one compound selected from the group including a compound having formula (I), a salt thereof, a prodrug thereof, a compound having formula (II), a salt thereof, a prodrug thereof, and a combination thereof, the compounds being described... Agent: Dla Piper LLP (us)

20100048524 - Novel c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens;synthesis in vitro biological activities, pharmacokinetics and antitumor activity: Described are steroidal C-17 benzoazoles, pyrimidinoazoles (azabenzoazoles) and diazines. Methods for their synthesis are also described, which include methods having a step of nucleophilic vinylic “addition-elimination” substitution reaction of 3β-acetoxy-17-chloro-16-formylandrosta-5,16-diene or analogs thereof and benzoazole or pyrimidinoazole nucleophiles and methods having a palladium catalyzed cross-coupling reaction of 17-iodoandrosta-5,16-dien-3β-ol or analogs... Agent: Wilson, Sonsini, Goodrich & Rosati

20100048525 - Androgen treatment in females: The present invention is directed to a method of improving ovarian reserve in a human female with diminished ovarian reserve as measured by the female's anti-Müllerian hormone level. The method may include evaluating a first anti-Müllerian hormone level of the female, administering dehydroepiandrosterone to the female for at least about... Agent: Beem Patent Law Firm

20100048526 - Pharmaceutical composition for transdermal or transmucous administration: The present invention relates to a novel pharmaceutical composition for transdermal or transmucous administration of at least one active substance, and comprising especially a fatty acid as a percutaneous absorption promoter, at least one alcoholic vehicle and also a stabilizer capable of stabilizing the fatty acid in the said pharmaceutical... Agent: Foley And Lardner LLP Suite 500

20100048527 - Methods and compositions for the non-surgical removal of fat: Compositions and methods useful in the non-surgical removal of localized fat deposits in patients in need thereof using pharmacologically active detergents are disclosed. The pharmacologically active detergent compositions can additionally include anti-inflammatory agents, analgesics, dispersion agents and pharmaceutically acceptable excipients but do not contain phosphotidylcholine. The pharmacologically active detergent compositions... Agent: K&l Gates LLP

20100048528 - Heterocyclic compounds as inhibitors of beta-lactamases: This invention discloses and claims methods for inhibiting bacterial β-lactamases and treating bacterial infections by inhibiting bacterial β-lactamases in man or an animal comprising administering a therapeutically effective amount to said man or said animal of a compound, or pharmaceutically acceptable salt thereof, of formula (I) either alone or in... Agent: Harness, Dickey & Pierce, P.L.C

20100048529 - New 2-azetidinone derivatives useful in the treatment of hyperlipidaemic conditions: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts, solvates, and prodrugs thereof, and to their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia. The invention also relates to processes for their manufacture and pharmaceutical compositions containing them.... Agent: Pepper Hamilton LLP

20100048530 - New 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions: The invention relates to 2-azetidinone derivatives of formula (I), including pharmaceutically acceptable salts, solvates and prodrugs thereof. The compounds inhibit cholesterol absorption and are useful in the treatment of hyperlipidaemic conditions. The invention also relates to processes for their manufacture and to pharmaceutical compositions containing them.... Agent: Pepper Hamilton LLP

20100048531 - Glyt1 receptor antagonists: R1, R2, X, Ar1 and Ar2 are as defined herein and to pharmaceutically acceptable acid addition salts, to a racemic mixtures, or to their corresponding enantiomers and/or optical isomers thereof. Compounds of the invention are good inhibitors of the glycine transporter 1 (GlyT-1), and have a good selectivity to glycine... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100048532 - Benzimidazole derivatives as selective acid pump inhibitors: This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein: R1, R2, R3, R4, A and E are each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the method of treatment and the use, comprising such compounds for... Agent: Scully Scott Murphy & Presser, PC

20100048534 - Crystalline lestaurtinib hydrates and crystalline lestaurtinib hemihydrate hemiacetonitrileate and crystalline lestaurtinib hemihydrate hemitetrahydrofuranate: Crystalline lestaurtinib hydrates and crystalline lestaurtinib hemihydrate hemicetonitrileate and crystalline lestaurtinib hemihydrate hemitetrahydrofuranate, processes to reproducibly make them and methods of treating patients using them are disclosed.... Agent: Paul D. Yasger Abbott Laboratories

20100048533 - Lestaurtinib crystalline form 1, crystalline lestaurimib anhydrate and amorphous lestaurimib: Lestaurtinib Crystalline Form 1, isolated crystalline lestaurtinib anhydrate and amorphous lestaurtinib, processes to reproducibly make them and methods of treating patients using them.... Agent: Paul D. Yasger Abbott Laboratories

20100048535 - Method and dosage regimens for eliminating a chemical substance in blood: A method of reducing the concentration of a chemical or drug substance in the blood plasma that targets the same or similar receptors as the normal neurotransmitters in the central or peripheral nervous system includes titrating an initial peak concentration of the chemical or drug substance in the blood for... Agent: Mesmer & Deleault, PLLC

20100048536 - Novel substituted diaryl azepine derivatives as integrin ligands: The invention relates to novel compounds which bind to integrin receptors, their use as ligands of integrin receptors, in particular as ligands of the αvβ3 integrin receptor, and pharmaceutical preparations comprising these compounds.... Agent: Wood, Phillips, Katz, Clark & Mortimer

20100048537 - Heteroaryl derivatives: In formula [1], one of X and Y is CH and the other is oxygen or sulfur; R is hydrogen, etc.; Z is hydrogen, etc.; Ar is phenyl, etc.; and n is 1 or 2 and or m is 1 or 2, excluding compounds where n is 2 and m... Agent: Darby & Darby P.C.

20100048538 - Therapeutical uses of eslicarbazepine: New applications of eslicarbazepine and eslicarbazepine acetate in the treatment of intractable conditions, selected from epilepsy, central and peripheric nervous system disorders, affective disorders, schizoaffective disorders, bipolar disorders, attention disorders, anxiety disorders, neurophatic pain and neuropathic pain-related disorders, sensorimotor disorders, vestibular disorders, and nervous function alterations in degenerative and post-ischemic... Agent: Conley Rose, P.C.

20100048539 - Compounds and compositions as protein kinase inhibitors: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to beat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of c-kit, PDGFRα and PDGFRβ kinases. Formula (I).... Agent: Genomics Institute Of The Novartis Research Foundation

20100048540 - Heterocyclic n-oxides as hypoxic selective protein kinase inhibitors: The invention relates to novel heterocyclic N-oxides which are useful as hypoxic selective cytotoxic agents that mediate and/or inhibit cell proliferation, for example, through the activity of protein kinases. The invention is further related to pharmaceutical compositions containing such compounds and compositions, and to methods of treating cancer as well... Agent: Heslin Rothenberg Farley & Mesiti PC

20100048541 - Substituted lactams as inhibitors of abeta protein production: having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the... Agent: Kelley Drye & Warren LLP

20100048542 - Methods and compositions for treating primary and secondary tumors of the central nervous system (cns): Methods and compositions for the treatment and/or prophylaxis and/or suppression of primary and/or secondary tumors of the central nervous system (brain and spinal cord, eyes) in mammalian subjects are disclosed, wherein an effective dose of a methylol transfer agent such as Taurolidine and/or Taurultam and/or a bioequivalent is administered to... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100048543 - Pyrimidine compounds having ties (tek) inhibitory activity: or salt thereof wherein Rx, Ry, Rz, R5, R6, A, B, L, n and m are as defined in the description. The invention also relates to pharmaceutical compositions of said compounds, the use of said compounds as medicaments and in the production of an anti-angiogenic effect in a warm-blooded animal.... Agent: Astrazeneca R&d Boston

20100048544 - Pyrrolo (3, 2, 1-ij) quinoline-4-one-derivatives for treating tuberculosis:

20100048545 - Compounds and compositions for use in the prevention and treatment of disorders of fat metabolism and obesity: The invention relates to 4-hydroxyisoleucine, isomers, analogs, lactones, salts, and prodrugs thereof, to processes for their preparation, and to pharmaceutical compositions comprising the same. More particularly, the invention relates to the use of those compounds in the prevention and treatment of disorders of fat metabolism and related syndromes. The invention... Agent: Clark & Elbing LLP

20100048546 - Fungicidal combinations comprising a glyoxalic acid methyl ester-o-methyloxime derivatives: e

20100048547 - Pi 3-kinase inhibitors and methods of their use: Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional... Agent: Novartis Institutes For Biomedical Research, Inc.

20100048548 - Imino-oxazolidines and use thereof: The present invention relates to novel iminooxazolidines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular thromboembolic disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100048549 - Peptidomimetics selective for the somatostatin receptor subtypes 1 and/or 4: The invention relates to (hetero)arylsulfonylamino based peptidomimetics of formula (I), wherein A, D, E, J, Q1 R1, R2, R3, p and j are defined as disclosed, or a pharmaceutically acceptable salt or ester thereof. Compounds of formula (I) possess high affinity and selectivity for the somatostatin receptor subtypes sst1 and/or... Agent: Oliff & Berridge, PLC

20100048550 - Selective tr-beta 1 agonist: The present invention relates to novel compounds of general formula (I) which are thyroid receptor ligands and are preferably selective for the thyroid hormone receptor beta(TR-Beta). Further, the present invention relates to processes of preparing such compounds, their tautomeric forms, novel intermediates involved in their synthesis, their pharmaceutically acceptable salts,... Agent: Ladas & Parry LLP

20100048552 - Compounds and compositions as protein kinase inhbitors: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, Bcr-Abl(T315I), ALK, BLK, BMX, BRK,... Agent: Genomics Institute Of The Novartis Research Foundation

20100048553 - Spirocyclic cyclohexane compounds: e

20100048554 - Spirocyclic cyclohexane compounds:

20100048551 - Tricyclic compounds useful as inhibitors of kinases: The present invention provides inhibitors of kinases, specifically IκB kinases, JAK1, JAK2, JAK3 and TYK2. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting said kinase activity by administering the compound to a patient in need of treatment for myeloproliferative disorders, cancer or NF-κB-mediated diseases.... Agent: Merck And Co., Inc

20100048555 - Imidazothiazole derivatives as mark inhibitors: Compounds of formula (I): are inhibitors of MARK, and hence useful for treatment of disorders involving 10 hyperphosphorylation of tau.... Agent: Merck And Co., Inc

20100048556 - Quinoxaline derivatives: m

20100048557 - Triazolopyridine jak inhibitor compounds and methods: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined herein, are useful as JAK kinase inhibitors. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of... Agent: Brinks, Hofer, Gilson & Lione

20100048558 - Thienopyridines: The invention relates to novel thienopyridine derivatives of formula (I), wherein R1, R2, R3, R4 and Y have the meaning cited in claim 1, are HSP90-inhibitors and can be used for producing a medicament for treating illnesses, wherein the inhibition, regulation and/or modulation of HSP90 plays a roll.... Agent: Millen, White, Zelano & Branigan, P.C.

20100048560 - Pyrazolo pyridine derivatives as nadph oxidase inhibitors: The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).... Agent: Baker & Daniels LLP

20100048559 - Pyrido(3,2-d)pyridmidines useful for treating viral infections: This invention provides pyrido(3,2-d)pyrimidine derivatives represented by the structural formula (I), wherein: R1 is amino, R4 is hydrogen, and R2 and R3 together provide a specific substitution pattern, pharmaceutical acceptable addition salts, stereochemical isomeric forms, N-oxides, solvates and pro-drugs thereof, are useful in the treatment of hepatitis C.... Agent: Gilead Sciences Inc

20100048565 - Benzimidazole derivatives: Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related conditions or disorders. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in inflammation, immune response regulation and cell proliferation. The subject compounds are 2-amino-imidazole derivatives.... Agent: Jones Day

20100048564 - Fused bicyclic heteroaryl derivative: R1 represents a C1-C6 alkyl group, a C6-C10 aryl group which may be substituted with 1 to 5 group(s) independently selected from Substituent Group a, or the like; R2 represents a C1-C6 alkyl group; R3 represents a C6-C10 aryl group which may be substituted with 1 to 5 group(s) independently... Agent: Locke Lord Bissell & Liddell LLP Attn:IPDocketing

20100048562 - Organic compounds: said compound is inhibitor of aldosterone synthase (CYP11B2), and/or 11 beta-hydroxylase (CYP11B1), and/or aromatase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase, aromatase, or CYP11B1. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart... Agent: Novartis Institutes For Biomedical Research, Inc.

20100048561 - Quinazolines for pdk1 inhibition: The invention provides quinazoline compounds that are inhibitors of PDK1. Also provided are pharmaceutical compositions including the compounds, and methods of treating proliferative diseases, such as cancers, with the compounds or compositions.... Agent: Novartis Vaccines And Diagnostics Inc.

20100048563 - Substituted indolepyridinium as anti-infective compounds: their N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites, wherein n is 1, 2 or 3; R1 is H, CN, halo, aminoC(═O), C(═O)OH, C1-4alkyloxyC(═O), C1-4alkylC(═O), mono- or di(C1-4alkyl)aminoC(═O), arylaminoC(═O), N-(aryl)-N—(C1-4alkyl)aminoC(═O), methanimidamidyl, N-hydroxy-methanimidamidyl, mono- or di(C1-4alkyl)methanimidamidyl, Het1 or Het2; R2 is H, C1-10alkyl, C2-10alkenyl, C3-7cycloalkyl, wherein said C1-10alkyl, C2-10alkenyl... Agent: Philip S. Johnson Johnson & Johnson

20100048566 - Antibacterial quinoline derivatives: The claimed compounds are useful for the treatment of a bacterial infection. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the claimed compounds or compositions for the manufacture of a medicament for the... Agent: Philip S. Johnson Johnson & Johnson

20100048569 - Diazole derivatives: wherein A, E, R1, R2 and R3 are as defined in application and pharmaceutical compositions containing them. The invention also relates to use of such compounds for the treatment of diseases mediated by the metabotropic glutamate receptors (mGluR), such as anxiety, chronic and acute pain, protection against liver damage, urinary... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100048567 - Inhibitors of syk and jak protein kinases: The present invention is directed to compounds of formula I-V and tautomers thereof or pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of syk kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such... Agent: Townsend And Townsend And Crew, LLP

20100048568 - Pyrimidine hydrazide compounds as pgds inhibitors: e

20100048570 - Thiazolidine derivatives and methods for the preparation thereof: The present invention relates to novel 2-carbonyl-3-acyl-1,3-thiazolidines having a β-amino group on the acyl chain, in free, prodrug form or pharmaceutically acceptable salt thereof, including their enantiomers, diastereomers and racemates, as efficient inhibitors against DPP-IV. The invention further relates to the pharmaceutical compositions comprising the disclosed compounds. The present invention... Agent: Hoxie & Associates LLC

20100048571 - Organic compounds: The present disclosure relates to XIAP inhibitor compound of the formula I:... Agent: Novartis Institutes For Biomedical Research, Inc.

20100048572 - Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof: e

20100048573 - Methods of inhibiting bacterial virulence and compounds relating thereto: The present invention relates to compounds and methods for the treatment of bacterial infections. Because their mechanism of action does not involve killing of bacteria or inhibiting their growth, the potential for these compounds to induce drug resistance in bacteria is minimized. Through inhibiting bacterial virulence, the present invention provides... Agent: Fulbright & Jaworski L.L.P.

20100048574 - Novel heterocyclic nf-kb inhibitors: e

20100048575 - Novel tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use: Formula (I) wherein R3, R4, R5, R6, Y, Het1, T, U, V, W, X, Ru, Rv and Rw are as defined in claim 1... Agent: Stites & Harbison PLLC

20100048577 - Method for treating benign prostate hyperplasia using resveratrol: The invention relates to the discovery that resveratrol, and substituted forms of resveratrol, are effective in alleviating benign prostate hyperplasia. Formulations containing the resveratrol or resveratrol derivative, lack omega-3 fatty acids, and also contain no other compounds which activate SIRT1 and PGCα.... Agent: Fulbright & Jaworski, LLP

20100048576 - Pyridopyrazines and derivatives thereof as alk and c-met inhibitors: e

20100048578 - Hydrazide compound and harmful arthropod-controlling agent containing the same: Disclosed is a hydrazine compound represented by the formula (1) below, which has an excellent control activity against a harmful arthropod. (1) (In the formula, R1, R5, R6 and R7 represent a hydrogen atom or the like; R2 and R3 are bonded together at their ends to form a 5-... Agent: Birch Stewart Kolasch & Birch

20100048579 - Pyridazine-, pyridine- and pyrane-derivatives as gpbar1 agonists: A compound of formula (I) wherein the substituents have various meanings, optionally in salt and/or solvate form, and their use as pharmaceuticals.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100048580 - Histamine h3 receptor agents, preparation and therapeutic uses: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using... Agent: Eli Lilly & Company

20100048581 - Thiazolyl compounds useful as kinase inhibitors: The invention provides compounds of formula I [INSERT CHEMICAL STRUCTURE HERE] (I) and pharmaceutically acceptable salts thereof. The formula I thiazolyl compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.... Agent: Louis J. Wille Bristol-myers Squibb Company

20100048582 - Heterocyclic compounds suitable for treating disorders that respond to modulation of the serotonin 5ht6 receptor: e

20100048584 - Pyridyl derivatives and their use as therapeutic agents:

20100048585 - Quinoline derivatives as antibacterial agents: Use of a compound for the manufacture of a medicament for the treatment of a bacterial infection provided that the bacterial infection is other than a Mycobacterial infection, said compound being a compound of formula (Ia) or (Ib) a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric... Agent: Philip S. Johnson Johnson & Johnson

20100048583 - Novel heterocyclic nf-kb inhibitors: e

20100048586 - Multifunctional bioactive compounds: The present invention discloses multifunctional bioactive compounds of formula (I) constituted of an immunoregulatory portion linked to a stabilizer moiety and pharmaceutical compositions thereof useful in the treatment of immune disorders and hemopoietic disorders such as immune cytopema, multiple myeloma, chronic lymphoid leucosis, lymphocytic lymphomas, lymphosarcomas.... Agent: Bereskin And Parr LLP/s.e.n.c.r.l., S.r.l.

20100048587 - Cysteine and cystine bioisosteres to treat schizophrenia and reduce drug cravings: The present invention provides cysteine and cystine bioisosteres for the treatment of schizophrenia and drug addiction. The invention further encompasses pharmaceutical compositions containing such bioisosteres and methods of using the bioisosteres for treatment of schizophrenia and drug addiction.... Agent: Quarles & Brady LLP

20100048588 - Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase: e

20100048589 - Cold menthol receptor antagonists:

20100048590 - N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds: useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100048591 - Chemical compounds and processes: The present invention relates generally to chemical compounds and methods for their use and preparation. In particular, the invention relates to chemical compounds which may possess useful therapeutic activity, use of these compounds in methods of therapy and the manufacture of medicaments as well as compositions containing these compounds.... Agent: Wolf Greenfield & Sacks, P.C.

20100048593 - Deazaflavin compounds and methods of use thereof: The present invention features 5-deazaflavin compounds, pharmaceutical compositions of 5-deazaflavin compounds and methods of treating a patient suffering from cancer, the method comprising administering to a patient one or more 5-deazaflavin compounds of the invention.... Agent: Edwards Angell Palmer & Dodge LLP

20100048592 - Use of sodium channel blockers for the management of musculoskeletal pain: The invention provides methods for managing musculoskeletal pain. The compounds useful in the methods of the invention are blockers of sodium ion channels, and in particular compounds that bind to the SS1 or SS2 extracellular mouth of the a-subunit thereof. Particularly useful compounds are saxitoxin and its derivatives and analogues... Agent: Fish & Richardson PC

20100048594 - Use of cytohesin inhibitors for chemically inducing longevity: The invention relates to compounds selected from among the group comprising general formulas (1), (2), (3), and/or (4) and/or the enantiomers, diastereomers, and derivatives thereof, and the pharmaceutically acceptable salts thereof for producing a medicament used for therapeutically and/or preventively treating disease and pathological conditions linked to regulation of the... Agent: Rankin, Hill & Clark LLP

20100048597 - Organic compounds and their uses: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100048598 - Topical compositions comprising 5-alpha reductase inhibitors: The present invention relates to topical compositions comprising 5α-reductase inhibitors. The present invention also includes processes for preparation of such topical compositions and methods of using them.... Agent: Dr. Reddy''s Laboratories, Inc.

20100048595 - Use of archaea to modulate the nutrient harvesting functions of the gastrointestinal microbiota: The invention generally relates to the use of archaea to modulate nutrient harvesting in a subject. In particular, the invention provides methods that use archaea to modulate the nutrient harvesting functions of the microbiota in the subject's gastrointestinal tract.... Agent: Polsinelli Shughart PC

20100048596 - Indole derivatives as antitumoral compounds: Antitumoural compounds of general formula (I); wherein Ar is an heterocyclic group of formula (a) and R1, R2, R3, R4, R5, R6, R7, n and the dotted line take permitted meanings can be obtained from a tunicate of the family Polyclinidae, genus Aplidium, species cyaneum, and the invention further provides... Agent: King & Spalding

20100048599 - Compounds as kinase inhibitors: The present invention relates to compounds of Formula I, processes for their preparation, pharmaceutical compositions containing them as active ingredient, methods for the treatment of disease states associated with angiogenesis, such as cancers associated with protein tyrosine kinases, to their use as medicaments for use in the production of inhibition... Agent: G. Paul Chen/advenchen Labs

20100048601 - Hydrochloride salts of 8-[-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor: Disclosed are hydrochloride and tosylate crystalline salt forms of (5S,8S)-8-S[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I and methods of preparing the same.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20100048600 - Novel benzimidazole derivatives: (wherein A, B, C and D are independently nitrogen or optionally substituted methine; E is nitrogen, methine or hydroxy substituted methine; n is 0 or 1; T, U, V and W are independently nitrogen or optionally substituted methine; X is —N(SO2R4)—, —N(COR5)— or —CO—; Y is —C(R6)(R7)—, —O— or —N(R8)—,... Agent: Merck And Co., Inc

20100048602 - Oligomer-opioid agonist conjugates: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.... Agent: Nektar Therapeutics

20100048603 - Broad-spectrum anti-cancer treatment based on iminocamptothecin derivatives: A subclass of camptothecin derivatives is disclosed to be useful for the preparation of a medicament for the treatment of a cancer or tumor pathology selected from the group consisting of head and neck carcinoma, pancreas carcinoma, melanoma, bladder carcinoma, mesothelioma and epidermoid skin carcinoma.... Agent: Lucas & Mercanti, LLP

20100048604 - Ligands for aldoketoreductases: The present invention relates to compounds useful for detecting the activity of human aldoketoreductase 1Cs, compounds useful for competitively inhibiting human aldoketoreductase 1Cs and compounds useful for treating human aldoketoreductase 1C-related cancers, as well as pharmaceutical compositions and methods of manufacture thereof.... Agent: Cooper & Dunham, LLP

20100048605 - Synergistic effects of combinations of nornicotine and opioids for the treatment of pain: This invention relates to pharmaceutical compositions and methods where S(−)-nornicotine, R(+)-nornicotine, or racemic nornicotine are co-administered with an opioid analgesic in amounts effective to cause or enhance a synergistic analgesic response to treat pain (including acute, chronic, and cancer related pain). Preferably the coadministration of nornicotine with the opioid results... Agent: Crowell & Moring LLP Intellectual Property Group

20100048606 - 10-substituted cytisine derivatives and methods of use thereof: The present invention relates to substituted cytisine compounds that are useful in treating diseases impacted by a nicotinic ACh receptor. One aspect of the invention relates to 10-substituted cytisine compounds. In certain instances, the cytisine is substituted in the 10-position by an alkyl, aryl or aralkyl group. The present invention... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20100048607 - Formulations comprising palonosetron: Pharmaceutical compositions comprising palonosetron and its pharmaceutically acceptable salts, in the form of a ready-to-use solution or a lyophilized form. Specific embodiments of the invention relate to stable pharmaceutical formulations of palonosetron and its pharmaceutically acceptable salts, wherein the formulation does not comprise a chelating agent or an antioxidant.... Agent: Dr. Reddy''s Laboratories, Inc.

20100048608 - Histone deacetylase inhibitors for the treatment of ocular neovascular or edematous disorders and diseases: Ophthalmic compositions containing HDAC inhibitors and their use for treating ocular neovascular or edematous diseases and disorders are disclosed.... Agent: Alcon

20100048609 - Pharmaceutical dosage forms for (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid: Provided herein are light protective pharmaceutical packages for enantiomerically pme (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid. In certain embodiments, the pharmaceutical packages comprise a glass vial containing SNS-595 drug product within a secondary container.... Agent: Jones Day

20100048610 - Carbinol derivatives having cyclic linker: o

20100048612 - Bicyclic heterocycles as cannabinoid-1 receptor modulators:

20100048611 - Tetrahydropyrrolopyridine, tetrahydropyrazolopyridine, tetrahydro-imidazopyridine and tetrahydrotriazolopyridine derivatives and use thereof: The invention relates to novel tetrahydropyrrolopyridine, tetrahydropyrazolopyridine, tetrahydroimidazopyridine and tetrahydrotriazolopyridine derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of thromboembolic disorders... Agent: Barbara A. Shimei Director, Patents & Licensing

20100048613 - Polymorphic form of granisetron hydrochloride and methods of making the same: Crystalline granisetron hydrochloride characterized by a powder x-ray diffraction pattern with peaks at about 14.3, 20.4, and 23.0±0.2 degrees two-theta and process of making the same are disclosed.... Agent: Cohen, Pontani, Lieberman & Pavane LLP

20100048614 - Therapeutic uses of bicyclic ligands of sigma 2 receptor: A series of N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamate analogs are disclosed, as well as methods of their preparation. Their affinities for sigma (σ1 and σ2) receptors are described. Two new compounds, N-(9-(4-aminobutyl)-9-azabicyclo[3.3.1]nonan-3α-yl)-N′-(2-methoxy-5-methylphenyl)carbamate and N-(9-(6-aminohexyl)-9-azabicyclo[3.3.1]nonan-3α-yl)-N′-(2-methoxy-5-methylphenyl)carbamate, are shown to have a high affinity and selectivity for σ2 versus σ1 receptors. Among the disclosed compounds... Agent: Washington University-snr C/o Sonnenschein Nath & Rosenthal L.l.p

20100048615 - Combinations comprising antimuscarinic agents and pde4 inhibitors: Combinations comprising (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma... Agent: Hoxie & Associates LLC

20100048616 - Combinations comprising antimuscarinic agents and pde4 inhibitors: A combination which comprises (a) a PDE4 inhibitor and (b) an antagonist of M3 muscarinic receptors which is (3R)-1-phenethyl-3-(9H-xanthene-9carbonyloxy)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid.... Agent: Hoxie & Associates LLC

20100048617 - Compounds: c

20100048618 - Derivatives of 8-epiblechnic acid and their effects on down-regulation of endothelin (eta) receptor mrna: The present application discloses derivatives of 8-epiblechnic acid and use thereof in treating a disease related to endothelin receptor A or endothelin-1 (ET-1) over-expression, such as hypertension, cancer, atherosclerosis, and myocardial infarction.... Agent: Cohen, Pontani, Lieberman & Pavane LLP

20100048619 - Cold menthol receptor antagonists: e

20100048620 - Composition for treatment of undifferentiated gastric cancer: Disclosed are: a therapeutic agent, a kit and a treatment method for undifferentiated gastric cancer; and a pharmaceutical composition, a kit and a treatment method which are more effective on a living organism having at least one cell selected from the group consisting of a cell overexpressing FGFR2 and a... Agent: Darby & Darby P.C.

20100048621 - Medicament for treating chronic obstructive pulmonary disease: The invention relates to a medicament for treating chronic obstructive pulmonary disease comprising as active ingredients a carbostyril derivative of formula (1): wherein A is a lower alkylene group, R is a cycloalkyl group, the bonding between 3- and 4-positions of the carbostyril skeleton is a single bond or a... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100048622 - Crystalline forms of a biphenyl compound: The invention provides crystalline forms of biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester, and pharmaceutically acceptable solvates thereof. The crystalline form can be a freebase, or a salt such as a diphosphate, monosulfate or dioxalate salt. The invention also provides pharmaceutical compositions comprising these crystalline compounds or prepared using these compounds; processes and... Agent: Theravance, Inc.

20100048623 - Piperidines and related compounds for the treatment of alzheimer's disease: Compounds of formula (I) are modulators of gamma-secretase, and hence are useful in treatment of Alzheimer's disease.... Agent: Merck And Co., Inc

20100048624 - Use of piperidine derivatives as dermo-decontracting agents: m

20100048627 - synergistic pharmaceutical combination for the prevention or treatment of diabetes: The invention refers to a synergistic pharmaceutical combination which comprises (a) a first pharmaceutical composition containing an antidiabetic or anti-hyperlipidemic active agent and one or more conventional carrier(s), and (b) a second pharmaceutical composition containing a hydroximic acid derivative of the formula I and one or more conventional carrier(s). The... Agent: Birch Stewart Kolasch & Birch

20100048626 - Aryl substituted pyridines and the use thereof: or a pharmaceutically acceptable salt, prodrug or solvate thereof, wherein Ar and R1-R4 are set in the specification. The invention is also directed to the use of compounds of Formula I for the treatment of neuronal damage following global and focal ischemia, for the treatment or prevention of neurodegenerative conditions... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100048625 - Piperidine gpcr agonists: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.... Agent: Osi Pharmaceuticals, Inc.

20100048628 - Method for suppressing discoloration over time of adhesive preparation containing donepezil: [Solution] At least one species of stabilizer selected from the group consisting of ascorbic acid, a metal salt or an ester thereof, isoascorbic acid or a metal salt thereof, ethylenediamine tetraacetic acid or a metal salt thereof, 2-mercaptobenzimidazole, 3(2)-t-butyl-4-hydroxyanisole, 2,6-di-t-butyl-4-methylphenol, tetrakis[3-(3′,5′-di-t-butyl-4′-hydroxyphenyl)propionic acid]pentaerythritol, (±)-α-tocopherol, (±)-α-tocopherol acetate, rutin, hypophosphorous acid, a metal... Agent: Birch Stewart Kolasch & Birch

20100048630 - Methods for treating cns disorders: The present invention relates to methods for treating central nervous system disorders, such as Alzheimer's disease, anxiety and major depressive disorder, by administering piperidine derivatives, e.g., 2-[4-(4-fluoro-benzyl)-piperidine-1-yl]-2-oxo-N-(2-oxo-2,3-dihydro-benzoxazol-6-yl)acetamide, and pharmaceutically acceptable salts thereof.... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20100048629 - Methods for treating neuropathic pain: The present invention relates to methods of treating diabetic neuropathic pain comprising administering piperidine derivatives, such as 2-[4-(4-fluoro-benzyl)-piperidine-1-yl]-2-oxo-N-(2-oxo-2,3-dihydro-benzoxazol-6-yl)acetamide, and pharmaceutically acceptable salts thereof. Methods of treating post-herpetic neuralgia, chronic lower back pain, osteoarthritis and acute inflammatory pain are described.... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20100048634 - Method for treating apathy syndrome: The present invention provides a method of treating apathy syndrome in a human subject. The human subject is first evaluated to determine whether one or more behavioral characteristics of apathy are observed. If such characteristics are observed, the subject is treated with a 2-oxopyrrolidine compound, such as nefiracetam, piracetam, aniracetam,... Agent: Howrey LLP-ca

20100048631 - Piperidine gpcr agonists: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.... Agent: Osi Pharmaceuticals, Inc.

20100048632 - Piperidine gpcr agonists: Compounds of formula (I): or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of obesity and diabetes.... Agent: Osi Pharmaceuticals, Inc.

20100048633 - Piperidine-4-acrylamides: A compound of formula (I), wherein substituents are as given above, useful in the treatment of a disease mediated by the action of CCR3.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100048635 - Use of collismycin and derivatives thereof as oxidative stress inhibitors: The present invention relates to the use of Collismycin and derivatives thereof as inhibitors of oxidative stress in cells and their use for the preparation of medicaments for the treatment and/or prevention of oxidative stress-induced diseases or conditions, especially neurodegenerative diseases, such as Alzheimer's Disease and Parkinson's Disease.... Agent: Intellectual Property / Technology Law

20100048636 - Aspartic protease inhibitors: The present invention is directed to aspartic protease inhibitors. Certain aspartic protease inhibitors of the invention can be represented by the following structural formula or a pharmaceutically acceptable salt thereof. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100048637 - Cyclohexylamines, phenylamines and uses thereof: e

20100048638 - Heparan sulfate inhibitors: Provided herein are heparan sulfate inhibitors, including modulators of heparan sulfate glycosylation, heparan sulfate sulfation, and/or heparan sulfate epimerization.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100048640 - Hydrazide compound and harmful arthropod-controlling agent containing the same: Disclosed is a hydrazine compound represented by the formula (1) below, which has an excellent control activity against a harmful arthropod. (1) (In the formula, R1, R5, R6 and R7 represent a hydrogen atom or the like; at least one of R2 and R3 represents a C1-C6 alkyl group substituted... Agent: Birch Stewart Kolasch & Birch

20100048639 - Oxadiazole derivates as s1p1 receptor agonists: s

20100048641 - Use of adenosine a1 and/or dual a1/2ab agonists for production of medicaments for treating diseases: The present invention relates to the use of A1 and/or dual A1/A2b agonists of the formulae (IA) and (IB) for preparing a medicament for treating dyslipidemia, metabolic syndrome and diabetes and dyslipidemia, metabolic syndrome and diabetes in association with hypertension and cardiovascular disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100048642 - Methods for treating cognitive disorders: Disclosed herein are methods of treating a patient suffering a cognitive disorder.... Agent: Allergan, Inc.

20100048643 - Novel polymorph forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine: Polymorph forms of (2S)-(4E)-N-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine p-hydroxybenzoate, and methods for their preparation, pharmaceutical composition containing said polymorph(s) and use, are disclosed. The polymorphs can be administered to patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, to treat and/or prevent such disorders.... Agent: Pepper Hamilton LLP

20100048645 - Solubilizing of metronidazole: Metronidazole is solubilized in an aqueous phase, by mixing same with niacinamide and at least two glycolic cosolvents; the resulting solutions and pharmaceutical compositions comprised thereof are useful for the treatment of dermatological conditions/afflictions, notably rosacea.... Agent: Buchanan, Ingersoll & Rooney PC

20100048644 - Use of composition comprising amlodipine in preparing medicaments for treating a lower urinary tract disorder: Use of composition comprising amlodipine in preparing medicaments for treating a lower urinary tract disorder. The lower urinary tract disorder is selected from the group consisting of benign prostate hyperplasia, lower urinary tract syndrome or overactive bladder, especially the lower urinary tract disorder accompanying with hypertension. Amlodipine is any one... Agent: Sheridan Ross PC

20100048646 - N'-cyano-n-halogenalkylimidamide derivatives: The present application relates to novel substituted N′-cyano-N-halogenalkylimidamide derivatives, to processes for their preparation and to their use for controlling animal pests, especially arthropods, in particular insects.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100048647 - Nematicidal agent composition and method of using the same: wherein Ar is a substituted phenyl group having one or more, the same or different substituents selected from a halogen atom, a (C1-C6)alkyl group, a halo(C1-C6)alkyl group, a (C1-C6)alkylthio group, a halo(C1-C6)alkylthio group, a (C1-C6)alkoxy group and a halo(C1-C6)alkoxy group, and the like, X may be the same or different,... Agent: Leydig Voit & Mayer, Ltd

20100048648 - Thiophene derivatives as s1p1/edge1 receptor agonists: The invention relates to novel thiophene derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.... Agent: Hoxie & Associates LLC

20100048649 - Combinations comprising bicyclic s1p lyase inhibitors: Methods and compositions for treating immunological and inflammatory diseases and disorders are disclosed. Particular methods and compositions comprise the administration of an agent that inhibits S1P lyase activity and at least one additional immunosuppressive and/or anti-inflammatory agent.... Agent: Lexicon Pharmaceuticals, Inc.

20100048650 - Two pore channels as a therapeutic target to protect against myocardial ischemia and as an adjuvant in cardiac surgery: The present invention relates to methods and compositions for modulating the activity of two-pore domain K+ channels (“K2P channels”) as a means for inducing preconditioning protection. Such preconditioning can be used to reduce the effect of ischemia associated with ischemic heart disease, myocardial infarcation or cardiac surgery. The invention is... Agent: Kenyon & Kenyon LLP

20100048651 - Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use: Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed.... Agent: Dorsey & Whitney, LLP Intellectual Property Department

20100048652 - Insecticidal compounds: A compound of formula (I): wherein A1, A2, A3, A4, R1, R2, R3, R4, G1, G2, Q1, Y1, Y2, and Y4 are as defined in claim 1; or salts or N-oxides thereof. Furthermore, the present invention relates to processes and intermediates for preparing compounds of formula (I), to insecticidal, acaricidal,... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100048653 - Neuroprotective modulation of nmda receptor subtype activities: In various aspects, the invention provides methods and compositions for modulating NMDA receptor subtype activity, to enhance NR2A-containing NMDA receptor activity relative to NR2B-containing NMDA receptor activity, so as to effect a neuroprotective reduction in excitotoxic NMDA receptor activity... Agent: Knobbe Martens Olson & Bear LLP

20100048654 - Use of valsartan or its metabolite to in hibit platelet aggregation: The invention relates to a method of inhibiting platelet aggregation comprising administering a therapeutically effective amount of an ARB or its metabolite, especially Valsartan or its metabolite valeryl 4-hydroxy valsartan. Conditions to be treated by inhibition of platelet aggregation include acute myocardial infarction, ischemic stroke, angina pectoris, acute coronary syndromes,... Agent: Novartis Corporate Intellectual Property

20100048655 - Comb polymers and use thereof for the production of active or effective ingredient formulations: e

20100048656 - Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders: wherein R6, R7, R8, R9, X, Ar, n, and m are as defined in the description. Uses of the compounds as medicaments, and in the manufacture of medicament for treating neurological and neuropsychiatric disorders, in particular psychoses, dementia or attention deficit disorder are also disclosed. The invention further discloses pharmaceutical... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100048657 - Control of malignant cells proliferation through the inhibition of casein kinase 2: Methods and related compositions are disclosed for treating an array of myeloproliferative disorders and hematological malignancies. In particular, treatment methods and compositions for treating chronic myelogenous leukemia are disclosed. The methods and compositions utilize certain casein kinases, and specifically CK2α agents.... Agent: Rankin, Hill & Clark LLP

20100048658 - Fused heterocyclic compounds: wherein R1 is an optionally substituted hydrocarbyl, a substituted amino, etc.; R2 is an aromatic group substituted with one or two substituents at the positions adjacent to the position bonded to Z, and said aromatic group may have additional substituent(s); X is —NR3— wherein R3 is a hydrogen, an optionally... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100048659 - Aqueous compositions containing metronidazole: An aqueous solution of metronidazole in which the concentration of metronidazole is higher than 0.7%. The solution contains a combination of solubility-enhancing agents, one of which is niacinamide. Methods of manufacture and therapeutic use of the solution are disclosed.... Agent: Howard Eisenberg, Esq.

20100048660 - Treatment of duchenne muscular dystrophy: There are disclosed compound of Formula (I) or (II) wherein A1, A2, A3, A4 and A5, which may be the same or different, represent N or CR1, R9 represents -L-R3, in which L is a single bond or a linker group and R3 represents hydrogen or a substituent and in... Agent: Jones Day

20100048661 - Active compound combinations having insecticidal and acaricidal properties: The novel active compound combinations consisting, firstly, of cyclic ketoenols and, secondly, of beneficial species (natural enemies) have very good insecticidal and/or acaricidal properties.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100048662 - Novel pyrone-indole derivatives and process for their preparation: The present invention relates to novel pyrone-indole derivatives, pharmaceutical formulations containing them, and use of the compounds in the manufacture of Medicaments for treating or preventing various diseases.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100048663 - Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents: This invention is directed to substituted aryl compounds, which are linked to a substituted indole moiety by various linkers, and the kynurenine/kynuramine-like metabolites of these agents, their preparation and pharmaceutical compositions containing these compounds. This invention further is directed to the pharmaceutical use of the compounds for inhibiting GSK3β kinase... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100048664 - Therapeutic substituted pyrroles: i

20100048665 - 3-aminopyrrolidone derivatives: 3-aminopyrrolidone compounds and pharmaceutically acceptable salts thereof that are active as sodium and/or calcium channel modulators and therefore useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to cardiovascular, inflammatory, ophthalmic, urologic, metabolic and gastrointestinal diseases.... Agent: Young & Thompson

20100048666 - Novel phenylacetic acid derivative: A compound represented by the formula (1) or a salt thereof ( represents a single bond, or a double bond; R1 represents hydrogen atom, or an alkyl group; R2 and R3 represent hydrogen atom, or an alkyl group; R4 and R5 represent hydrogen atom, hydroxy group, an alkoxyl group, a... Agent: Greenblum & Bernstein, P.L.C

20100048667 - Thiolactones: This invention provides new compounds, pharmaceutical compositions and diagnostic kits comprising such compounds, and methods of using such compounds for inhibiting NAALADase enzyme activity, detecting diseases where NAALADase levels are altered, inhibiting angiogenesis, effecting a TGF-β activity or a neuronal activity, and treating a glutamate abnormality, a compulsive disorder, neuropathy,... Agent: Arnold & Porter LLP (20595) Attn:IPDocketing Dept.

20100048668 - Compositions and methods to control abnormal cell growth: A class of compounds commonly containing a trialkylammonium group have been synthesized and characterized as anticancer compounds. They can be used alone or in combination with other therapies to treat cancer and other cell proliferative diseases. Representative compounds of this class, N,N-diethyl-N-methyl-2-[(9-oxo-9H-thioxanthen-2-yl)methoxy]ethanaminium iodide and N,N-diethyl-N-allyl-3-(2-methyl-9H-thioxanthen-9-ylidene)-propane-1-aminium bromide, were shown in various... Agent: Faegre & Benson LLP Patent Docketing - Intellectual Property

20100048669 - Therapeutic compounds: c

20100048684 - Egf receptor transactivation by g-protein-coupled receptors requires metalloproteinase cleavage of prohb-egf: The present invention relates to agents and methods for growth-factor receptor activation by modulating the G-protein mediated signal transduction pathway.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100048685 - Pharmaceutical composition containing docetaxel-cyclodextrin inclusion complex and its preparing process: A docetaxel inclusion complex having improved water-solubility (up to 15 mg/ml) and stability (stability constant Ka=2056M−1-13051M−1), comprises docetaxel and hydroxypropyl-beta-cyclodextrin and/or sulfobutyl-beta-cyclodextrin in a ratio of 1:10-150. The method includes steps as follows: docetaxel dissolved in ethanol is added into water solution of cyclodextrin via stirring, until docetaxel is completely... Agent: Schmeiser, Olsen & Watts

20100048686 - Perfume composition for temperature sense control, sense control article, sense control method, and perfume map: It is an object of the present invention to discover that a perfume can change a person's temperature sense and humidity sense, to identify a perfume component that can change temperature sense, and to provide a perfume composition for controlling temperature sense that contains this perfume component, and to a... Agent: Rankin, Hill & Clark LLP

20100048687 - Use of phosphatase inhibitors for the treatment of neurodegenerative diseases: Provided are novel a target and drugs in the treatment of neurological disorders related to amyloid beta pathology/amyloidosis. More specifically, the use of phosphatase inhibitors for the treatment of brain impairments mediated by Aβ-oligomers is described.... Agent: Latimer & MayberryIPLaw, LLP

20100048688 - Dietary and pharmaceutical compositions containing carnosol and/or rosmanol and their uses: The present invention refers to carnosol and rosmanol for use (as medicament) in the treatment of a disorder connected to reduced neurotransmission, cognitive dysfunction and/or symptoms caused by headache and/or migraine, as well as to dietary and pharmaceutical compositions and their uses.... Agent: Nixon & Vanderhye, PC

20100048689 - Process of obtainment of soy isoflavones: The present invention relates to the process for the recovery of conjugated isoflavones of residues and sub-products of food industries based on the use of soy and its derivatives. It also concerns of isoflavones obtained from food composition containing isoflavones and from the fungus genetically modified used in this process,... Agent: Ladas & Parry LLP

20100048690 - Antitumoral dihydropyran-2-one compounds: Antitumoral compounds obtained from a porifera, of the family Raspailiidae, genus Lithoplocamia, species lithistoides, and derivatives thereof are provided.... Agent: King & Spalding

20100048691 - Composition useful for the prevention of type 2 diabetes and its complications in pre-diabetic patients with insulin resistance: The present invention relates to the use of acetyl L-carnitine in combination with an anti hypertensive drug, and a statin, for the preparation of a medicament for the prevention or delay of onset of type 2 diabetes and its complications, in pre-diabetic patients with insulin resistance.... Agent: Lucas & Mercanti, LLP

20100048692 - Naphthofuranone derivatives as specific inhibitors of thymidylate synthases: Synthetic compounds of 1,2-naphthalein moelcules (I) having specific inhibitory properties of the enzymatic activity of thymidylate synthases of bacterial species, their preparation, their pharmaceutical composition and use in the treatment and prophylaxis of infectious pathologies are disclosed.... Agent: Dilworth & Barrese, LLP

20100048693 - Treatment of copd: The present invention provides methods for treating chronic obstructive pulmonary disease. In some embodiments of the invention, methods for treating COPD comprise administering PGI2 or a prostacyclin analog to a subject in need of such treatment.... Agent: Don D. Cha

20100048695 - Anti-fatigue agent: Anti-fatigue agents containing dioxabicyclo[3.3.0]octane derivatives such as sesamin which is an ingredient contained in sesame, as well as pharmaceutical compositions and physiologically functional foods that contain such anti-fatigue agents are disclosed. These compounds can safely be administered to humans and animals alike and hence allow for continued ingestion while proving... Agent: Drinker Biddle & Reath (dc)

20100048694 - Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality: Methods of using dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality, articles of manufacture and packages related thereto.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100048696 - Agricultural disease control agent: The present invention provides a disinfectant comprising as an active ingredient maleic acid and/or maleic anhydride.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100048697 - Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions: Compounds and pharmaceutical compositions for use in the treatment and/or prophylaxis of cartilage and/or bone conditions and for methods of treating such condition. The compounds are salts of strontium that have a water-solubility of from about 1 g/l to about 100 g/l at room temperature, especially amino acid salts of... Agent: Jones Day

20100048698 - Macrocyclic diterpenes for treating conditions associated with protein kinase c: The present invention relates generally to chemical agents useful in the treatment and prophylaxis of inflammatory conditions or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammalian animal including human and primate, non-mammalian animal and avian species. More particularly, the present invention provides... Agent: Scully Scott Murphy & Presser, PC

20100048699 - Chemical compounds: e

20100048700 - Liquid formulation of pyrethroids:

20100048701 - Amide compound and use thereof for controlling plant diseases: In the formula, X1 represents a fluorine atom or a methoxy group; X2 represents a hydrogen atom, a halogen atom, a C1-C4 alkyl group or the like; X3 represents a halogen atom, a C1-C4 alkyl group or the like; Z represents an oxygen atom or a sulfur atom; and A... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100048702 - Prevention of neutrophil recruitment: Aspirin (ASA) triggers a switch in the biosynthesis of lipid mediators, inhibiting prostanoid production and initiating 15-epi-lipoxin generation, through the acetylation of cyclooxygenase II.... Agent: Fulbright & Jaworski L.L.P. Attn: MnIPDocket

20100048703 - Hair care product: A substance having a testosterone 5α-reductase inhibiting action, a hair papilla cell growth promoting action, a fibroblast growth factor-7 production promoting action, a vascular endothelial growth factor production promoting action or a bone morphogenetic protein-2 production promoting action, and a hair care product having this substance blended therein. A hair... Agent: Posz Law Group, PLC

20100048706 - Ethoxylated and/or hydrogenated oil adduct: A composition of matter comprising an oil adduct synthesized by an oil and an addition material, wherein the oil includes at least one member chosen from an ethoxylated oil, a hydrogenated oil, and an ethoxylated and hydrogenated oil: wherein the average degree of ethoxylation in the ethoxylated (optionally hydrogenated) oil... Agent: Colgate-palmolive Company

20100048705 - Methods of treating and preventing neovascularization with omega-3 polyunsaturated fatty acids: Disclosed are methods for treating or preventing ocular neovascularization in a subject at risk. The method comprises administering to the subject an effective amount of omega-3 polyunsaturated fatty acid to thereby treat or prevent the ocular neovascularization. This method is suitable for treating or preventing retinopathy of prematurity, retina vein... Agent: David S. Resnick

20100048704 - Pharmaceutical and nutraceutical products comprising vitamin k2: A pharmaceutical and nutraceutical product is provided comprising vitamin K2 or a compound within the vitamin K2 class of compounds, optionally and preferably in combination with one or more polyunsaturated fatty acids, either in purified form or as a marine oil (i.e. fish and/or krill oil). Also provided is the... Agent: Kalow & Springut LLP

20100048707 - Polymeric reagents comprising a terminal vinylic group and conjugates formed therefrom: The present invention provides conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates. Methods of making polymeric reagents and conjugates, as well as methods for administering conjugates and compositions, are also provided.... Agent: Nektar Therapeutics

20100048708 - Tamibarotene capsule preparation: The present invention provides a practical preparation form of Tamibarotene and dosage form thereof, which exhibit high absorptivity by the body with minimized toxicity, and which are safe and stable without any risk of contamination. It is provided a Tamibarotene capsule preparation which encapsulates a composition comprising an oil component... Agent: Birch Stewart Kolasch & Birch

20100048709 - Treatment of prostate cancer with ddc inhibitor: Prostate cancer comes in various forms and has proven difficult to treat. Provided herein are various methods and compositions for treating all forms of prostate cancers with dopa decarboxylase (DDC) inhibitors. These dopa decarboxylase inhibitors include carbidopa (α-Methyl-dopahydrazine), MFMD (α-monofluoromethyldopa), NSD-1015 (3-hydroxybenzylhydrazine), Methyldopa (L-α-Methyl-3,4-dihydroxyphenylalanine) or benserazide, and the inhibitors may... Agent: Larson & Anderson, LLC

20100048710 - Methods and compositions for modulating muscle fat in livestock: The present invention relates to compositions and methods for modulating the degree of adipose tissue deposited intramuscularly in livestock animals. In particular, the present invention relates to compositions and methods for the use of non-steroidal antiinflammatory drugs to preferentially increase the amount of intramuscular adipose tissue in cattle.... Agent: Medlen & Carroll, LLP

20100048711 - Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states: This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of... Agent: Stinson Morrison Hecker LLP Attn: Patent Group

20100048712 - Acyclic sulfamide derivatives: The present invention is related to acyclic sulphamide derivatives of formula (I), wherein R1 and R2 may be the same or different, when R1 and R2 are different, R1 is a linear C12-C20 alkyl group or a linear C12-C20 alkenyl group comprising 1, 2, 3 or 4 double bonds; and... Agent: King & Spalding

20100048713 - Compounds acting on the serotonin transporter: The invention relates to new chemical compounds acting on the serotonin transporter (SERT), and associated pharmaceutical compositions, methods for use as therapeutic agents, and methods of preparation thereof. In particular the new chemical compounds are useful for the treatment of a variety of central nervous system (CNS) disorders—for example anxiety,... Agent: Davis Wright Tremaine LLP - San Francisco

20100048714 - Methods and compositions related to inhibition of ceramide synthesis: Disclosed are compositions and methods related to the ceramide synthesis pathway and various diseases and disorders associated therewith, such as insulin resistance and inflammation.... Agent: Ballard Spahr LLP

20100048716 - Crystalline forms of aliskiren hemifumarate: This invention relates to crystal forms of aliskiren hemifumarate and various embodiments related thereto, e.g. pharmaceutical preparations, processes for the manufacture of the crystal forms, pharmaceuticals uses and the like. The crystal forms have particularly advantageous properties e.g. they are useful in the manufacture of blood-pressure lowering pharmaceutical preparations and... Agent: Novartis Corporate Intellectual Property

20100048715 - Insecticidal compounds: A compound of formula (I), wherein A1, A2, A3, A4, R1, R2, G1, G2, Q1 and Q2 are as defined in claim 1; or salts or N-oxides thereof. Furthermore, the present invention relates to processes and intermediates for preparing compounds of formula (I), to insecticidal, acaricidal, molluscicidal and nematicidal compositions... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100048717 - Cathepsin b inhibitors: Compounds of formula (I): are found to be selective inhibitors of cathepsin B, and hence useful in treating a variety of pathological conditions.... Agent: Merck And Co., Inc

20100048718 - Process for the preparation of and crystalline forms of optical enantiomers of modafinil: The invention relates to a polymorphic form of (−)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 5.23, 5.03, 4.22 and 4.10 Å, and a process for the preparation thereof.... Agent: Ross J. Oehler Cephalon, Inc.

20100048719 - Process for the preparation of and crystalline forms of optical enantiomers of modafinil: The invention relates to a polymorphic form of (−)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 12.31, 8.54, 7.27 and 3.62 Å, and a process for the preparation thereof.... Agent: Ross J. Oehler Cephalon, Inc.

20100048720 - Process for the preparation of and crystalline forms of optical enantiomers of modafinil: The invention relates to a polymorphic form of (−)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 14.14, 10.66, 7.80 and 4.02 Å, and a process for the preparation thereof.... Agent: Ross J. Oehler Cephalon, Inc.

20100048721 - Use of 2,2,3,3, tetramethylcyclopropane carboxylic acid derivatives for treating psychiatric disorders: The invention relates to the use of 2,2,3,3 tetramethylcyclopropane carboxylic acid derivative compounds for the preparation of a medicament for treating a psychiatric disorder preferably a bipolar disorder. The invention additionally relates to the use of the compounds for the preparation of an inhibitor of MIP synthase and to a... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100048722 - Formation of accumbens glur2-lacking ampa receptors mediates incubation of cocaine craving: The present invention provides a method for ameliorating cue-induced cravings for an addictive substance in abstinent addicts by administering a compound capable of blockade of GluR2-lacking AMPA receptors.... Agent: Joseph A. Fuchs Rockey, Depke & Lyons, LLC

20100048723 - Compositions and methods for preventing or treating obesity in animals: Compositions useful to prevent or treat obesity in an animal are disclosed. The compositions comprise a capsaicinoid, preferably capsaicin, or an active metabolite thereof, in an amount effect to prevent or treat obesity in an animal. Also disclosed are methods to prevent or treat obesity in an animal comprising administering... Agent: Colgate-palmolive Company

20100048724 - Subunguicide, and method for treating onychomycosis: Onychomycosis is a fungal infection of the nail bed and is difficult to treat topically because penetration of the nail plate is difficult, and systemic antifungal treatments are prone to side effects and drug interactions. The present invention treats onychomycosis by applying an antifungal composition to the nail bed directly... Agent: Baker & Hostetler LLP

20100048725 - Use of cyclopamine in the treatment of basal cell carcinoma and other tumors: This invention concerns the use of cyclopamine in vivo on basal cell carcinomas (BCC's) to achieve therapeutic effect by causing differentiation of the tumor cells and, at the same time, apoptotic death and removal of these tumor cells while preserving the normal tissue cells, including the undifferentiated cells of the... Agent: Vidas, Arrett & Steinkraus, P.A.

20100048726 - Memantine for the treatment of mild and mild to moderate alzheimer's disease: The present invention provides a method for the treatment, prevention, or delay of progression of mild, or mild-to-moderate Alzheimer's disease, by administering an effective dose of memantine. The present invention also provides a method for preventing the decrease in glucose metabolism in the cortical and sub-cortical regions of the brain... Agent: Forest Laboratories, Inc. Attn: Charles S. Ryan

20100048727 - Perfluoroketone compounds and uses thereof: Novel perfluoroketone compounds of formula [I] and [Ia] are described. Also described are uses thereof, such as for inhibition of phospholipase A2 activity. Therapeutic uses thereof are also described, such as for the treatment of neural conditions and/or inflammatory conditions, such as demyelinating (e.g., multiple sclerosis) and neural injury (e.g.,... Agent: Klarquist Sparkman, LLP

20100048728 - Polycyclic dianthraquinones as inhibitors of inflammatory cytokines: The present invention relates to the therapeutic use of polycyclic dianthraquinones including hypericin, helianthrones and helianthrone derivatives as inhibitors of the proinflammatory cytokine cascade mediated inflammatory conditions such as inflammatory bowel disease and cachexia. In addition the compositions can be used for prevention of development of inflammation, fibrosis and vasculopathy... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100048729 - Composition based on xanthoxyline and its use in cosmetic: The present invention relates to the use of xanthoxyline, and of plant extracts containing it, in cosmetic compositions.... Agent: The Firm Of Hueschen And Sage

20100048730 - Sulfoperoxycarboxylic acids, their preparation and methods of use as bleaching and antimicrobial agents: The present invention relates to novel sulfoperoxycarboxylic acid compounds, and methods for making and using them. The sulfoperoxycarboxylic compounds of the invention are storage stable, water soluble and have low to no odor. Further, the compounds of the present invention can be formed from non-petroleum based renewable materials. The compounds... Agent: Ecolab Inc.

20100048731 - Hydroxylated long-chain resveratrol derivatives useful as neurotrophic agents: The present invention relates to a compound of general formula (I) below in which R1, R2 and R3 represent, independently of one another, a hydrogen atom or a C1-C6 alkyl group or a (C1-C6 alkyl)carbonyl group, R4, R5, R6 and R7 represent a hydrogen or a C1-C6 alkyl group, a... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20100048732 - Method of mediating airway smooth muscle construction due to airway irritation: Methods of minimizing bronchospasm and contraction of airway smooth muscle due to irritation of the airway are provided. More particularly, a method is provided of mitigating bronchospasm or airway smooth muscle constriction due to irritation. This method includes administering to a subject in need of such treatment an amount of... Agent: Bryan Cave LLP

20100048733 - Penetration enhancer for fungicides: The invention relates to the field of chemical plant protection, especially the use of a specific compound as a penetration enhancer for agrochemical active ingredients from the group of fungicides and plant protection agents containing said compound. The compound used is tributoxyethyl phosphate (TBEP).... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100048734 - Hydrophilic copolymers and assemblies containing the same: A water soluble copolymer includes first and second hydrophilic block segments or graft chains. The first hydrophilic block segment or graft chain contains cyclodextrin groups in at least a majority of its repeating units, and the second hydrophilic block segment or graft chain contains repeating units other than cyclodextrin groups.... Agent: Julia Church Dierker Dierker & Associates, P.C.

20100048735 - Polyaminoacids functionalized wtih alpha-tocopherol, and uses thereof, especially therapeutic uses: The invention concerns novel biodegradable polyaminoacid materials, useful in particular for vectoring active principles(s). The invention also concerns novel pharmaceutical, cosmetic dietetic or phytosanitary compositions based on said polyaminoacids. The invention aims at providing a novel polymer raw material, capable of being used for vectoring active principles and enabling optimal... Agent: Patton Boggs LLP

20100048736 - Anionic charge-dynamic polymers for release of cationic agents: Materials and methods for the generation of polyelectrolyte multilayers that can erode to release cationic components. The multilayers comprise layers that contain one or more cations and one or more charge-dynamic anionic polymers. Charge-dynamic anionic polymers contain side chains having removable functional groups. Removal of the functional groups results in... Agent: Greenlee Winner And Sullivan P C

20100048737 - Cosmetic preparations based on molecularly imprinted polymers: The present invention relates to cosmetic or dermatological formulations comprising at least one active compound, at least one polymer which is molecularly imprinted in the presence of this active compound and at least one fatty phase.... Agent: Connolly Bove Lodge & Hutz LLP

20100048738 - Hybrid compounds based on polyol(s) and at least one other molecular entity, polymeric or non-polymeric, in particular of the polyorganosiloxane type, process for the preparation thereof, and applications thereof: The invention relates to novel hybrid compounds comprising at least one polyon entity (Po)—for example oligomer or polymer—in which at least one of the hydroxyl functions of Po is substituted by at least one entity A that can be of a variable nature, for example polymer (e.g. polyorganosiloxane-POS), hydrocarbonated or... Agent: Pearne & Gordon LLP

20100048739 - Surface-active material and its applications: There is provided a surface-active material that comprises fibres made of a waxy material, said material having a contact angle at the air/water interface or the oil/water interface between 60° and 120°. The surface-active material can be used for foam and emulsion formation and stabilisation, coatings, encapsulation and drug delivery.... Agent: Unilever Patent Group

20100048740 - Naturally derived emulsifier system: A naturally-derived emulsifier system for use in topically-applied dermatocosmetic products comprising (i) vegetal cholesterol derived semi-synthetically from a plant of the Dioscorea species (D. composite, D. terpinapensis and/or D. villosa) and/or Trillium erectum; (ii) a botanically-derived phospholipid; and (iii) a botanical oil having a fatty acid content of at least... Agent: Louis C. Paul

  
02/18/2010 > patent applications in patent subcategories. patent applications/inventions, industry category

20100041587 - Combination therapy for inhibition of platelet aggregation: The invention features methods for preventing platelet activation and aggregation and for treating individuals suffering from conditions or undergoing procedures that may result in unwanted platelet aggregation. The methods are based on the intravenous, subcutaneous, or transdermal administration of a platelet activation or aggregation inhibitor, e.g., xemilofiban, followed by oral... Agent: Clark & Elbing LLP

20100041588 - Derivatives of apf and methods of use: Derivatives of a novel antiproliferative factor comprising a glycopeptide is disclosed. In specific embodiments, the novel antiproliferative factor is associated with the bladder. Compositions, diagnostic kits and reagents, and methods of using the compounds for identifying and/or treating interstitial cystitis and cancer are disclosed. In particular embodiments, the glycopeptide comprises... Agent: Fulbright & Jaworski, LLP

20100041584 - Gem difluorinated c-glycopeptides, their preparation and their use for the preservation of biological materials and/or in cryosugery: The invention concerns a gem-difluorinated C-glycopeptide compound of formula (I) in which N is an integer between 1 and 5, R4=H, AA1, AA1-AA2 and R5=OH, AA1, AA1.AA2, with AA1, and AA2 are independents and representing amino acids with a non functionalised side chain and R1, R2, R3 are independent groups... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100041586 - Method of improving efficacy of biological response-modifying proteins and the exemplary muteins: Disclosed is a protein variant which substitutes valine for phenylalanine residue in a binding domain having a biological response-modifying function by binding to a receptor, ligand or substrate. Also, the present invention discloses a DNA encoding the protein variant, a recombinant expression vector to which the DNA is operably linked,... Agent: Sheridan Ross PC

20100041585 - Use of oritavancin for prevention and treatment of anthrax: Glycopeptide antibiotics, such as oritavancin, demonstrate significant activity against B. anthracis. Methods for the treatment, prophylaxis and prevention of B. anthracis infection and disease in animals, including humans, are described.... Agent: Roylance Abrams Berdo & Goodman, LLP

20100041590 - Compounds: y

20100041589 - Methods for preparing purified lipopeptides: The present invention relates to crystalline and crystal-like forms of lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against gram-positive bacteria, including strains that are resistant to conventional antibiotics. The present invention relates to methods of purifying lipopeptides, including daptomycin, a lipopeptide antibiotic with potent bactericidal activity against... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100041591 - Hcv protease inhibitors and uses thereof: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.... Agent: Choate, Hall & Stewart LLP

20100041593 - Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy: The present invention relates to the use of a nonimmunosuppressive cyclosporin A derivative for reducing mitochondrial dysfunction and the rate of apoptosis of muscle cells of patients diagnosed with Ullrich congenital muscular dystrophy or Bethlem myopathy.... Agent: Nixon & Vanderhye, PC

20100041592 - Use of amphiphilic biocompatible polymers for solubilization of hydrophobic drugs: The present invention provides polymer aggregates as delivery vehicles for therapeutics and diagnostics. The present invention additionally provides methods of synthesis and uses for such aggregates.... Agent: Dann, Dorfman, Herrell & Skillman

20100041594 - Use of aplidine for the treatment of pancreatic cancer: Aplidine is active against cancer of the pancreas, including metastatic pancreatic cancer.... Agent: Fish & Richardson PC

20100041596 - Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain (plad) of tumor necrosis factor receptors: The present invention provides a polypeptide comprising the isolated amino acid sequence of a pre-ligand assembly domain (PLAD) of a TNF receptor-like receptor. Also provided by this invention is a polypeptide comprising the isolated amino acid sequence of a pre-ligand assembly domain (PLAD), wherein the PLAD is selected from the... Agent: National Institute Of Health C/o Ballard Spahr LLP

20100041595 - Bone morphogenetic protein 3 and osteogenic devices and pharmaceutical products containing thereof: The present invention relates to reindeer bone formation inducing protein called bone morphogenetic protein 3c (BMP-3c), nucleotide molecules encoding the protein and host cells expressing the protein. The present invention relates also to the use of said BMP-3c for treating disorders related to bone and cartilage formation. Osteogenic devices and... Agent: Young & Thompson

20100041599 - Compositions and methods for bone formation, bone remodeling and toxin protection: The present invention identifies compounds that disrupt the interaction between anthrax proteins and LRP5/6 receptors, resulting in a reduction in anthrax toxicity. The compounds act to disrupt the intracellular transport of toxin complexes into a target cell. The present invention also provides methods for testing the effect of compounds on... Agent: Enzo Biochem, Inc.

20100041610 - Insecticidal toxin complex fusion protiens: The subject invention relates to insecticidal toxin complex (“TC”) fusion proteins and to polynucleotides that encode these fusion proteins. In some embodiments, the invention provides a fusion protein comprising a Class A protein, a Class B protein, and a Class C TC protein fused together to form a single protein.... Agent: Baker & Daniels LLP- Dow Agrosciences

20100041600 - Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects: The invention provides methods, nucleic acids, compositions and kits for predicting a subject's outcome with an inflammatory condition and a subject's response to treatment with activated protein C or protein C like compound to identify subjects having a greater benefit from treatment with activated protein C. The method generally comprises... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20100041609 - Interleukin-1 receptor antagonists, compositions, and methods of treatment: Peptides that are designed to inhibit the biological activity of the IL-1R type 1 receptor and inhibit IL-1R/IL-1RacP related cell signaling and biological activity are disclosed. Compositions comprising IL-1R antagonists of the present invention are useful in the treatment of IL-1 related diseases or conditions such as arthritis, rheumatoid arthritis,... Agent: Choate, Hall & Stewart LLP

20100041608 - Method for stimulating wound healing: The present invention relates to a method for stimulating wound healing, and more particularly to a method for stimulating wound healing in a subject in need thereof, comprising administering to a wound of the subject an effective amount for stimulating wound healing of a composition, wherein the composition comprises p43... Agent: Seed Intellectual Property Law Group PLLC

20100041603 - Method of promoting wound healing: The present disclosure relates to methods of administering relaxin to promote wound healing and reduce scar formation. The disclosure further contemplates the use of relaxin in reconstructive and plastic surgery.... Agent: Morrison & Foerster LLP

20100041602 - Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules: The present invention provides use of soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig in the treatment of immune disorders associated with graft transplantation.... Agent: Louis J. Wille Bristol-myers Squibb Company

20100041606 - Methods of use of eggshell polypeptides: Identified herein is an active component of chicken eggshells, which is shown ex-vivo studies to have a stimulating effect on bone building cells (osteoblasts). The substance is a polypeptide mixture extracted from eggshells. It has been discovered herein that a composition comprising eggshell polypeptides stimulates osteoblasts, and has osteoinductive/osteogenic properties,... Agent: Cantor Colburn, LLP

20100041604 - Novel antiviral peptides against influenza virus: The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.... Agent: Patent Docket Department Armstrong Teasdale LLP

20100041597 - Peptides targeted to protein kinase c isoforms and uses thereof: Peptides having a sequence of general formula (I), or the retro form thereof, and having an affinity for one or more mammalian protein kinase C-alpha isoforms are provided: X—[(HY—HB)n-linker]m-(HB—HY)2—HB—(HY)m-Z (I) wherein: HY represents a block of 1 to 4 hydrophobic amino acid residues selected from the group of: Ala, Gly,... Agent: Pillsbury Winthrop Shaw Pittman LLP

20100041611 - Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue: A method for purifying bone-derived osteoinductive proteins including a demineralization process, a protein extraction process, a high molecular weight ultrafiltration process, a low molecular weight ultrafiltration process, and a recover process. The high and low ultrafiltration processes preferably select proteins having a nominal molecular weight between approximately 8 kilodaltons and... Agent: Howrey LLP-hn

20100041607 - Unctuous compositions: The present invention relates to unctuous composition containing at least one solid active ingredient, at least one hydrophobic protective colloid and at least one edible oil. The active ingredient is preferably a carotenoid. The preferred protective colloids are prolamines. The invention compositions are simple to produce, have good bioavailability and... Agent: Connolly Bove Lodge & Hutz, LLP

20100041598 - Use of prolactin in the prophylactic treatment of cancer: The present invention relates to compositions and methods for treating cancer. In particular, the invention describes prolactin containing compositions for the prophylactic treatment of breast cancer.... Agent: Foley And Lardner LLP Suite 500

20100041601 - Use of vegf and homologues to treat neuron disorders: The present invention relates to neurological and physiological dysfunction associated with neuron disorders. In particular, the invention relates to the involvement of vascular endothelial growth factor (VEGF) and homologues in the aetiology of motor neuron disorders. The invention further concerns a novel, mutant transgenic mouse (VEGFm/m) with a homozygous deletion... Agent: Amster, Rothstein & Ebenstein LLP

20100041605 - Use of vegf-c or vegf-d in reconstructive surgery: The present invention provides materials and methods for repairing tissue and using vascular endothelial growth factor C (VEGF-C) genes and/or proteins. Methods and materials related to the use of VEGF-C for the reduction of edema and improvement of skin perfusion is provided. Also provided is are materials and methods for... Agent: Marshall, Gerstein & Borun LLP

20100041612 - Fragments of the glucagon-like peptide-1 and uses thereof: GLP-1 fragments and derivatives thereof are able to interact with and activate the GLP-1 receptor GLP-1 fragments and derivatives thereof are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies that are known to benefit from activation... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100041613 - Novel antibiotic compositions: This invention is directed to antibiotic compositions comprising a targeting moiety covalently linked to an antibiotic moiety. This invention is also directed to pharmaceutical compositions comprising the antibiotic compositions of the invention and methods of making and using the antibiotic compositions of the invention.... Agent: Klarquist Sparkman, LLP

20100041614 - Metastasis-specific peptides and their diagnostic and therapeutic applications: The present invention concerns peptide sequences that specifically recognize cells of human hepatic metastases. The invention comprises also the use of nucleic acids coding for such peptides, as well as conjugates and formulations of such peptides for diagnostic and therapeutic purposes.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100041615 - Protein-binding methotrexate derivatives, and medicaments containing the same: The invention relates to methotrexate derivatives which contain a protein-binding group and can be enzymatically cleaved in the body such that the active substance or a low-molecular active substance derivative is released. Also disclosed is a method for producing methotrexate derivatives, the use thereof, and medicaments comprising methotrexate derivative.... Agent: Knobbe Martens Olson & Bear LLP

20100041616 - Formulations for nonsurgical exogenous crosslink therapy: Improved methods and compositions for the treatment of native tissues with crosslinkers are provided. The methods and compositions will find particular use in increasing resistance to tearing, fissuring, rupturing, and/or delamination.... Agent: Fulbright & Jaworski L.L.P.

20100041617 - Modulating mxa expression: The invention provides compositions and methods for inhibiting cell motility, metastatic cancer and viral infections in a mammal that involve increasing the activity or expression of MxA.... Agent: Schwegman, Lundberg & Woessner, P.A.

20100041618 - 6-11 bridged oxime erythromycin derivatives: which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the... Agent: Elmore Patent Law Group, PC

20100041619 - Lasonolide compounds as reagents for inducing premature chromosome condensation and methods for treating disorders: The present invention is directed towards lasonolide derivatives, methods of inducing premature chromosome condensation using lasonolide derivatives, and methods of treating disorders, such as cancer, in a subject, the method comprising administering to the subject a lasonolide derivative.... Agent: Cantor Colburn LLP - National Institutes Of Health

20100041736 - Isolated mcpip and methods of use: A monocyte chemoattractant protein (MCP-1)-inducible protein, MCPIP, its polynucleotide and amino acid sequences from mouse and human, and methods for its use are disclosed.... Agent: Timothy H. Van Dyke

20100041732 - Methods for identifying compounds that inhibit hiv infection: This invention provides novel methods for identifying agents that inhibit HIV infection. The anti-HIV agents are identified by screening test compounds for ability to down-regulate the kinase activity or the expression of a PAK3 molecule. Such PAK3 modulators can be further examined for their activity in inhibiting HIV infection. These... Agent: Genomics Institute Of The Novartis Research Foundation

20100041735 - Modulation of toll-like receptor 3 expression by antisense oligonucleotides: Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of TLR3. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TLR3. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding TLR3 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100041734 - Modulation of toll-like receptor 7 expression by antisense oligonucleotides: Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of TLR7. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TLR7. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding TLR7 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100041733 - Novel rnai therapeutic for treatment of hepatitis c infection: Small interfering RNAs (siRNAs) or small hairpin RNA (shRNAs) and compositions comprising same are provided that specifically target human cyclophilin A (CyPA) to effectively inhibit Hepatitis C(HCV) infection in a cell. Such siRNA and shRNAs may have a length of from about 19 to about 29 contiguous nucleotides corresponding to... Agent: Vedder Price, PC

20100041740 - Flu vaccines and methods of use thereof: This disclosure is directed, inter alia, to polynucleotides, polypeptides, vectors, cells and compositions comprising the same, and their use in affecting viral pathogenesis, in particular for influenza viral infection.... Agent: Luce, Forward, Hamilton & Scripps LLP

20100041737 - Gene vector: A gene vector comprising a miRNA sequence target.... Agent: Steptoe & Johnson LLP

20100041738 - Hybridization-stabilizing construct: A Z-shaped construct having the capacity to hybridize to double stranded DNA in a trans fashion to affect transcription is produced from at least two oligonucleotides, connected to each other, wherein the oligonucleotides are connected to one another through one of sequence specific Watson-Crick base pairing; a covalent linker or... Agent: Morrison & Foerster LLP

20100041742 - Riboswitches, methods for their use, and compositions for use with riboswitches: It has been discovered that certain natural mRNAs serve as metabolite-sensitive genetic switches wherein the RNA directly binds a small organic molecule. This binding process changes the conformation of the mRNA, which causes a change in gene expression by a variety of different mechanisms. Modified versions of these natural “riboswitches”... Agent: Patent Correspondence Arnall Golden Gregory LLP

20100041741 - Suppression of mitochondrial oxidative stress: Compositions for suppressing and inhibiting mitochondrial oxidative stress. The compositions include a human mitochondrial superoxide dismutase (SOD2) gene. Methods of treating patients suffering from diseases or disorders associated with mitochondrial oxidative stress.... Agent: Gregory A. Nelson Novak Druce & Quigg LLP

20100041739 - Transfection reagent: The present invention relates to a polyalkyleneimine polymer having a repeat unit comprising a hydrophilic group, agents containing the same and methods for their use.... Agent: Crowell & Moring LLP Intellectual Property Group

20100041743 - Transgenic animal with enhanced immune response and method for the preparation thereof: The present invention provides a method for producing a transgenic (Tg) non-human animal capable of developing an enhanced humoral immune response against an antigen as compared to a non-transgenic control animal of the same species, comprising introducing into said non-human animal a genetic construct providing for enhanced MHC class I-related... Agent: Quarles & Brady LLP

20100041620 - Methods for improving frontal brain bioenergetic metabolism: The invention provides methods and compositions for augmenting bioenergetic metabolism in the frontal brain involving administration of a cytidine-containing or uridine-containing compound to a human.... Agent: Clark & Elbing LLP

20100041621 - Methods and compositions for improving cognitive performance: The invention provides methods and compositions for improving cognitive performance involving administration of a cytidine-containing or uridine-containing compound to a neuropsychologically healthy human.... Agent: Clark & Elbing LLP

20100041622 - Compositions containing aminoalkanes and aminoalkane derivatives: Provided are palatable liquid compositions that contain 2-aminoalkanes that have vasoconstrictor activity, and other additives, including taste-modifying agents. Also provided are methods for making and using the compositions to provide stimulant activity for increasing energy, alertness, endurance, and/or any other consequent physical manifestation of the vasoconstrictor activity.... Agent: K&l Gates LLP

20100041623 - Aqueous liquid preparation comprising gatifloxacin: Disclosed is an aqueous liquid preparation comprising (A) gatifloxacin, a pharmacologically acceptable salt thereof or a hydrate gatifloxacin or the salt, (B) hyaluronic acid or a pharmacologically acceptable salt thereof, and (C) a polyhydric alcohol. The aqueous liquid preparation is an ophthalmic aqueous liquid preparation excellent in the retention of... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100041624 - Buprenorphine formulations for intranasal delivery: Aqueous formulations suitable for intranasal administration comprise buprenorphine or a physiologically acceptable salt or ester thereof and (a) a pectin having a degree of esterification of less than 50%, (b) chitosan and a polyoxyethylene-poly-oxypropylene copolymer (poloxamer) or (c) chitosan and hydroxypropylmethylcellulose. Such formulations can induce rapid and prolonged analgesia when... Agent: Nixon & Vanderhye, PC

20100041625 - Pharmaceutical composition comprising cyclodextrin paclitaxel inclusion and preparation method thereof: A pharmaceutical composition comprising cyclodextrin/paclitaxel inclusion, which consists of paclitaxel, cyclodextrin and a pharmaceutically acceptable excipient, wherein the mass ratio of the paclitaxel to cyclodextrin is 1:10-150, the said cyclodextrin is hydroxylpropyl-sulfobutyl-7-β-cyclodextrin, or sulfobutylether-7-β-cyclodextrin, or their mixture; the stability constant of the cyclodextrin/paclitaxel inclusion is Ka=5396M−1−1412M−1. The preparation method of... Agent: Schmeiser, Olsen & Watts

20100041626 - Glycomimetic inhibitors of the pa-il lectin, pa-iil lectin or both the lectins from pseudomonas: Compositions and methods are provided related to Pseudomonas bacteria. The compositions and methods may be used for diagnosis and therapy of medical conditions involving infection with Pseudomonas bacteria. Such infections include Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis. A compound useful in the present methods may be... Agent: Seed Intellectual Property Law Group PLLC

20100041627 - Compositions comprising polymeric emulsifiers and methods of using same: Provided are compositions comprising a polymeric emulsifier, a hydrophobic agent, a wetting agent having at least one sulfonate group and at least one base-neutralizable carboxylic acid group, and a hydrophilic particulate material. Also provided are methods of mitigating diaper dermatitis using the composition, and methods of promoting the benefits associated... Agent: Philip S. Johnson Johnson & Johnson

20100041628 - Novel indole derivative having ikappab kinase beta inhibitory activity: Disclosed is a compound represented by the general formula (1) or a salt thereof. The compound or a salt thereof has an inhibitory activity on IKKβ and is therefore useful as preventive and/or therapeutic agent for a disease associated with IKKβ. In the formula, R1 represents a hydrogen atom, a... Agent: Frishauf, Holtz, Goodman & Chick, PC

20100041629 - Nanoemulsions and processes for their preparation, and their use as formulations of plant protection agents and/or pesticides and/or cosmetic preparations: Nanoemulsions and processes for their preparation, and their use as formulations of plant protection products and/or pesticides and/or cosmetic preparations.... Agent: Frommer Lawrence & Haug

20100041630 - Methods for treating or preventing inflammation using a glycerophosphate salt: Glycerophosphate salts have been found to mitigate the syndromes or conditions of discomfort associated with inflammation. Therefore, methods are provided for treating or preventing an inflammatory condition using a glycerophosphate salt. In particular, methods are provided for treating or preventing an inflammatory condition using calcium glycerophosphate (CGP).... Agent: Panitch Schwarze Belisario & Nadel LLP

20100041631 - Methods and agents for treating tuberculosis: The present invention relates to the treatment of tuberculosis (mycobacterial infections) by the use of KshAB complex inhibitors, or a KstD molecule, or a HsaAB complex, or a HsaC molecule, or a HsaD molecule. The application also includes a method for identifying an inhibitor or modulator of the previously mentioned... Agent: Fenwick & West LLP

20100041632 - Uses of the carboxy-amido-triazole compounds and salts thereof: The present invention relates to new medical use of CAI and its analogs/derivates together with the pharmaceutically acceptable salts thereof. Particularly, the use of CAI and its analogs/derivates, together with pharmaceutically acceptable salts thereof as TNF-α and IL-1β inhibitor and the use of these compounds in preparation of formulations for... Agent: EagleIPLimited

20100041633 - Nitric oxide releasing steroids: The invention relates to nitrooxyderivative of corticosteroids of general formula (I) and pharmaceutically acceptable salts or stereoisomers thereof wherein R is a corticosteroid residue selected from: The compounds are useful in the treatment of respiratory diseases.... Agent: Arent Fox LLP

20100041634 - N-(amino-heteroaryl)-1h-pyrrolopyridine-2-carboxamides derivatives preparation thereof and their use in therapy: e

20100041636 - Novel kinase inhibitors: The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof. The Formula (I) compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2, FGFR-1 and IGFR-1, thereby making them useful as anti-cancer agents. The formula (I) compounds are also useful for the treatment of... Agent: Louis J. Wille Bristol-myers Squibb Company

20100041635 - Oxindole compounds: The invention provides compounds that inhibit PIM kinases and Flt3 kinase, and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation.... Agent: Morrison & Foerster LLP

20100041637 - 1,3-oxazepan-2-one and 1,3-diazepan-2-one inhibitors of 11ß-hydroxysteroid dehydrogenase 1: This invention relates to novel compounds of the Formula (I), (I*), (I**), I, Ia, Ib, Ic, Id, Ie, If, Ig, Il1-3, Im1-3, In1-3, or Io1-2, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11β-HSD1... Agent: Foley & Lardner LLP

20100041638 - Chemical compounds 293: i

20100041639 - Cyclic malonamides as inhibitors of a beta protein production: to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of... Agent: Kelley Drye & Warren LLP

20100041640 - Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it:

20100041641 - Uses of metabotropic glutamate receptors: The invention concerns the use an mGluR modulator, e.g. an mGluR5 modulator, for the treatment, prevention or delay of progression of cognitive dysfunction.... Agent: Novartis Corporate Intellectual Property

20100041642 - Urea inhibitors of map kinases: Urea containing compounds that inhibit MAP kinases, pharmaceutical compositions including such compounds and methods for using these compounds to treat inflammatory diseases and cancer are described herein.... Agent: Pepper Hamilton LLP

20100041643 - Thienotriazolodiazepine compound and medicinal use thereof: e

20100041644 - Stabilized solid pharmaceutical composition of candesartan cilexetil: The present invention relates to a solid pharmaceutical composition containing candesartan cilexetil as active ingredient and a stabilizing agent selected from the group consisting of esters of saturated fatty acids and monohydroxy alcohols, esters of hydroxycarboxylic acids and monohydroxy alcohols, ethers of C1-C4 monohydroxy alcohols and C2-C9 polyhydroxy alcohols, saturated... Agent: Berenbaum Weinshienk PC

20100041645 - Rho kinase inhibitors: Substituted amide and urea derivatives useful as inhibitors of Rho kinase are described, which inhibitors can be useful in the treatment of various disorders such as cardiovascular diseases, cancer, neurological diseases, renal diseases, bronchial asthma, erectile dysfunction and glaucoma.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100041646 - Phenylene-bis-oxazolidine derivatives and their use as anticoagulants: The present application relates to novel 1,4-phenylene-bis-oxazolidine derivatives, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular thromboembolic disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100041647 - 3-substituted-[1,2,3]-benzotriazinone compounds for enhancing glutamatergic synaptic responses: This invention relates to the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for higher order behaviors. These brain networks are involved in cognitive abilities related to memory impairment, such as is observed in a variety of dementias and in imbalances... Agent: Coleman Sudol Sapone, P.C.

20100041648 - Methods for treating retroviral infections: The present invention provides compositions for treating an HIV infection comprising administering a compound according to formula I where Ar, R1-R5, R11c and X1 are as defined herein with at least one carrier, excipient or diluent.... Agent: Grant D. Green Patent Law Department, M/s A2-250

20100041649 - Inhibitors of papilloma virus: e

20100041650 - Purine compounds as cannabinoid receptor blockers: The present invention relates to purine-based cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, dyslipidemias, cardiovascular disorders, inflammatory disorders, hepatic disorders, and a combination thereof.... Agent: Vance Intellectual Property, PC

20100041651 - Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof: e

20100041652 - Tyrosine kinase inhibitors: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises an indole-sulfonamide moiety. The present invention is also related to the pharmaceutically acceptable salts,... Agent: Merck And Co., Inc

20100041653 - Composition and methods for the design and development of metallo-enzyme inhibitors: This disclosure further provides a focused library of compounds for use in the discovery and design of metallo-enzyme inhibitors. This fragment-based approach provides an assembly of a library of low molecular weight compounds (MW<300 Da) containing a variety of potential metal-chelating groups. The identification of the inhibitory scaffolds among these... Agent: Dla Piper LLP (us)

20100041654 - Pyrimidine derivatives and their use as cb2 modulators: This relates to novel pyrimidine derivatives, pharmaceutical compositions containing these compounds and their use in the treatment of diseases, particularly pain, which diseases are caused directly or indirectly by an increase or decrease in activity of the cannabinoid receptor.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100041655 - Triazole derivative: (where A represents an oxygen atom, a sulfur atom, a group represented by Formula —SO—, a group represented by Formula —SO2— or the like, R1 represents a hydrogen atom, an alkyl group having 1-6 carbon atoms, or the like, R1A represents a hydrogen atom or the like, R2 represents an... Agent: Sughrue Mion, PLLC

20100041656 - Novel amide derivatives and medicinal use thereof: The above-mentioned amide derivative, an optically active form thereof and a pharmaceutically acceptable salt thereof are promising as an agent for the treatment or prophylaxis of diseases or syndromes caused by inflammation caused by C5a [e.g., autoimmune diseases such as rheumatism, systemic lupus erythematosus and the like, sepsis, adult respiratory... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100041657 - Haloalkylsulfone substituted compounds useful for treating obesity and diabetes: The present invention relates to compounds of formula I, in which at least one of R5, R6 and R7 is SR12, S(O)R12 or S(O)2R12 group where R12 is a C1-6haloalkyl group, that act, as chemical uncouplers. Compounds of the invention are useful in the treatment, including prevention, of obesity, diabetes... Agent: High Point Pharmaceuticals, Inc.

20100041658 - Hydroxyphenyl derivatives and biological applications thereof: The invention relates to hydroxyphenyl derivatives of formula (I); and uses thereof as anti-bacterial and/or anti-parasitic agents.... Agent: Nixon & Vanderhye, PC

20100041659 - Compositions for the control of plant pests: e

20100041660 - Novel 2-pyridinecarboxamide derivatives:

20100041661 - Caspase inhibitors based on pyridazinone scaffold: The present invention relates to a pyridazinone derivative which can be used as a caspase inhibitor, process for the preparation thereof, and pharmaceutical composition for inhibiting caspase comprising the same.... Agent: Birch Stewart Kolasch & Birch

20100041664 - Bicyclic lactam factor viia inhibitors useful as anticoagulants: e

20100041662 - Heterocyclic compounds as antiinflammatory agents: A compound of Formula Ia or Ib in free or salt or solvate form, where R1, R2, R3, R4, R5 R20, R24, R25, X, Y and Z have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. These compounds are... Agent: Novartis Institutes For Biomedical Research, Inc.

20100041663 - Organic compounds as smo inhibitors: The present invention relates generally to novel compounds relating to the diagnosis and treatment of pathologies relating to the Hedgehog pathway, including but not limited to tumor formation, cancer, neoplasia, and non-malignant hyperproliferative disorders. The present invention includes novel compounds, novel compositions, methods of their use and methods of their... Agent: Novartis Institutes For Biomedical Research, Inc.

20100041665 - N-phenyl-prenylamine derivatives for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders: The present invention is related to a family of N-phenyl-prenylamine derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or Parkinson's Disease. The present invention also relates to pharmaceutical compositions comprising the same. Further, the present... Agent: Hoffmann & Baron, LLP

20100041666 - Use of n-phenyl-2-pyrimidineamine derivativea against mast cell-based diseases like allergic disorders: in which the symbols and substituents have the meaning as given herein in free form or in pharmaceutically acceptable salt form in the manufacture of a pharmaceutical composition for the treatment of anergic rhinitis, allergic dermatitis, drug allergy or food allergy, angioedema, urticaria, sudden infant death syndrome, bronchopulmonary aspergillosis, multiple... Agent: Novartis Corporate Intellectual Property

20100041669 - 4-(heterocyclyl)alkyl-n-(arylsulfonyl)indole compounds and their use as 5-ht6 ligands: Compounds including 4-(Heterocyclyl)alkyl-N-(arylsulfonyl)indole compounds of the formula (I), their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them as well as a process for the preparation of these compounds, their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. These compounds are... Agent: Iphorgan, Ltd.

20100041670 - Triazolopyridine carboxamide derivatives and triazolopyrimidine carboxamide derivatives, preparation thereof and therapeutic use thereof: m

20100041671 - Methods for treating glaucoma: A method for treating glaucoma comprising administering to a patient pharmaceutically effective amounts of a Rho kinase inhibitor and a prostaglandin.... Agent: Frishauf, Holtz, Goodman & Chick, PC

20100041672 - Use of quinoline derivatives in the treatment of pain and irritable bowel syndrome: m

20100041668 - Compositions and methods for treating thrombocytopenia: The present invention in certain embodiments is directed to a pharmaceutical dosage form comprising a therapeutically effective amount of a first agent that agonizes a human TPO receptor by binding to the rhTPO binding site of the human TPO receptor; and a therapeutically effective amount of a second agent that... Agent: Davidson, Davidson & Kappel, LLC

20100041667 - Piperidine and pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease: which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of... Agent: Merck And Co., Inc

20100041673 - 5-(heterocyclyl)alkyl-n-(arylsulfonyl)indole compounds and their use as 5-ht6 ligands: Compounds including 5-(Heterocyclyl)alkyl-N-(arylsulfonyl)indole, their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them and a process for the preparation of these compounds, their derivatives, their stereoisomers, their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. These compounds are useful in the treatment of various disorders... Agent: Iphorgan, Ltd.

20100041674 - Hcv protease inhibitors and uses thereof: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.... Agent: Choate, Hall & Stewart LLP

20100041675 - Methods for the use of pyrimidine derivatives which are antagonists of vitronectin receptor: e

20100041676 - Kinase inhibitors:

20100041678 - Compositions and methods for treating inflammatory disorders: The present disclosure relates to methods of treating inflammatory disorders by administering a Syk inhibitory 2,4-pyrimidinediamine compound and a second agent.... Agent: Rigel Pharmaceuticals, Inc. Bozicevic, Field & Francis LLP

20100041677 - Inhibitors of bruton's tyrosine kinase: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination... Agent: Wilson, Sonsini, Goodrich & Rosati

20100041679 - Oral dieting composition comprising conjugated linoleic acid and caffeine: The invention relates to a dieting composition for oral administration, comprising a mixture of conjugated linoleic acid and caffeine as active ingredient and an acceptable support for oral administration.... Agent: Alston & Bird LLP

20100041680 - Piperidine derivatives: Compounds of formula I: I selectively inhibit production of Ab(1-42) and hence find use in treatment of Alzheimer's disease and other conditions associated with deposition of A(b) in the brain.... Agent: Merck And Co., Inc

20100041681 - 2-amino pyrimidine compounds as potent hsp-90 inhibitors: m

20100041683 - Novel chain-breaking antioxidants: Compounds, preferably 5-pyrimidinol and 3-pyridinol derivatives, that act as effective chain breaking antioxidants of both the lipid and water-soluble variety (analogous to the natural Vitamins E and C), many of which are more reactive toward peroxyl radicals than the most potent form of Vitamin E. These compounds may exhibit many... Agent: Stites & Harbison PLLC

20100041682 - Ternary pesticidal mixtures: Ternary pesticidal mixtures comprising, as active components, an anthranilamid compound of the formula (I) wherein the variables are defined according to the description, and two fungicidal compounds II and III selected from the following groups: azoles, strobilurins, carboxamides, heterocylic compounds, carbamates, guanidines, antibiotics, nitrophenyl derivates, sulfur-containing heterocyclyl compounds, organometal compounds... Agent: Brinks, Hofer, Gilson & Lione

20100041684 - Pyrimidyl derivatives as protein kinase inhibitors: Objects of the present invention are the compounds of formula (I), their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100041686 - 4,5-dihydro-oxazol-2yl derivatives: R1, R2, X, Y, and n are defined in the specification and to pharmaceutically acceptable acid addition salts thereof. The invention also provides pharmaceutical compositions and methods of manufacture of such compounds. The compounds are useful for the treatment of diseases related to the biological function of the trace amine... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100041685 - Stat3 inhibitors: Small molecule inhibitors of Stat3 and their derivatives are disclosed. Also described are methods to inhibit cell growth by use of Stat3 inhibitors, and the use of Stat3 inhibitors for the prevention and/or treatment of cancer. Further, inhibitors of Stat3 that also do not inhibit Stat1 are described as well... Agent: Fulbright & Jaworski, LLP

20100041687 - Hydrobromide salt of an anti-hiv compound: Solid dispersions and dosage forms comprising the hydrobromide salt of a diarylpyrimidine derivative, useful as an anti-HIV agent.... Agent: Philip S. Johnson Johnson & Johnson

20100041688 - Revaprazan-containing solid dispersion and process for the preparation thereof: The present invention provides a solid dispersion in which revaprazan particles are surface-modified with a water-soluble polymer, a water-soluble saccharide, a surfactant, or a mixture thereof and a process for preparing the same. The present invention also provides a pharmaceutical composition containing the solid dispersion and a process for preparing... Agent: Sughrue Mion, PLLC

20100041689 - Combined effects of topiramate and ondansetron on alcohol consumption: The present invention provides for the use of combinations of drugs to treat addictive disorders. More specifically, the present invention relates the use of drugs in conjunction with behavioral intervention to treat alcohol-related diseases and disorders as well as treatment of obesity and regulating weight.... Agent: University Of Virginia Patent Foundation

20100041690 - Co-administration of dopamine-receptor binding compounds: Methods for treating a patient having neurological, psychotic, and psychiatric disorders are described comprising the steps of administering to the patient an effective amount of a partial and/or full dopamine D1 receptor agonist, and administering to the patient an effective amount of a dopamine D2 receptor antagonist, Pharmaceutical compositions comprising... Agent: Morgan, Lewis & Bockius LLP

20100041691 - Pharmaceutical compositions comprising combinations of an ampa/kainate antagonistic compound and an inhibitor of a multidrug resistance protein: This invention relates to pharmaceutical compositions comprising a combination of an AMPA/kainate antagonistic compound and an inhibitor of a multidrug resistance protein and its use for combating epileptic disorders.... Agent: Birch Stewart Kolasch & Birch

20100041692 - Pyrrolo[4,3,2-de]quinolin-8-amine compounds and methods of their preparation and use: i

20100041694 - Agricultural composition for controlling or preventing plant diseases caused by plant pathogenic microbes:

20100041693 - Indolylmaleimide derivatives:

20100041695 - Thieno[2,3-b]pyridines as potassium channel inhibitors:

20100041696 - Compounds:

20100041697 - Pneumonia treatment: This invention relates to a method of treating pneumonia by orally administering to a subject in need thereof a quinolone compound of formula (I), shown in the disclosure, at a daily dose of 2-30 mg/kg.... Agent: Occhiuti Rohlicek & Tsao, LLP

20100041698 - Heterocyclic compounds and their use as binding partners for 5-ht5 receptors: The invention relates to compounds of general formula (I), corresponding enantiomeric, diastereomeric and/or tautomeric forms thereof as well as pharmaceutically acceptable salts thereof and the prodrugs of said compounds. The invention also relates to the use of said compounds as binding partners for 5-HT5 receptors for treating diseases that are... Agent: Abbott Laboratories C/o Polsinelli Shughart PC

20100041699 - Microcrystalline (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid: The invention relates to a microcrystalline form of a compound which is an inhibitor of PGD2 at the CRTH2 receptor. The microcrystalline form is obtained from a simple chemical reaction without the need for a milling process.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100041700 - Substituted 1-(azolin-2-yl)-amino-1,2-heterocyclyl-ethane compounds for combating pests: The present invention relates to 1-(Azolin-2-yl)-amino-1,2-heterocyclyl-ethane compounds, which are useful for combating insects, arachnids and nematodes. The present invention also relates to methods for combating animal pests and to compositions for combating animal pests. It has been found that animal pests can be combated by 1-(Azolin-2-yl)-amino-1,2-heterocyclyl-ethane compounds of the general... Agent: Brinks, Hofer, Gilson & Lione

20100041701 - Biphenyl compounds useful as muscarinic receptor antagonists: wherein a, b, c, d, n, R1, R2, R3, R6, R7, W, and A are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of using such... Agent: Theravance, Inc.

20100041702 - Benzimidazole cannabinoid agonists: The present invention is related to novel benzimidazole compounds of Formula (I) having cannabinoid receptor agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals, in particular humans.... Agent: Philip S. Johnson Johnson & Johnson

20100041703 - Rapid disintegration monolayer film for the oral administration of active substances: Rapid-disintegration monolayer film for the oral administration of active substances, comprising a water-soluble support containing at least one active substance, characterized in that it comprises a polymeric mixture of a hydrophilic film-forming agent formed from a copolymer of polyvinyl alcohol and of polyethylene glycol (PVA-PEG), of an active substance and... Agent: Birch Stewart Kolasch & Birch

20100041704 - Dermal compositions of substituted amides and the use thereof as medication for pain and pruritus: Dermal compositions comprising topical formulations of bupivacaine or ropivacaine, characterized by effective dermal absorption and long duration of dermal anesthetic activity, and intended for use in patients suffering from pruritus and dermal pain, including neuropathic pain, are provided. Compositions containing both bupivacaine and capsaicin are provided. Methods of alleviating pain... Agent: Nields, Lemack & Frame, LLC

20100041706 - Compounds 501: The present invention relates to a novel crystalline form of 4-(5-{(1R)-1-[5-(3-chlorophenyl)isoxazol-3-yl]ethoxy}-4-methyl-4H-1,2,4-triazol-3-yl)pyridine. Further, the present invention also relates to the use of the novel crystalline form for the treatment of gastrointestinal disorders, pharmaceutical compositions containing it as well as processes for the preparation of the novel crystalline form.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100041707 - Inhibitors of ion channels: Compounds, compositions and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides heterocyclic aryl sulfonamides, compositions and methods that are useful in the treatment of central or peripheral nervous system disorders, particularly... Agent: Townsend And Townsend And Crew, LLP

20100041708 - N-phenylarylsulfonamide compound, pharmaceutical composition comprising the compound as active ingredient, synthetic intermediate for the compound and process for it's preparation: (R1 is COOH etc.; R2 is hydrogen, methyl, etc.; R3 and R4 are a combination of methyl and methyl, etc.; R5 is isopropyl etc.; Ar is thiazolyl, pyridyl, 5-methyl-2-furyl each optionally substituted with methyl; n is zero or 1), a synthetic intermediate for the compound and a process for its... Agent: Sughrue-265550

20100041705 - Organic compounds: 1

20100041709 - Substituted n-(4-cyano-1h-pyrazol-3-yl)methylamine derivatives, preparation thereof and therapeutic use thereof:

20100041710 - Penetration enhancer for insecticides: Methods for enhancing penetration of agrochemical active substances through the cuticle of a plant are disclosed. Also disclosed are compositions comprising at least one penetration enhancer.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100041711 - Urea glucokinase activators: This application relates to novel urea glucokinase activators and use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes. Further encompassed is a pharmaceutical composition comprising a compound according to the invention and a... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100041712 - Substituted imidazole combinations: This invention relates to a composition comprising a combination of a) an alpha substituted 2-benzyl substituted imidazole and b) a 1-N-arylpyrazole, and optionally c) an insect growth regulator, and their use as a parasiticide in mammals.... Agent: Pharmacia & Upjohn

20100041713 - Substituted aminotetralines: and pharmaceutically acceptable salts and esters thereof, wherein R1-R4 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100041714 - Bi-aryl aminotetralines: and pharmaceutically acceptable salts and esters thereof, wherein R1-R5, A, B, Q, W, and X are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100041715 - Sphingosine-1-phosphate (s1p) receptor antagonists and methods for use thereof: The invention provides certain well-defined benzamides that are useful as sphingosine-1-phosphate antagonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with modulation of sphingosine-1-phosphate receptors.... Agent: Allergan, Inc.

20100041717 - N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases: Compounds of formula (Ia) and (Ib), wherein A, B, C, R1and R14 are described herein.... Agent: Louis J. Wille Bristol-myers Squibb Company

20100041716 - Nitroxides for use in treating or preventing hypercholesterolemia: Pharmaceutical compositions are provided that are useful in treating hypercholesterolemia. The compositions comprise a pharmaceutically acceptable carrier, and an effective therapeutic or prophylactic amount of a nitroxide antioxidant that alters the expression of one or more genes related to hypercholesterolemia. Methods are also provided for the use of the pharmaceutical... Agent: Knobbe Martens Olson & Bear LLP

20100041718 - Pesticidal compositions: A pesticidal composition comprising a pesticide, an ammonium salt, and a nonionic surfactant, is provided.... Agent: Dow Agrosciences LLC

20100041719 - Mitotic kinesin inhibitors and methods of use thereof: This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment of various disorders.... Agent: Viksnins Harris & Padys Pllp

20100041720 - Novel compounds as cannabinoid receptor ligands: i

20100041721 - Selective androgen receptor modulators: This invention provides compounds of formulas I, Ia, Ib, Ic, Id, Ie, If or Ig or salts thereof, pharmaceutical compositions comprising a compound of formulas I, Ia, Ib, Ic, Id, Ie, If or Ig and a pharmaceutically acceptable excipient, methods of modulating the androgen receptor, methods of treating diseases beneficially... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100041722 - Organic compounds: i

20100041723 - Thiazole compound (as ppar delta) ligand and pharmaceutical, cosmetic and health food comprised thereof: The present invention relates to a thiazole compound as a peroxisome proliferator activated receptor δ (PPARδ) activator or pharmaceutically acceptable salts thereof, and a pharmaceutical composition, a functional cosmetic composition, a health food, health beverages, a food additive and animal feeds containing the same.... Agent: The Webb Law Firm, P.C.

20100041724 - Process for synthesizing a cetp inhibitor: An efficient process is disclosed for producing a compound that is an inhibitor of CETP. The last step of the process is the coupling of an oxazolidinone derivative with a biphenyl moiety to provide a compound of formula (I). In a specific embodiment of this synthesis, a crystalline product is... Agent: Merck And Co., Inc

20100041725 - Stable pharmaceutical composition: or a salt thereof, and a pharmaceutically acceptable carrier, wherein the composition does not substantially contain a reducing sugar and/or a carrier containing a reducing sugar as an ingredient as the pharmaceutically acceptable carrier, or when the composition contains a reducing sugar and/or a carrier containing a reducing sugar as... Agent: Birch Stewart Kolasch & Birch

20100041726 - Inhibitors of akt activity: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20100041727 - Crystalline modification of fipronil: The present invention relates to a crystalline modification of fipronil, to process for the preparation of the same, to pesticidal and parasiticidal mixtures and compositions comprising said crystalline modification and to their use for combating pests and parasites.... Agent: Brinks, Hofer, Gilson & Lione

20100041728 - Hcv inhibiting macrocyclic phenylcarbamates: e

20100041729 - Dithiolopyrrolones compounds and their therapeutic applications: The present invention provides dithiolopyrrolone compounds of the general formula I, and their salts, wherein A is sulfur or carbon, and R1, R2, and R3 are selected from groups defined herein, and wherein when A is sulfur, then B is oxygen, and n=1 or 2, and when A is carbon,... Agent: Oyen, Wiggs, Green & Mutala LLP 480 - The Station

20100041730 - Alkylated heterocyclic reaction products useful as antioxidants: This invention relates to novel macromolecular compositions having oxidation inhibition characteristics that are exhibited when added to organic material normally susceptible to oxidative degradation in the presence of air or oxygen, such a petroleum products, synthetic polymers, and elastomeric substances.... Agent: Albemarle Corporation Patent Department

20100041731 - Solid states of atorvastatin potassium: Atorvastatin potassium crystalline Forms A, B, E, F, and G are provided. Also provided are methods of preparing atorvastatin potassium crystalline Forms A, B, E, F, and G. Atorvastatin potassium crystalline Forms A, B, E, F, and G may be used to prepare pharmaceutical compositions useful for the treatment of... Agent: Kenyon & Kenyon LLP

20100041744 - Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof: Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof solubilizing paclitaxel in an oily contrast medium. The composition of the present invention solubilizes paclitaxel and has an advantage of delivering anticancer drug to the target cells by chemoembolization since it is possible to visualize the blood vessel during... Agent: Buchanan, Ingersoll & Rooney PC

20100041745 - Aigialomycin d and derivatives thereof and their use in treating cancer or malaria or a microbial infection: The invention describes a process for making compound (2), comprising the step of cyclising diene (3). Compound (2) may be aigialomycin D or a derivative thereof or may be elaborated to make aigialomycin D or derivative thereof. Furthermore compound (2) or derivative thereof can be used in treating cancer or... Agent: Fenwick & West LLP

20100041746 - Novel use of organic compounds: The present invention refers to compounds of the general formulae Ia to Ie as defined above for use as/in a composition (especially foods and dietary supplements, cosmetic, as well as pharmaceutical compositions) for the prevention and improvement of muscular disorders and for the improvement of muscle function. Other fields of... Agent: Nixon & Vanderhye, PC

20100041747 - Use of certain chemical compounds for the inhibition of the peptidyl-prolyl cis/trans isomerase activity of cyclophilins: The present invention relates to the use of certain spiro, ketone and carboxylic acid compounds for the inhibition of the peptidyl-prolyl cis/trans isomerase activity of cyclophilins and the use of these compounds for the production of a cosmetic or pharmaceutical composition for the promotion of hair growth or for the... Agent: Connolly Bove Lodge & Hutz LLP

20100041748 - Fatty acid acetylated salicylates and their uses: The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.... Agent: Wilmerhale/boston

20100041749 - Organo-arsenoxide compounds and use thereof: The present invention relates to organo-arsenoxide compounds and to methods for their synthesis. The invention also relates to pharmaceutical compositions comprising these compounds and to their use in the treatment of diseases and disorders, in particular proliferative diseases and disorders, including treatment of solid tumors and leukaemia.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100041750 - Ester compound and use thereof: e

20100041751 - Method to reduce oxidative damage and improve mitochondrial efficiency: Methods for the reduction of mitochondrial oxidative damage and improved mitochondrial efficiency in an animal by administration of medium chain triglycerides or prodrug of medium chain triglycerides to the animal are provided.... Agent: Swanson & Bratschun, L.L.C.

20100041753 - Inhibition of biofilm formation: The present invention relates to compositions and methods for reducing or inhibiting biofilm comprising modulating expression of a cysB gene in a cell. The invention also provides methods for modulating the expression of a cysB, cysD, cysI, cysJ, cysK, and ybiK. The invention further provides methods for identifying gene(s) involved... Agent: Gallop, Johnson & Neuman, L.c.

20100041752 - Production of peracids using an enzyme having perhydrolysis activity: A method is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity derived from Bacillus sp. to produce peroxycarboxylic acids.... Agent: Potter Anderson & Corroon LLP Attn: Janet E. Reed, Ph.d.

20100041754 - Novel natural oil gels and their application: The invention is an article of manufacture, comprising a blend of: (A) from 1 to 50 weight percent of at least one block copolymer, wherein the block copolymer has at least one polystyrene block and at least one unsaturated rubber segment; and (B) from 99 to 50 weight percent of... Agent: Gearhart Law, LLC

20100041755 - Fatty acid treatment for cardiac patients: A method of treating patients in need of treatment for a cardiac disorder has been found which comprises administering to the patient a seven carbon fatty acid compound or derivative thereof, wherein the compound or derivative thereof is able to readily enter the mitochondrion without special transport enzymes. A dietary... Agent: Chalker Flores, LLP

20100041756 - method of modulating b cell functioning: The present invention relates generally to a method of modulating cellular functioning. More particularly, the present invention relates to a method of modulating B cell functioning, for example B cell proliferation, utilising an IDO-mediated tryptophan metabolite as herein defined (particular examples of such IDO-mediated tryptophan metabolites include 3-hydroxykynurenic acid, 3-hydroxyanthranilic... Agent: Wilson, Sonsini, Goodrich & Rosati

20100041757 - N-aryl-hydroxyalkylidene-carboxamide compounds and their use: This disclosure generally relates to chemicals that affect sensory processes. More particularly, this present invention relates to peripheral sensory compounds (including, e.g., 2-Isopropyl-5-methyl-cyclohexanecarboxylic acid [2′-hydroxy-2′-(3″-hydroxy-phenyl)-ethyl]-N-methyl-amide) that are useful in sensory refreshment, inhibit the perception of itch and pain, and alleviation of skin irritation, itch, and pain. These compositions have surprising... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100041758 - Adhesive preparation: An adhesive preparation which has a pressure-sensitive adhesive layer comprising two components, i.e., a C1-4 alcohol ester of 4-{[2-((1R,2R,3R)-3-hydroxy-2-{(1E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl}-5-osocyclopentyl)ethyl]sulfanyl}butanoic acid and a silicone-based pressure-sensitive adhesive. This is an effective and safe preparation which is stable, shows little change in skin permability and release a drug not rapidly but continuously.... Agent: Sughrue-265550

20100041759 - Multi-phase release potassium guaiacolsulfonate compositions: Formulations have been developed administering a guaiacolsulfonate salt, preferably potassium salt, in multi-phases. In a preferred embodiment, the formulation contains potassium guaiacolsulfonate in an immediate release (“IR”) form and a sustained or delayed release (“DR”) form and/or pulsed release (“PR”) form. In another embodiment, the potassium guaiacolsulfonate is released in... Agent: Sheridan Ross PC

20100041760 - Monoaryl aminotetralines: and pharmaceutically acceptable salts and esters thereof, wherein R1, R2 and R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100041761 - New halo active aromatic sulfonamide organic compounds and odor control uses therefor: Aromatic N-halosulfonamide organic compounds have been known for over one hundred years. The ability of these compounds to release active halogen ions has been utilized in a range of biocidal and fungicidal applications. The most widely used halogen sulfonamide organic compound for these applications is Chloramine-T. This invention deals with... Agent: Fay Sharpe LLP

20100041762 - Substituted fused-ring compounds for inflammation and immune-related uses: o

20100041763 - Salicylamide derivatives as nicotinic alpha 7 modulators:

20100041764 - Therapeutic agent for diabetic neuropathy: A therapeutic agent for the treatment of diabetic neuropathy which comprises (±)-[2-[4-(3-ethoxy-2-hydroxypropoxy)phenylcarbamoyl]-ethyl]dimethylsulfonium p-toluenesulfonate of the formula (1) as an active ingredient.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100041765 - High concentration local anesthetic formulations: A transdermal topical anesthetic formulation, which can be used to ameliorate or inhibit pain, has been developed. In the preferred embodiment, the topical anesthetic is a local anesthetic such as lidocaine, most preferably lidocaine free-base in a gel, and the dosage of the local anesthetic is effective in the painful... Agent: Pabst Patent Group LLP

20100041766 - Medthods, devices and formulations for targeted endobronchial therapy: The present invention provides an improved means of treating tracheobronchitis, bronchiectasis and pneumonia in the nosocomial patient, preferably with aerosolized anti gram-positive and anti-gram negative antibiotics administered in combination or in seriatim in reliably sufficient amounts for therapeutic effect. In one aspect, the invention assures this result when aerosol is... Agent: Medlen & Carroll, LLP

20100041767 - Stabilized compositions of volatile alkylating agents and methods of using thereof: A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the Nitrogen Mustard or the HX salt of the Nitrogen Mustard is in a non-aqueous vehicle or carrier that does not include... Agent: Gfd Patents, LLC

20100041768 - Composition and method of adipose cell differentiation inhibition: The present invention is related to a composition and method of adipose cell differentiation inhibition.... Agent: Wpat, PC Intellectual Property Attorneys

20100041769 - Stable and ready-to-use oil-in-water propofol microemulsion: e

20100041770 - Polymer-ceramic composite and method: Methods and devices are shown for a composite material that is easily applied to a surface such as a bone defect in need of filling or reinforcement, etc. The composite material provides good mechanical properties such as compressive strength upon curing in the presence of water. Selected materials and methods... Agent: Schwegman, Lundberg & Woessner / Synthes

20100041771 - Bioreponsive polymers: The invention features biodegradable polymers for the delivery of biologically active agents. The polymers include at least one biologically active agent covalently attached via a polyamide linker susceptible to selective hydrolysis by peptidase enzymes. Hydrolysis of the polyamide linker releases the biologically active agent in vivo.... Agent: Clark & Elbing LLP

20100041772 - Sprayable liquid emulsion polymer coating compositions: Sprayable liquid emulsion polymer coating compositions comprised of polymer resin and a plurality of additives for the purpose of protecting, restoring, reconditioning, rejuvenating, and enhancing the color, luster and durability of a multitude of different newer and older substrate types. These coating and sealing compositions are anti-mold, anti-graffiti, they withstand... Agent: Robert Richard Liversage

20100041773 - Disruptors of early/recycling endosomes: A delivery system for introducing a cargo molecule into cytosol of a living cell can include: a first membrane binding element linked to an endosomal compartment disrupting element through a first linker having one or more anionic moieties; and a second membrane binding element linked to an exogenous cargo molecule... Agent: Workman Nydegger 1000 Eagle Gate Tower

20100041774 - Chemical compositions for skin care emulsions and heavy duty hand cleansers: The present invention provides preservative compositions suitable for replacing, partially or in totality, conventional preservatives in skin care emulsions and heavy duty hand cleansers comprised of alternative molecular compounds than found in conventional preservative formulations. The preservative formulation for skin care formulations includes a fatty acid and/or ester of fatty... Agent: Dowell & Dowell P.C.

  
02/11/2010 > patent applications in patent subcategories. patent applications/inventions, industry category

20100035793 - Modulators: Use of a composition that modulates a STAT in the manufacture of a medicament for treating or preventing a fibroproliferative disease. The fibroproliferative disease may comprise keloid scarring. The composition may modulate one or more of; activity; phosphorylation; level of expression; or sub-cellular localisation of the STAT. The STAT may... Agent: Jacobson Holman PLLC

20100035794 - Use of ultrarapid acting insulin: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.... Agent: K&l Gates LLP

20100035795 - Use of ultrarapid acting insulin: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.... Agent: K&l Gates LLP

20100035796 - 17-alpha-substituted derivatives of estradiol with wound-healing activity: The invention relates to 17α-(5-hydroxy-C5-hydrocarbyl)-1,3,5(10)-estratrien-3,17β-diol derivatives having cicatrising activity, preferably for topical use on wounds, without significant systemic effects, and to pharmaceutical compositions containing them. In particular, the invention relates to estradiol 17α-(5-hydroxypentyn-1-yl)derivatives and 3-esters, 5′-esters and 3,5′-diesters thereof and to a process for the preparation thereof by reaction of... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20100035798 - Methods and compositions for the topical oxygenation of hypoxic tissue: The invention provides methods, delivery devices, and compositions for topically oxygenating hypoxic tissue with a hemoglobin-based oxygen earner (HBOC), such as Oxyglobin (Oxyb) in order to promote wound healing and/or reducing hypoxia in post-harvest transplant tissue. The invention can be used, among other things, to stimulate angiogenesis and blood flow... Agent: Calfee Halter & Griswold, LLP

20100035797 - Nitric oxide-blocked cross-linked tetrameric hemoglobin: The present invention includes compositions containing carboxamidomethylated cross-linked hemoglobin where the cysteine moiety of the hemoglobin includes a thiol protecting group and where the hemoglobin has a reduced ability to bind with nitric oxide. Preferably, the hemoglobin is deoxygenated, endotoxin free, and stroma free. The present invention also includes method... Agent: Wilson, Sonsini, Goodrich & Rosati

20100035799 - Method for the synthesis of anthracycline-peptide conjugates: wherein R1 represents OH, NH2 or NH-peptide; R2 represents H or —CO-peptide; R3 represents OCH3, OH or H; R4 represents H, or COCF3; R5 represents OH, O-tetrahydropyranyl or H; R6 represents OH or H; R7 represents H, OH, OCO(CH2)3CH3 or OCOCH(OC2H5)2; R8 represents OH or H; R9 represents OH or... Agent: Knobbe Martens Olson & Bear LLP

20100035801 - Method for accelerating cutaneous barrier recovery: A method for accelerating cutaneous barrier recovery by inducing efflux of potassium ion from an epidermal cell as well as a method for preventing epidermal hyperplasia induced by inducing efflux of potassium ion from an epidermal cell are provided.... Agent: Fish & Richardson PC

20100035800 - Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof: In accordance with the present invention, there are provided compositions and methods useful for the in vivo delivery of substantially water insoluble pharmacologically active agents (such as the anticancer drug paclitaxel) in which the pharmacologically active agent is delivered in the form of suspended particles coated with protein (which acts... Agent: Morrison & Foerster LLP

20100035810 - Adiponectin production enhancer: The present invention relates to an adiponectin production enhancer comprising sericin as an active ingredient, and to a pharmaceutical composition and food and drink comprising sericin. These are effective in the prevention and/or amelioration of various diseases caused by reduction of blood adiponectin level such as arteriosclerosis, fatty liver and... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100035807 - Composition and method for treatment of tumors: The present invention relates to a composition which is useful in the treatment of a tumor, a method for making such a composition, and a method for using such a composition. The invention relates also to a method for assaying for inhibitors of the activity of Core 1 protein and/or... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100035806 - Compositions and methods for detection and modulation of t cell mediated immune responses against viral vectors utilized for gene therapy: Compositions and methods are provided for inhibiting T cell mediated destruction of virally transduced, trangene containing cells.... Agent: Dann, Dorfman, Herrell & Skillman

20100035816 - Medicament comprising a peptide extract of avocado, which is intended for the treatment and prevention of illnesses that are linked to an immune system deficiency or oxidative stress or skin ageing or dry skin: The invention relates to a medicament which comprises a peptide extract of avocado and which can also comprise a composition containing D-mannoheptulose an/or perseitol, such as a water-soluble extract of avocado sugars, and/or a peptide extract of lupine. The inventive medicament is intended for the treatment and/or prevention of illnesses... Agent: Foley And Lardner LLP Suite 500

20100035817 - Method for the production of conjugates of insulin-like growth factor-1 and poly(ethylene glycol): The present invention relates to a fusion protein comprising IGF-I or an IGF-I variant N-terminally linked to the C-terminus of a propeptide. The invention relates also to a method involving the use of the aforementioned fusion protein in the production of a lysine-PEGylated IGF-I or IGF-I variant. The method comprises... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100035819 - Method of promoting skin collagen production: It is intended to provide a skin collagen production promoter, foods and drinks for promoting skin collagen production and cosmetics for promoting skin collagen production which are useful in preventing skin chapping, wrinkles, worsening in skin fitness, etc. Namely, a skin collagen production promoter, foods and drinks for promoting skin... Agent: Young & Thompson

20100035808 - Methods and compositions for promoting organ development: Compositions and methods are provided for promoting organ development in warm blooded animals, and in particular in certain aspects a premature infant or fetus. Compositions and methods are also provided for the administration of at least one colony stimulating factor-1 protein (CSF-1), precursor, variant, analogue, derivative thereof, or combinations thereof,... Agent: Jones Day

20100035812 - Modified bovine g-csf polypeptides and their uses: Modified bovine G-CSF polypeptides and uses thereof are provided.... Agent: Attn: John W. Wallen, Iii Ambrx, Inc.

20100035814 - N-terminal pegylated prolactin receptor molecules: The invention is concerned with N-terminally pegylated polypeptides capable of binding to the prolactin receptor. Such polypeptides may for instance be N-terminally pegylated antagonists of the prolactin receptor, such as for instance prolactin variants.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100035805 - Non-aqueous liquid formulation for nasal or buccal administration: A formulation for administration to a nasal or buccal cavity of a subject which comprises a non-aqueous liquid environment, preferably an emollient oil base, and at least one active molecule, preferably a dopamine agonist and especially apomorphine, in solution or suspension therein, wherein in one embodiment the formulation has such... Agent: Proskauer Rose LLP

20100035818 - Optimized expression of hpv 52 l1 in yeast: Synthetic DNA molecules encoding the HPV 52 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV 52 L1 protein, wherein said polynucleotides are codon-optimized for high level expression in a yeast cell. In alternative embodiments of the invention, the nucleotide sequence of the synthetic molecule is altered... Agent: Merck And Co., Inc

20100035802 - Particular short-chain peptide cancer drug and its treatment: The invention relates to a particular short-chain peptide cancer drug and its treatment. The cancer drug includes a short-chain peptide composed of amino acids interlinked in a unique sequence. The treatment is based on a cancer angiogenesis targeted therapy model, proceeded by an arterial injection of the short-chain peptide cancer... Agent: Wang Law Firm, Inc.

20100035811 - Phosphoinositide modulation for the treatment of neurodegenerative diseases: The present invention relates to the use of agents that inhibit the toxic effects of amyloid oligomers by increasing intracellular levels of phosphoinositol 4-phosphate (PI(4)P, or “PIP”) and/or phosphotidylinositol 4,5-biphosphate (PI(4,5)P2 or “PIP2”), the use of such agents for the treatment of neurodegenerative diseases, methods of treating neurodegenerative diseases by... Agent: Baker Botts L.L.P.

20100035804 - Polypeptide antagonist: We describe a circularly permuted growth hormone polypeptide antagonist; compositions comprising said antagonist and methods to treat conditions that would benefit from administration of said antagonist.... Agent: Speckman Law Group PLLC

20100035803 - Polypeptides and polynucleotides encoding the same: Provided herein are lactation-associated polypeptides and polynucleotides, expression vectors a host cells for expressing lactation-associated polypeptides and polynucleotides, and methods of producing said polypeptides and polynucleotides.... Agent: Schwegman, Lundberg & Woessner, P.A.

20100035813 - Recombinant e-selectin made in insect cells: The inventive features include recombinant mammalian E-selectin peptides, nucleic acids encoding said peptides, vectors and cells having these nucleic acids, and methods of making the peptides. Further inventive features include methods of treating diseases and conditions associated with inflammation using recombinant mammalian E-selectin peptides to induce mucosal tolerance to E-selectin.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20100035815 - Skin wound healing compositions and methods of use thereof: A wound healing composition comprising an amount of heat shock protein effective to promote wound healing and a method thereof to apply the composition. A preferred heat shock protein is either full-length hsp90α or the middle domain plus the charged sequence of hsp90α. The composition is topically applied to skin... Agent: Mcdermott Will & Emery LLP

20100035809 - Stable liquid compositions for treating stomatitis comprising epidermal growth factor: Provided is a liquid composition for treating stomatitis, the liquid composition including: an epidermal growth factor; an adhesive polymer; and at least one stabilizer selected from the group consisting of ethylenediaminetetraacetic acid (EDTA) and salts thereof, histidine, lysine and inorganic acid salts thereof, arginin and inorganic acid salts thereof, and... Agent: Cantor Colburn, LLP

20100035820 - Amidated dopamine neuron stimulating peptides for cns dopaminergic upregulation: The present invention relates to novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), that are useful for treating brain diseases and injuries that result in dopaminergic deficiencies.... Agent: Crowell & Moring LLP Intellectual Property Group

20100035821 - Amide linkage cyclic natriuretic peptide constructs: where R, R′, Q, Y, W, Z, J, x and n are as defined in the specification, and a cyclic linkage including one or two amide bonds, pharmaceutical compositions including such cyclic constructs, and methods of treating congestive heart failure or other conditions, syndromes or diseases for which induction of... Agent: Palatin Technologies, Inc.

20100035822 - Proline-rich peptides, pharmaceutical composition, use of one or more peptides and method of treatment: The present invention provides oligopeptides with amino acid sequences comprised in set forth in SEQ ID NO 1 to 18, capable of binding to diverse targets, generating increase and sustenance to nitric oxide (NO) production in mammalian cells, potentiate the argininosuccinate synthase activity of animal cells and/or increase the intracellular... Agent: Smith, Gambrell & Russell

20100035823 - Ligands of sh3 domains: Provided are compounds that bind to SH3 domains. Also provided are combinatorial libraries for discovering such compounds. Methods of identifying a compound that binds to an SH3 domain are also provided. Methods of inhibiting an activity of a protein comprising an SH3 domain are additionally provided. Additionally provided are methods... Agent: Amster, Rothstein & Ebenstein LLP

20100035824 - Synergistic pharmaceutical composition: The invention relates to pharmaceutical compositions containing an isoflavone or isoflavone glycoside or a pharmaceutically acceptable salt or solvate of said isoflavone or isoflavone glycoside as an active substance. Also disclosed are uses of such pharmaceutical compositions.... Agent: Buchanan Ingersoll & Rooney PC

20100035825 - Treatment of disease by inducing cell apoptosis: The present invention relates generally to the treatment and prevention of diseases characterized by excess cell proliferation and/or activation. In particular, the present invention provides compositions and methods to suppress the activation and/or proliferation of various cells. In some preferred embodiments, the present invention provides compositions and methods to suppress... Agent: Medlen & Carroll, LLP

20100035826 - Controlled release of phenolic opioids: A method of providing a patient with controlled release of a phenolic opioid using a prodrug capable, upon enzymatic activation, of releasing the phenolic opioid through intra-molecular cyclization leading to formation of a cyclic urea, carbamate or thiocarbamate.... Agent: Pharmacofore, Inc. Bozicevic, Field & Francis LLP

20100035827 - Multivalent metal salts of boronic acids: Salts of a pharmaceutically acceptable divalent metal and an organoboronic acid drug. Examples of such metals are calcium, magnesium and zinc. The organoboronic acid drug may be a boropeptide protease inhibitor. The salts may be formulated in oral dosage form.... Agent: Klarquist Sparkman, LLP

20100035830 - Iron-carbohydrate complex compounds: The invention provides an iron-carbohydrate complex compound which is characterized by a content of iron(II). The invention also provides processes for the preparation of the iron-carbohydrate complex compound and the use thereof for treatment of iron deficiency anaemias.... Agent: Rankin, Hill & Clark LLP

20100035829 - Method of treating intrauterine inflammation: A method of treating intrauterine inflammation in a subject associated with intrauterine bacterial infection includes administering to the subject a therapeutically effective amount of a toll-like receptor 4 antagonist. The therapeutically effective amount administered to the subject is an amount effective in reducing intrauterine inflammation in the subject.... Agent: Tarolli, Sundheim, Covell & Tummino, LLP

20100035828 - Milk oligosaccharide for stimulating the immune system: The present invention relates to methods and nutritional compositions for stimulating the immune system, particularly in subjects with an impaired immune system such as 5 infants, said method comprising administering a composition comprising sheep milk and/or short chain oligosaccharides.... Agent: Foley And Lardner LLP Suite 500

20100035831 - Anti-wrinkle agent and adam inhibitor: Disclosed is an anti-wrinkle agent for ameliorating a wrinkle (particularly a fine wrinkle) developed when the barrier function is decreased by dryness and the like. Also disclosed is an ADAM inhibitor. The anti-wrinkle agent or the ADAM inhibitor comprises an alkyl glucoside represented by the general formula: (1) [wherein R... Agent: Darby & Darby P.C.

20100035833 - Antibiotic macrocycle compounds and methods of mnaufacture and use thereof: The invention encompasses an active metabolite of the 18-membered macrocyclic antimicrobial agents, specifically, a metabolite of tiacumicin B and in certain embodiments, R-Tiacumicin B or and its related compounds. In particular, the invention encompasses a compound that acts as a potent antibiotic agent for the treatment of bacterial infections, specifically... Agent: Morgan Lewis & Bockius LLP

20100035832 - Macrolides: This invention relates to a novel class of antibiotic agents, more specifically to macrolides comprising an oxazolidinone structure, their preparation, pharmaceutical compositions containing them, their use and methods of treatment using them.... Agent: Cantor Colburn, LLP

20100035834 - Novel 1,4-benzothiepin-1, 1-dioxide derivatives with improved properties method for producing the same, drugs containing said compounds and the use thereof: This invention relates to Novel 1,4-benzothiepin-1,1-dioxide derivatives with improved properties, method for producing the same, drugs containing said compounds and use thereof.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100035964 - Antisense modulation of connective tissue growth factor expression: Antisense compounds, compositions and methods are provided for modulating the expression of connective tissue growth factor. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding connective tissue growth factor. Methods of using these compounds for modulation of connective tissue growth factor expression and for treatment of... Agent: Cooper & Dunham, LLP

20100035968 - Mediated cellular delivery of lna oligonucleotides: The present invention relates to novel modified oligomeric compounds and to methods of making and using such compounds. The invention further relates to methods of enhancing the cellular uptake of oligomeric compounds comprising conjugating a metal chelator to those.... Agent: Clark & Elbing LLP

20100035966 - Methods and compositions for regulating cell cycle progression: In one aspect, a method is provided of inhibiting proliferation of a mammalian cell comprising introducing into said cell an effective amount of at least one at least one small interfering RNA agent (iRNA), wherein said iRNA comprises a nucleotide sequence of at least 15 nucleotides, wherein the nucleotide sequence... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20100035967 - Modulation of toll-like receptor 9 expression by antisense oligonucleotides: Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of TLR9. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TLR9. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding TLR9 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100035963 - Oligoribonucleotides and methods of use thereof for treatment of cardiovascular disease: The invention relates to a double-stranded compound, preferably an oligoribonucleotide, which down-regulates the expression of one or more cardiovascular-related gene. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates... Agent: Cooper & Dunham, LLP

20100035969 - Rnai inhibition of ctgf for treatment of ocular disorders: RNA interference is provided for inhibition of connective tissue growth factor mRNA expression in ocular disorders involving CTGF expression. Ocular disorders involving aberrant CTGF expression include glaucoma, macular degeneration, diabetic retinopathy, choroidal neovascularization, proliferative vitreoretinopathy and wound healing. Such disorders are treated by administering interfering RNAs of the present invention.... Agent: Alcon

20100035965 - Sirna inhibition of p13k p85, pa110, and akt2 and methods of use: The present invention provides polynucleotides, compositions including polynucleotides, and the uses thereof for treating cancer in a subject. The polynucleotides silence the expression of coding regions that encode polypeptides such as p85α, p110α, and Akt2. The cancers treatable using the methods described herein include colorectal cancer, breast cancer, lung cancer,... Agent: Mueting, Raasch & Gebhardt, P.A.

20100035974 - Compositions comprising a sirna and lipidic 4,5-disubstituted 2-deoxystreptamine ring aminoglycoside derivatives and uses thereof: The present invention relates to a composition comprising a siRNA and a transfecting compound consisting of an aminoglycoside of the class of 4,5-disubstituted 2-deoxystreptamine ring linked via a spacer molecule to a lipid moiety of formula —(R1)R2 wherein R1 and R2 represent, independently of one another, a hydrogen atom or... Agent: Adeli & Tollen, LLP

20100035973 - Disruption of programmed death 1 (pd-1) ligand to adjuvant adeno-associated virus vector vaccines: The invention provides for methods of modulating an immune response against a therapeutic polypeptide or an antigenic polypeptide delivered via rAAV comprising administering a modulator of programmed death-1 (PD-1) signaling.... Agent: Marshall, Gerstein & Borun LLP

20100035976 - Method of treating a tumor or a viral disease by administering a 2' , 5' -oligoadenylate analog: e

20100035971 - Methods and means related to diseases: The present invention relates to the fields of genetics and oncology and provides methods for detecting cutaneous T-cell lymphomas (CTCL) or susceptibility to CTCL. Specifically, the present invention relates to a novel method for the diagnosis and follow-up of CTCL or CTCL subtype, the method comprising determination of expression of... Agent: Ladas & Parry LLP

20100035975 - Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide sequences: The invention provides methods of preventing and/or treating infection by a respiratory virus such as respiratory syncytial virus (RSV), particularly reducing infection and/or one or more symptoms of respiratory virus infection. A polynucleotide comprising an immunostimulatory sequence (an “ISS”) is administered to an individual which is at risk of being... Agent: Morrison & Foerster LLP

20100035970 - Methylation markers for diagnosis and treatment of cancers: Two hundred ten markers are provided which are epigenetically silenced in one or more cancer types. The markers can be used diagnostically, prognostically, therapeutically, and for selecting treatments that are well tailored for an individual patient. Restoration of expression of silenced genes can be useful therapeutically, for example, if the... Agent: Banner & Witcoff, Ltd.

20100035972 - Oligonucleotide and use thereof: An oligonucleotide with a nucleotide sequence of 5′-cctcctcctcctcctcctcctcct-3′ (SEQ ID NO: 1) inhibits proliferation of human PBMC activated by TLR9 agonist and interferon production from human PBMC induced by TLR9 agonist, HSV-1, flu virus and serum from SLE patients, and rescues the mice from cytokine-mediated lethal shock. This oligonucleotide can... Agent: Cohen, Pontani, Lieberman & Pavane LLP

20100035835 - Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection: The present invention provides nucleoside aryl phosphoramidates of structural formula (I) which are precursors to inhibitors of RNA-dependent RNA viral polymerase. These compounds are precursors to inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as precursors to... Agent: Merck And Co., Inc

20100035836 - Bicyclic nucleosides and nucleotides as therapeutic agents: The present disclosure relates to the use and methods of manufacture of bicyclic nucleosides and nucleotides for the treatment and prevention of infectious and proliferative diseases, including microbial infections and cancer.... Agent: Quarles & Brady LLP

20100035837 - Therapeutic or prophylactic agent for vasoconstriction: The above problems are solved by an agent for treating and preventing vasospasm, cerebral ischemia, or cerebral infarction, comprising trehalose as the active ingredient. It is possible, by using such a trehalose-comprising agent, to suppress phenomena such as contraction of blood vessel and thickening of tunica intima and tunica media... Agent: Osha Liang L.L.P.

20100035838 - Cross-linked polysaccharide gels: The present invention relates to a process for preparing a cross-linked polysaccharide gel comprising contacting a polysaccharide with a cross-linking agent and a masking agent to form a cross-linked polysaccharide gel having resistance to degradation under physiological conditions.... Agent: O'brien Jones, PLLC

20100035839 - Merocyanine derivatives: Disclosed are merocyanine derivatives which correspond to the formula (I), wherein L1, L2 and L3 independently of each other are hydrogen; or L1 and L3 may be linked together to form a carbocyclic ring; R3 and R4 independently of each other are CN; —COR5; —COOR5; —CONR5R6; C1-C22alkyl; C2-C22alkenyl; C2-C22alkinyl; C3-C12cycloalkyl;... Agent: Joann Villamizar Ciba Corporation/patent Department

20100035840 - Pesticidal composition comprising fosetyl-aluminium, propamocarb-hcl and an insecticide substance: The present invention relates to a pesticide composition intended for protecting plants, crops or seeds against phyto-pathogenic fungi or damaging insects, and the corresponding methods of treatment using the said composition. More precisely, the subject of the present invention is a pesticide composition based on fosetyl-Al, propamocarb-HCl, an insecticide active... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100035841 - Inhibitors of tyrosine kinases and uses thereof: Disclosed herein are compounds that inhibit the activity of particular tyrosine kinases. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of tyrosine kinase-mediated... Agent: Wilson, Sonsini, Goodrich & Rosati

20100035842 - Amino alcohol compounds or phosphonic acid derivatives thereof: , wherein R1 and R2 are hydrogen lower alkyl, lower aliphatic acyl, or lower alkoxycarbonyl; R4 is C1-C4 alkyl; n is 2 or 3; X is a formula ═N-D, wherein D is hydrogen, C1-C6 alkyl or phenyl; Y is ethylene, ethynylene, —CO—CH2—, —CH(OH)— CH2— or phenylene; Z is C1-C6 alkylene;... Agent: Frishauf, Holtz, Goodman & Chick, PC

20100035843 - Methods for attenuating allergen-induced airway hyperreactivity using cd1d dependent antagonists: The present invention is directed to a method of inhibiting allergen-induced airway CD1d activation by administering a composition containing a moiety that blocks CD1d activation. Methods of the invention are useful for treatment and prevention of air-way hyperactivity caused by an allergen, and results in the attenuation of CD1d-restricted immune... Agent: David S. Resnick

20100035844 - Pesticide composition comprising propamocarb-fosetylate and an insecticidally active substance: The present invention relates to a pesticide composition intended for protecting plants, crops or seeds against phyto-pathogenic fungi or damaging insects, and the corresponding methods of treatment using the said composition. More precisely, the subject of the present invention is a pesticide composition based on propamocarb-fosetylate, an insecticide active substance... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100035847 - Genes for biosynthesis of tetracycline compounds and uses thereof: The invention relates to genetically engineered cells, and to proteins and genes useful in the production of tetracycline compounds, to methods of producing tetracycline compounds, and to tetracyclines thereby produced. The present invention is based on the cloning and heterologous expression of genes encoding the chelocardin biosynthetic pathway.... Agent: Renner Otto Boisselle & Sklar, LLP

20100035846 - Method for the treatment of acne and certain dosage forms thereof: An oral dosage form, including 65 mg of minocycline, an amount of lactose monohydrate, and an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is hydroxypropylmethylcellulose that is about 8.9±0.2% hydroxypropoxylated. An oral dosage form, including 115 mg of minocycline, an amount of lactose monohydrate, and an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is... Agent: Ohlandt, Greeley, Ruggiero & Perle, LLP

20100035845 - Tigecycline formulations: The invention is directed to a frozen pharmaceutical formulation suitable for administration to a subject parenterally, comprising a therapeutically effective amount of tigecycline and an agent selected from the group consisting of lactose, dextrose, glucose, mannose, sucrose, ribose, xylose and a combination thereof, wherein the formulation in a pre-frozen state... Agent: Wyeth LLC Patent Law Group

20100035849 - Novel methylenedioxy phenolic compounds and their use to treat disease: The present invention provides novel methylenedioxy phenolic compounds and their derivatives, methods of making them and methods of using them to treat or prevent cardiovascular disease, vascular disease and/or inflammatory disease, as well as Type I and Type II Diabetes and Dyslipidemia patients at risk for hypertension, stroke, cardiovascular and... Agent: Macmillan Sobanski & Todd, LLC

20100035848 - Therapy for disorders of the proximal digestive tract: A method for managing or treating an inflammatory, erosive, dyspeptic or reflux disorder of the proximal digestive tract of a subject comprises administering to the subject a therapeutically effective amount of an ACE2 inhibitor. A therapeutic combination, useful to treat any disease or condition in which an NSAID is indicated,... Agent: Harness, Dickey, & Pierce, P.l.c

20100035850 - Method of treatment for inflammatory bowel disease: The present invention provides methods of treating inflammatory bowel disease comprising administering to a subject in which remission has not been achieved after a first treatment of about 4-8 weeks of 5-ASA (mesalamine or 5-ASA), a further daily dose greater than about 4 g of 5-ASA in controlled release form... Agent: Darby & Darby P.C.

20100035851 - Agent for improving insulin resistance: To inhibit production of adipocytokines, in particular, adipocytokines that elicit insulin resistance and to prevent onset of pathosis caused by the insulin resistance, or improve the pathosis, the present invention provides an agent or a food or drink which contains a compound having a cyclolanostane skeleton, or an organic solvent... Agent: Knobbe Martens Olson & Bear LLP

20100035852 - Compositions and methods for treating inflammatory conditions of the bowel: The present invention provides compositions and methods for treating inflammatory conditions (e.g., of the bowel). In particular, the present invention provides methods of treating (e.g., therapeutically and/or prophylactically treating) inflammatory conditions (e.g., of the bowel), compositions useful for such methods (e.g., antagonists and/or inhibitors of angiotensin II (AngII) receptor Type... Agent: Casimir Jones, S.c.

20100035853 - Method for preventing or treating cisplatin-induced nephrotoxicity: Provided is a method for preventing or treating cisplatin induced nephrotoxicity, which comprises administering a patient who is receiving cisplatin a therapeutically effective amount of an aldosterone blocker such as eplerenone or spironolactone.... Agent: Sughrue Mion, PLLC

20100035854 - Dry powder formulations: A dry powder suitable for inhalation in a dry powder inhaler, the powder comprising a carrier, an active agent and at least 0.5% by weight of magnesium stearate, the powder being further characterized in that the less than 10% of the surface of the carrier material is covered with particles... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100035855 - Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on apoe allelic profile of a mammalian subject: A method for treating cardiovascular disease in a mammalian subject includes providing to the subject at least one treatment regimen including at least one estrogen receptor modulator, wherein the at least one treatment regimen is determined based on the APOE allelic profile in the subject, and based on the steroid... Agent: Searete LLC Clarence T. Tegreene

20100035856 - Beta-lactam-containing formulations with increased stability in aqueous solution: The invention relates to novel formulations for dissolution in water which contain a β-lactam antibiotic and urea and whose pH after dissolution of the formulation in water is in the range of from 4.5 to 8. The formulations are suitable in particular for the treatment of bacterial diseases in animals.... Agent: Bayer Healthcare LLC

20100035857 - Anti-hypercholesterolemic compounds: This invention provides cholesterol absorption inhibitors of Formula I:I and the pharmaceutically acceptable salts thereof. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating and preventing atherosclerosis and atherosclerotic disease events.... Agent: Merck And Co., Inc

20100035858 - Novel compositions and methods for binding and inhibiting 5-ht4 receptor: The present invention relates to compositions that bind to 5-HT4 receptors and inhibit proliferation of activated lymphocytes. The invention also provides methods for inhibiting proliferation and inducing cell death in activated immune cells, as well methods for treating diseases associated with activated immune cells by administering 5-HT4 receptor ligands.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100035859 - Treatment of protein aggregation diseases: A method of treatment for the prevention or therapy of a protein aggregation disease includes the administration in combination of a first active medicament and a second active medicament, wherein the first active medicament is active to impede aggregation of amyloid protein and the second active medicament is active to... Agent: Pillsbury Winthrop Shaw Pittman, LLP

20100035860 - Inhibitors of protein tyrosine phosphatase for the promotion of physiological cardiac hypertrophy: The invention relates to the use of protein tyrosine phosphatase inhibitors for the promotion of physiological cardiac hypertrophy and the treatment of pathological cardiac hypertrophy.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100035861 - Meptazinol biligand derivatives and/or their salts, preparation method and uses thereof: The present invention belongs to pharmaceutical field. It relates to a novel family of bivalent (−)-meptazinol compounds and/or their salts, as well as the preparation and utilization of the compounds in the treatment of neurodegenerative disorders and dementias such as Alzheimer's Disease (AD). In the present invention, bivalent (−)-meptazinol compounds... Agent: Ware Fressola Van Der Sluys & Adolphson, LLP

20100035862 - Novel aza-cyclic indole-2-carboxamides and methods of use thereof: The invention relates to aza-cyclic-indole-2-carboxamide derivatives, compositions comprising such compounds, and methods of preventing or treating conditions and disorders using such compounds and compositions.... Agent: Paul D. Yasger Abbott Laboratories

20100035863 - 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions: The present invention concerns novel 2 amino pyrimidine derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use as harmaceuticals.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20100035864 - Diacylglycerol acyltransferase inhibitors: e

20100035865 - Sulfonamides and pharmaceutical compositions thereof: The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula (I), as defined in the specification. The invention is also directed to compositions containing the compounds of formula (I).... Agent: Pfizer Inc Mary J Hosley

20100035866 - Novel substituted-1, 1-dioxo-benzo[1,2,4]thiadiazin-3ones, preparation method thereof, and pharmaceutical composition containing the same: The present invention relates to compounds of substituted-1,1-dioxo-benzo[1,2,4]thiadiazin-3-ones acting as a 5HT6 receptor antagonist, a preparation method thereof, and a pharmaceutical composition containing the same for treatment of the central nervous system disorders. The compounds of substituted-1,1-dioxo-benzo[1,2,4]thiadiazin-3-ones according to the present invention have excellent binding affinity for the 5HT6 receptor... Agent: Lucas & Mercanti, LLP

20100035867 - Inhibitors of cyclic nucleotide synthesis and their use for therapy of various diseases: We disclose a method of inhibiting activity of adenylyl cyclase or guanylyl cyclase in a mammal by administering to the mammal an amount of a composition effective to inhibit the activity, wherein the composition contains at least one compound selected from the group consisting of structural formulae (Ia) and (Ib)... Agent: Williams, Morgan & Amerson

20100035868 - Methods of treatment of uterine pathological conditions: A method of treating or preventing a pathological condition of the uterus in an individual the method comprising administering to the individual any one or more of an inhibitor of cyclooxygenase-2 (COX-2), an inhibitor of prostaglandin E synthase (PGES), or an EP2 or EP4 receptor antagonist. Typically, the pathological condition... Agent: Nixon Peabody LLP - Patent Group

20100035869 - Targeted nitroxide agents: Provided herein are compositions and related methods useful for free radical scavenging, with particular selectivity for mitochondria. The compounds comprise a nitroxide-containing group attached to a mitochondria-targeting group. The compounds can be cross-linked into dimers without loss of activity. Also provided herein are methods, for preventing, mitigating and treating damage... Agent: Hirshman Law, LLC

20100035870 - Pyrimidin-4-yl-3, 4-dihydro-2h-pyrrolo[1,2a] pyrazin-1-one compounds: The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts thereof, wherein Z is NR11, NHCO, NHSO2, NHCH2, CH2, CH2CH2, or CH═CH; X is a hydrocarbyl group optionally substituted by one or more R12 groups; R10 and R11 are each independently II or alkyl; R1-R4 are each... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20100035871 - Benzoxazine derivatives and uses thereof: Compounds of formula (I) or pharmaceutically acceptable salts thereof are provided, wherein each of Z, X, R1, R2, R3, R4, y, n, and Ar are as defined, and described in classes and subclasses herein, which are agonists or partial agonists of the 2C subtype of brain serotonin receptors. The compounds,... Agent: Choate, Hall & Stewart LLP/wyeth LLC

20100035872 - Pde10 inhibitors and related compositions and methods: Compounds that inhibit PDE10 are disclosed that have utility in the treatment of a variety of conditions, including (but not limited to) psychotic, anxiety, movement disorders and/or neurological disorders such as Parkinson's disease, Huntington's disease, Alzheimer's disease, encephalitis, phobias, epilepsy, aphasia, Bell's palsy, cerebral palsy, sleep disorders, pain, Tourette's syndrome,... Agent: Seed Intellectual Property Law Group PLLC

20100035873 - Diaryl compounds and uses thereof: m

20100035874 - Organic compounds: There are described pyrazolo[5.1-b]oxazole derivatives useful as corticotropin releasing factor (CRF1) receptor antagonists.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100035875 - Triazolopyridine jak inhibitor compounds and methods: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined herein, are useful as JAK kinase inhibitors. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of... Agent: Brinks, Hofer, Gilson & Lione

20100035877 - Methods and compositions for treating pathologies associated with bdnf signaling: A method of treating ncm-neurødegenerative pathologies associated with derangement in brain-derived neurotrophic factor signaling in the brain stem includes administering to the subject an amount of at least one arnpakine effective to increase brain-derived neurotrophic factor nodose sensory neurons of the subject.... Agent: Tarolli, Sundheim, Covell & Tummino, LLP

20100035876 - Use of a kinase inhibitor for the treatment of particular resistant tumors: The invention provides low molecular weight compounds, namely tetrahydropyrrolo[3,4-c]pyrazoles, showing a high affinity for the ATP pocket of ABL tyrosine kinase. These compounds are thus ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency also, and in particular, towards BCR-ABL inhibitor-resistant T315I ABL mutants. The compounds of the invention find... Agent: Scully Scott Murphy & Presser, PC

20100035878 - Inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation: The present invention provides novel compounds of formula I and their use in the inhibition of c-Jun N-terminal kinases. The present invention further provides the use of these compounds in medicine, in particular in the prevention and/or treatment of neurodegenerative disorders related to apoptosis and/or inflammation.... Agent: Wilmerhale/boston

20100035879 - N-sulfonylcarboximidamide apoptosis promoters: e

20100035880 - Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as vr1 receptor antagonists:

20100035881 - Wrinkle-improving agent: The invention provides a novel wrinkle-improving agent that has an effect of improving wrinkles, that does not entail problems of safety or pain even when applied to the skin, and that contains a very safe substance as an active component. A discovery was made that N-benzoyl-β-alanine, other specific β-alanine derivatives,... Agent: Turocy & Watson, LLP

20100035882 - Inhibition of pde2a: The invention relates to the use of PDE2A inhibitors for the manufacture of a medicament for the treatment and/or prophylaxis of coronary diseases, especially stable and unstable angina pectoris, acute myocardial infarction, prophylaxis of myocardial infarction, heart failure, and high blood pressure and the sequelae of atherosclerosis, and vascular disorders,... Agent: Eichen & Associates

20100035883 - Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp): wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to... Agent: Wilson, Sonsini, Goodrich & Rosati

20100035885 - Compositions for manipulating the lifespan and stress response of cells and organisms: Provided herein are methods and compositions for modulating the activity of sirtuin deacetylase protein family members; p53 activity; apoptosis; lifespan and sensitivity to stress of cells and organisms. Exemplary methods comprise contacting a cell with an activating compound, such as a flavone, stilbene, flavanone, isoflavone, catechin, chalcone, tannin or anthocyanidin;... Agent: Harvard University & Medical School C/o Wolf, Greenfield & Sacks, P.C.

20100035884 - Kinase inhibitor: o

20100035886 - Parenteral formulations of dopamine agonists: This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics.... Agent: Darby & Darby P.C.

20100035887 - Therapeutic compounds for blocking dna synthesis of pox viruses: This invention provides methods of inhibiting replication of a poxvirus by contacting a poxvirus with a compound having formula I, formula XXI, formula XXXII, or formula XLI which in turn reduce, inhibit, or abrogate poxvirus DNA polymerase activity and/or its interaction with its processivity factor. Formula I, formula XXI, formula... Agent: Pearl Cohen Zedek Latzer, LLP

20100035888 - Diaryl urea for treating pulmonary hypertension: The present invention relates to pharmaceutical compositions for treating, preventing or managing pulmonary hypertension comprising 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide optionally combined with at least one additional therapeutic agent.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100035889 - Use of pde iii inhibitors for the treatment of asymptomatic (occult) heart failure: The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca2+-sensitizing agent or a pharmaceutically acceptable derivative thereof for the preparation of a medication for the prolongation of time until onset of clinical symptoms in patients having an asymptomatic (occult) heart failure or for the... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100035890 - Use of ranolazine for the treatment of cardiovascular diseases: Disclosed are methods for treating patients suffering from cardiovascular diseases comprising administering an intravenous (IV) infusion of ranolazine. In one embodiment, the IV infusion of ranolazine is followed by an orally administered sustained release ranolazine dosage formulation to maintain human ranolazine plasma levels at therapeutic levels in patients.... Agent: Cv Therapeutics, Inc. Gilead Palo Alto, Inc.

20100035891 - Pharmaceutically active compounds: wherein R1, R2, R4 and R13 are as defined or a pharmaceutically or veterinarily acceptable salt or polymorph thereof, or a pharmaceutically or veterinarily acceptable solvate or pro-drug thereof: are potent and selective inhibitors of type 5 cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP PDE5) and have utility in the treatment of,... Agent: Pfizer Inc. Patent Department

20100035892 - Method for assembling high-purity chemical libraries, compounds suppressing acetyl coenzyme a carboxylase activities discovered by same: e

20100035893 - Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof:

20100035894 - Aqueous liquid preparation having improved intraocular gatifloxacin penetration: An object is to provide an ophthalmic aqueous preparation excellent in the retention of gatifloxacin in a tear fluid and the preparation of gatifloxacin into an aqueous humor and a conjunctiva. Another object is to prevent the formation of any precipitate and the reduction in viscosity in the aqueous liquid... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100035895 - 2-aminocarbonyl-pyridine derivatives: The present invention relates to 2-aminocarbonyl-pyridine derivatives of Formula (I) and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis.... Agent: Hoxie & Associates LLC

20100035896 - Combination of n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic cytotoxic agent: A combination, comprising N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and an anti-mitotic cytotoxic agent.... Agent: Astrazeneca R&d Boston

20100035897 - Pyridine, pyrimidine and pyrazine derivatives as gpcr agonists: Compounds of formula (I): R1-A-V—B—R2, wherein V is phenyl or a 6-membered heteroaryl ring containing up to three N-atoms, or pharmaceutically acceptable salts thereof, are agonists of GPR116 and are useful for the treatment of obesity, and for the treatment of diabetes.... Agent: Osi Pharmaceuticals, Inc.

20100035898 - Organic compounds: There are described cyclohexyl amide derivatives useful as corticotropin releasing factor (CRF1) receptor antagonists.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100035899 - 5,7-disubstituted[1.3]thiazolo[4,5-d]pyrimidin-2(3h)-amine derivatives and their use in therapy: There are disclosed novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives of formula (I) wherein R1, R2, R3, R4 and n are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX3CR1... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100035900 - 6-arylmethyl-substituted pyrazolopyrimidines: The invention relates to novel 6-arylmethyl-substituted pyrazolopyrimidines, process for their preparation and their use for producing medicaments for improving perception, concentration, learning and/or memory.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100035901 - Adenine derivative as inhibitors of hsp90 for the treatment of cancer: The invention provides a compound which is (a) an amino acid derivative of formula (I) or a tautomer thereof, or (b) a pharmaceutically acceptable salt, N-oxide, hydrate or solvate thereof: wherein R1, R2, L1, Het, A, x, y and W are as defined herein. The compounds are useful in the... Agent: Foley And Lardner LLP Suite 500

20100035902 - 5-aryl-substituted dihydropyridopyrimidines and dihydropyridazines and use thereof as mineral corticoid antagonists: The present application relates to novel aryl-substituted heterobicyclic compounds, a process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for the manufacture of medicaments for the treatment and/or prophylaxis of diseases, especially cardiovascular disorders.... Agent: Edwards Angell Palmer & Dodge LLP

20100035903 - Pyrrolo[2,3-d]pyrimidine compounds: wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer,... Agent: Pharmacia Corporation Global Patent Department

20100035904 - Phenobarbital salts; methods of making; and methods of use thereof: Disclosed are new phenobarbital salts, methods of preparation, and uses thereof.... Agent: Cantor Colburn, LLP

20100035905 - Hydrates of 2-chloro-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1-(2h)-pyrimidinyl]-4-fluoro-n-[[methyl(1-methylethyl)amino]sulfonyl]benzamide: The present invention relates to hydrates of 2-chloro-5-[3,6-dihydro-3-methyl-2,6-dioxo-4-(trifluoromethyl)-1-(2H)pyrimidinyl]-4-fluoro-N-[[methyl(1-methylethyl)amino]-sulfonyl]benzamide. The invention also relates to a process for the preparation of these hydrates and to plant protection formulations which comprise hydrates of the phenyluracil I.... Agent: Brinks, Hofer, Gilson & Lione

20100035906 - Dipyridyl-dihydropyrazolones and their use: The present application relates to novel dipyridyl-dihydropyrazolones, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100035907 - New 2,4-dianilinopyrimidines, preparation thereof as drugs, pharmaceutical compositions and use thereof essentially as ikk inhibitors: e

20100035908 - Substituted acetophenones useful as pde4 inhibitors: The present invention relates to a compound according to formula: (I); wherein X1, X2, X3, X4 and X5 independently of each other represent —CH— or N; or X3, X4 and X5 independently of each other represent —CH— or N, and Xi and X2 independently of each other represent C and... Agent: Birch Stewart Kolasch & Birch

20100035909 - Novel substituted diaza-spiro-pyridinone derivatives for use in mch-1 mediated diseases: a pharmaceutically acceptable acid or base addition salt thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein the variables are defined in claim 1. It further relates to their preparation, compositions comprising them and their use as a medicine. The compounds according to the invention are useful... Agent: Philip S. Johnson Johnson & Johnson

20100035910 - Process for the preparation of quaternary n-alkyl morphinan alkaloid salts: An improved process for the N-alkylation of tertiary morphinan alkaloid bases to form the corresponding quaternary morphinan alkaloid derivatives.... Agent: Mallinckrodt Inc.

20100035911 - Drug combinations to treat hyperproliferative disorders: A method of treating a hyperproliferative disorder, including a cancer, in a subject in need of such treatment, comprising administering to said subject a pharmaceutical combination containing a treatment effective amount of: (a) a vitamin A derivative (i.e., a retinoid), or a pharmaceutically acceptable salt thereof, and an inhibitor of... Agent: Myers Bigel Sibley & Sajovec

20100035912 - Small molecule inhibitors of retroviral assembly and maturation: Chemical compounds that disrupt retroviral assembly and maturation are presented herein. More particularly, this disclosure provides small molecule compounds that disrupt the formation and maturation of virus particles and methods of using such small molecules to treat HIV-1 infection.... Agent: K&l Gates LLP

20100035913 - Novel guanidinyl-substituted hydroxy-6-phenylphenanthridines as effective phosphodiestrase (pde) 4 inhibitors: e

20100035914 - Azabicyclic compounds as inhibitors of monoamines reuptake:

20100035916 - Azabicycloalkane derivatives, preparation thereof and use thereof in therapy:

20100035915 - Indolizine derivatives and the use thereof as antidiabetics: Novel compounds of the formula (I), in which X, Y, R, R1, R1, R1′, R2, R2′, R3, R4, R4′, R5 and n have the meanings indicated in patent claim 1, are suitable as antidiabetics.... Agent: Millen, White, Zelano & Branigan, P.C.

20100035919 - Compounds useful as inhibitors of protein kinases: v

20100035918 - Imidazolone compounds and methods of making and using the same: In one aspect, the invention features a compound of the general Formula (I). Compounds of Formula (I) possess high affinity for Alk 5 and/or AIk 4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders.... Agent: Honigman Miller Schwartz & Cohn LLP

20100035917 - Pyrrolo[2,3-b]pyridin-4-yl-benzenesulfonamide compounds as 1kk2 inhibitors: The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to Formula (1) and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular 1KK2 activity.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100035920 - Substituted pyrazolo[1,5-a] pyridine compounds and their methods of use: The present invention is directed to substituted pyrazolo[1,5-a]pyridines and related methods for their synthesis and use.... Agent: King & Spalding LLP

20100035921 - 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists: wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity,... Agent: Theravance, Inc.

20100035922 - Quinuclidine carbonate salts and medicinal composition thereof: Quinuclidine carbonate derivatives act as muscarinic receptor antagonists and are effective for the prevention and/or treatment of a broncho-obstructive or inflammatory diseases.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100035923 - Vr1 vanilloid receptor antagonists with a iononic substructure: The invention provides compounds of formula (I), wherein Y, R, n and X are as defined in the description, a process for their preparation and pharmaceutical compositions containing them. The compounds of formula (I) inhibit the Transient Receptor Potential Vanilloid 1 (TRPV1), which plays a pivotal role in the development... Agent: Steinfl & Bruno

20100035925 - Compounds, pharmaceutical compositions an dmethods for inhibiting hiv infectivity: Compounds that possess anti-infective activity are described. Methods of using these compounds for the treatment or prevention of infectious diseases such as acquired immunodeficiency syndrome (AIDS) are also described. The compounds inhibit HIV infectivity and do not exhibit significant cytotoxicity in HIV producing cells.... Agent: Steven B. Kelber Berenato, White & Stavish

20100035924 - Novel 4-amino-pyridine derivatives and their use as potassium channel modulators: This invention relates to novel 4-amino-pyridine derivative useful as modulators of small-conductance calcium-activated potassium channels (SK channels). In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.... Agent: Birch Stewart Kolasch & Birch

20100035926 - Pyrazole derivatives as non-steroidal glucocorticoid receptor ligands: i

20100035927 - Medicament for prophylactic and/or therapeutic treatment of alzheimer-type dementia: A medicament for prophylactic and/or therapeutic treatment of Alzheimer-type dementia, which comprises donepezil hydrochloride and valproic acid or a salt thereof in combination.... Agent: Greenblum & Bernstein, P.L.C

20100035928 - Method of treating attention deficit disorders with d-threo methylphenidate: Methods for treating Attention Deficit Disorder, Attention Deficit Hyperactivity Disorder, AIDS Dementia Complex and cognitive decline in HIV-AIDS while minimizing drug hypersensitivity, toxicity, side effects, euphoric effect, and drug abuse potential by administration of d-threo-methylphenidate or pharmaceutically acceptable salts thereof.... Agent: Woodcock Washburn LLP

20100035929 - Unnatural dispyrin analogues, preparation and uses thereof: t

20100035930 - Urea and sulfamide derivatives as inhibitors of tafia:

20100035931 - Tripyridyl carboxamide orexin receptor antagonists: The present invention is directed to tripyridyl carboxamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the... Agent: Merck And Co., Inc

20100035932 - Novel formyl peptide receptor like 1 agonists that induce macrophage tumor necrosis factor alpha and computational structure-activity relationship analysis of thereof: The present invention provides compounds of structural formula (I), which are agonists of formyl peptide receptor (FPR), particularly formyl peptide receptor like 1 (FPRL1). The present invention also provides the therapeutic use of the compounds of formula (I).... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20100035933 - Kits, recloseable containers, blanks and methods of treatment: Kits include a recloseable container and an inner container housed within the recloseable container. The recloseable container can include a front wall and a front flap operable to transition between an open position and a closed position, wherein the front flap releasably engages the front wall when in the closed... Agent: The Procter & Gamble Company Global Legal Department - Ip

20100035935 - Anthranilamide compounds, process for their production and pesticides containing them: Anthranilamide compounds, a process for their production, and pesticides containing these compounds as active ingredients. This Abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention in any way.... Agent: Greenblum & Bernstein, P.L.C

20100035934 - Pyridinyl-pyrazole derivatives and their use as potassium channel modulators: This invention relates to novel pyridinyl-pyrazole derivatives and their use as potassium channel modulating agents. Moreover the invention is directed to pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels.... Agent: Birch Stewart Kolasch & Birch

20100035936 - Heterocyclyl substituted tetrahydronaphthalene derivatives as 5-ht7 receptor ligands: The present invention relates to heterocyclyl-substituted-tetrahydro-naphthalen compounds of general formula (I), methods for their preparation, and compositions comprising these compounds as well as their use for the treatment or prophylaxis of various disorders in humans or animals.... Agent: Heslin Rothenberg Farley & Mesiti PC

20100035937 - Solubilized non-steroidal anti-inflammatory drugs: A process for producing a solubilized non-steroidal anti-inflammatory drug (NSAID) the process comprising the steps of: providing a mixture comprising solid NSAID and a first base which is selected from the group of bases which have a pH of at least 11 as 0.1 molar aqueous solution or dispersion, and... Agent: Hoxie & Associates LLC

20100035938 - Cooling compounds: p

20100035939 - Penetrating carrier, anti-fungal composition using the same and method for treatment of dermatophytes: An antifungal liquid composition for topical administration is provided that contains turpentine and at least one of peppermint oil, mineral oil, and essential oil alcohols, and one or more antifungal medications selected from ciclopirox olamine, terbinafine, tolnaftate, microconazole, itraconazole, ketoconazole, econazole, and fluconazole, and optionally one or more antifungal essential... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100035940 - Cyclin dependent kinase inhibitors: The invention relates to cyclin dependent kinase inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions for treating cell proliferative disorders, especially cancer.... Agent: Edwards Angell Palmer & Dodge LLP

20100035941 - Methods for increasing blood flow and/or promoting tissue regeneration: Methods for increasing blood flow and/or regenerating tissue using compounds which bind to the chemokine receptor CXCR4 are disclosed. Preferred embodiments of such compounds are of the formula Z-linker-Z′) wherein Z is a cyclic polyamine containing 9-32 ring members of which 2-8 are nitrogen atoms, said nitrogen atoms separated from... Agent: Morrison & Foerster LLP

20100035942 - 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors: are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds... Agent: Novartis Institutes For Biomedical Research, Inc.

20100035943 - Oxa-and thiadiazoles and their use as metalloproteinase inhibitors: Compounds formula (IA) or (IB), wherein W represents HO(C═O)—, HONH(C═O)— or H(C═O)N(OH)—; X represents —O— or —S—; and R1, R2, and R3 are as defined in the description and claims, are inhibitors of matrix metal oproteinases, in particular MMP9 and/or MMP12.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

20100035944 - Compounds and methods for modulating g protein-coupled receptors: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating G protein-coupled receptor 20 (GPR20), and methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated GPR20.... Agent: Genomics Institute Of The Novartis Research Foundation

20100035945 - Small molecule inhibitors of bacterial dam dna methyltransferases: Disclosed are compounds, crystal structures, data representations, methods of using, and methods of identifying compounds in relation to DNA methylation and inhibition of methylation. In embodiments, DNA methylation is by DNA-adenine methyltransferases (Dam). In an embodiment, compounds are used to treat a host suspected of infection by a pathogenic organism.... Agent: Greenlee Winner And Sullivan P C

20100035946 - Indoline anti-cancer agents: Indoline compounds having anti-mitotic activity, useful for the treatment of cancer and other proliferative disorders are provided.... Agent: Morrison & Foerster LLP

20100035947 - Method for manufacturing neuraminic acid derivatives: d

20100035948 - Furanone compounds and lactam analogues thereof: The present invention provides a compound of formula I and a compound of formula II, methods of use and formulations thereof.... Agent: Nixon & Vanderhye, PC

20100035949 - Microemulsion dosage forms of valsartan and methods of making the same: A drug delivery system, e.g., microemulsion preconcentrate, that spontaneously forms a microemulsion when brought in contact with an aqueous medium. The drug delivery system contains valsartan, a hydrophilic component, a lipophilic component and a surfactant. A particularly useful hydrophilic component in the system is a polymer that is solid at... Agent: Novartis Corporate Intellectual Property

20100035950 - Microbiocidal treatment of edible fruits and vegetables: Methods of controlling bacterial, yeast, and/or mold contamination of edible fruits or vegetables comprise applying thereto an aqueous microbiocidal composition stabilized against ultraviolet light-induced degradation formed from water and (A) at least one component selected from (I) a solid-state microbiocidal compound having at least one bromine atom per molecule; (II)... Agent: Albemarle Corporation

20100035951 - 2-amino benzimidazole derivatives and their use as modulators of small-conductance calcium-activated potassium channels: t

20100035952 - Radiosensitizer formulations and methods for use: The present invention provides radiosensitizer compositions, in controlled-release formulations or other acceptable formulations, particularly nitrohistidine radiosensitizer compositions, which may be administered by any suitable means including oral, intravenous, arterial infusion, intraperitoneal, intramuscular, subcutaneous, surgical, and topical. Optionally, radiosensitizer compositions may be formulated with other agents, including chemotherapy agents and agents... Agent: Sunstein Kann Murphy & Timbers LLP

20100035953 - Pyrazole phenyl derivatives: and X1, X2, R1 to R15 and n are as defined in the description, and pharmaceutically acceptable salts and/or esters thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100035954 - Acid addition salts of muscarinic receptor antagonists: Provided herein are acid addition salts of muscarinic receptor antagonists. Such acid addition salts are muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. Also provided herein are processes for the preparation of... Agent: Ranbaxy Inc.

20100035955 - Stabilised composition comprising ace inhibitors: A pharmaceutical composition comprising a) an ACE inhibitor prone to degradation or a pharmaceutically acceptable acid addition salt thereof; b) a stabilizing amount of an alkaline stabilizing agent; and c) pharmaceutically acceptable excipients wherein the composition further includes moisture controlling means.... Agent: Summa, Additon & Ashe, P.A.

20100035956 - Compounds having crth2 antagonist activity: Compounds of general formula (I) wherein R is phenyl optionally substituted with one or more halo substituents; and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20100035957 - Methods for the use of inhibitors of cytosolic phospholipase a2: and pharmaceutically acceptable salt forms thereof. The invention provides methods for the use of the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A2 enzymes, and for the medical treatment, prevention and inhibition diseases and disorders including asthma, stroke, atherosclerosis, multiple sclerosis, Parkinson's disease, arthritic disorders,... Agent: Wyeth LLC Patent Law Group

20100035958 - Novel compounds and compositions thereof: The invention relates to novel compounds containing a carboxylic acid head group. The invention further provides compositions containing the novel compounds, a particulate solid and an organic medium or water.... Agent: Legal Department Lubrizol Advanced Materials, Inc

20100035959 - Novel sphingosine kinase type 1 inhibitors, compositions and processes for using same: Provided are novel compositions which uniquely inhibit sphingosine kinase Type 1 (SphK1) and which are useful in a number of applications including killing or damaging cancer cells, inducing apoptosis, inhibiting growth, metastasis and development of chemoresistance in cancer cells, leukemia, increasing the effectiveness of anti-cancer agents, attenuating immune reactivity, inhibiting... Agent: Enzo Biochem, Inc.

20100035960 - Biosynthetic pathway and genes required for tropodithietic acid biosynthesis in silicibacter tm1040: Production and use of a sulfur-containing compound, tropodithietic acid (TDA), from the roseobacter Silicibacter sp. TM1040 is described. Specifically, a biosynthetic and regulatory pathway for TDA biosynthesis in roseobacters is described. The TDA produced from roseobacters, specifically Silicibacter sp. TM1040, is shown to have antibacterial activity, in particular against Vibrio... Agent: Intellectual Property / Technology Law

20100035962 - Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with cyclohexyl groups, method for producing the same, drugs containing said compounds and use thereof: This Invention relates to Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with cyclohexyl groups, method for producing the same, drugs containing said compounds and use thereof.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100035961 - Novel 1,4-benzothiepine 1,1-dioxide derivatives substituted by benzyl radicals, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof: This invention relates to Novel 1,4-benzothiepine 1,1-dioxide derivatives substituted by benzyl radicals, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof.... Agent: Andrea Q. Ryan Sanofi-aventis U.s. LLC

20100035977 - Two-component taxane containing pharmaceutical composition: A stabilized, injectable pharmaceutical composition for human administration comprises (a) an antineoplastic compound, (b) a solubilizing/dispersing agent, and (c) a stabilizing amount of an anti-oxidant.... Agent: Ladas & Parry LLP

20100035978 - Combination of cannabinoids for the treatment of peripheral neuropathic pain: The present invention relates to the use of a combination of cannabinoids in the treatment of neuropathic pain, in particular peripheral neuropathic pain. A combination of cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) may be used, wherein the ratio of CBD:THC by weight is between 10:1 and 1:10.... Agent: Wolf Greenfield & Sacks, P.C.

20100035979 - Compositions and methods of sensitizing methicillin resistant staphylococcus aureus to oxacillin: Contemplated methods and compositions further increase susceptibility of sensitized MRSA against various antibiotic drugs. Most preferably, the MRSA is already sensitized with a galloylated catechin (e.g., ECG), and further sensitization is achieved by exposure to a non-galloylated catechin (e.g., EC), and most preferably the corresponding non-galloylated catechin.... Agent: Fish & Associates, PC Robert D. Fish

20100035980 - Antiparasitic agents: n

20100035981 - Particulate aqueous system for the preparation of a formulation for the treatment of adipose diseases: Aqueous particulate system comprising at least one water dispersible biopolymer, at least one surfactant, and water for the preparation of a formulation for the treatment of adipose diseases and/or conditions with improved bioavailability and good retardation of the release of active substances.... Agent: The Firm Of Hueschen And Sage

20100035982 - Oxaliplatin formulations: The present invention provides a pharmaceutical liquid formulation of oxaliplatin for parenteral administration, said formulation having (i) oxaliplatin, (ii) water; and (iii) an additive selected from the group of tartaric acid, a salt of tartaric acid, a pharmaceutically acceptable derivative of tartaric acid and mixtures thereof.... Agent: Winston & Strawn LLP Patent Department

20100035983 - Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof: The present invention provides compositions and methods based on genetic polymorphisms that are associated with cardiovascular diseases, particularly coronary heart disease (especially myocardial infarction) or hypertension. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting... Agent: Celera Corporation

20100035984 - Use of an antibacterial compound which is derived from alliaceae, as a natural additive in animal feed: The invention relates to the use of an antibacterial compound, which is derived from alliaceae, as a natural additive in animal feed, intended as an antimicrobial agent in animal feed, and as an alternative, due to its antibacterial nature, to the use of antibiotics as growth promoters, proposing the use... Agent: Davidson, Davidson & Kappel, LLC

20100035985 - Ester compound and use thereof: e

20100035986 - Methods for the treatment and prevention of age-related retinal dysfunction: A method of treating or preventing age-related retinal dysfunction involves administering to a patient a pharmaceutically effective amount of a synthetic retinal derivative repeatedly over a duration of at least about 3 months. Effective synthetic retinal derivatives include 9-cis-retinyl esters, 11-cis-retinyl esters, derivatives and congeners thereof, and combinations thereof. Suitable... Agent: Buchanan, Ingersoll & Rooney PC

20100035987 - Pleuromutilin derivatives for the treatment of diseases mediated by microbes: A pleuromutilin derivative compound of general formula (I)... Agent: Workman Nydegger 1000 Eagle Gate Tower

20100035988 - Methods for activating ppar gamma-type receptors: p

20100035990 - Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (ppar): wherein R1 and R2 are the same or different and may be selected from a group of substituents consisting of hydrogen, a hydroxy group, an alkyl group, a halogen atom, an alkoxy group, an acyloxy group, an acyl group, an alkenyl group, an alkynyl group, an aryl group, an alkylthio... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100035989 - Compositions and methods for the treatment of mucositis: The invention relates to methods of treating mucositis comprising administering a compound of formula A, compound of any one of formulae 1 to 46, lipoxin compound, or oxylipin compound.... Agent: Ropes & Gray LLP

20100035991 - Amide base salts of saha and polymorphis thereof: The present invention provides amine base salts of SAHA, polymorphs and pharmaceutical compositions thereof. The invention provides a method of treating cancer by administering the pharmaceutical composition. The invention also provides a crystalline composition comprising the amine base and SAHA. The invention also provides methods of obtaining the amine base... Agent: Merck And Co., Inc

20100035992 - Methods and compositions for treating inflammation and inflammation-related pathologies: Methods and compositions are provided for the treatment of inflammation and disorders, diseases, and adverse conditions, i.e., pathologies, caused by or otherwise associated with inflammatory processes. A metal ion sequestering agent that directly or indirectly exerts an anti-inflammatory effect is administered to a subject in combination with a sequestration inactivating... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100035993 - Methods and compositions comprising 2-[(3-chlorophenyl) amino] phenylacetic acid for hyperpermeability and neovascularization disorders of the retina: Method of preventing or arresting the progression of hyperpermeability and neovascularization of the retina by administering to a patient at risk for retinal microvascular disease a composition comprising a compound or pharmaceutically acceptable salt thereof that lowers the ocular ratio of VEGF to PEDF.... Agent: Morgan, Lewis & Bockius LLP

20100035994 - Novel hydrate form of o-desmethyl venlafaxine succinate: The present invention relates to a novel hydrate form of O-desmethyl venlafaxine succinate. The present invention further relates to processes for the preparation of the novel hydrate form, pharmaceutical compositions comprising it, second medical uses of the novel hydrate form, and methods using it for treating diseases such as generalised... Agent: Fulbright & Jaworski L.L.P. Attn: MnIPDocket

20100035995 - Compositions comprising cyclohexylamines and aminoadamantanes: The invention is directed to formulations of pharmaceutical compounds, such as the Cyclohexylamines and Aminoadamantanes which have antimicrobial properties. In particular, it is directed to aqueous based formulations with reduced amounts of preservatives which allow safe and convenient administration and flexible dosing and which, in the case of oral formulations,... Agent: The Firm Of Hueschen And Sage

20100035996 - Glucose metabolism stimulating agent: e

20100035997 - Kit for applying a polymerizable adhesive composition to tissues: The invention relates to a kit for the topical and/or internal application of a polymerisable adhesive composition to tissues, enabling improved control of the polymerisation speed on the surface of the tissue, in addition to the effective disinfection of the wound. The kit consists of at least one receptacle and... Agent: Henkel Corporation

20100035998 - Combination s-nitrosothiol pharmaceutical products for restoring normal breathing rhythms: The present invention is directed to a method of treating a lack of normal breathing control including the treatment of apnea and hypoventilation associated with sleep, obesity, certain medicines and other medical conditions. In an aspect, the invention is directed to treating disordered control of breathing by administering an composition... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100035999 - Additives and products includings oligoesters: The present invention relates to oligoesters and their use for the creation of additives. Oligoester containing additives and/or oligoesters themselves may be used for formulating pharmaceutical preparations, cosmetics or personal care products such as shampoos and conditioners. These oligoesters are particularly useful for the creation of multi-purpose additives that can... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20100036000 - Controlled release antimicrobial compositions and methods for the treatment of otic disorders: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with antimicrobial agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).... Agent: Wilson, Sonsini, Goodrich & Rosati

20100036001 - Heparosan polymers and methods of making and using same for the enhancement of therapeutics: The present invention includes compositions, methods, and systems for the development and use of heparosan, a natural polymer related to heparin, as a new therapeutic modifying agent or vehicle which can modulate drug cargo pharmacokinetics and behavior within a mammalian patient.... Agent: Dunlap Codding, P.C.

20100036002 - Pharmaceutical composition comprising porous dry matrix: The invention provides a porous dry matrix preparation comprising at least a polymeric thickener and an excipient ingredient, wherein (1) the content of the polymeric thickener is down to 0.5 w/w % and up to 14 w/w %, (2) the content of the excipient ingredient is down to 30 w/w... Agent: Leydig Voit & Mayer, Ltd

  
02/04/2010 > patent applications in patent subcategories. patent applications/inventions, industry category

20100029543 - Methods for treating nucleoside-induced pain: The present invention is directed to the use of a class of peptide compounds for treating tumor pain, in particular bone cancer pain, for treating chemotherapy-induced pain and for treating nucleoside-induced pain.... Agent: Harness, Dickey, & Pierce, P.l.c

20100029542 - Protein sterilisation by radiation and addition of a stabilising composition: A method of sterilising a protein, comprises exposing to ionising radiation an at least substantially dry composition comprises a protein and a protective compound or combination of protective compounds having both of the following characteristics: (i) a rate of reaction with singlet oxygen greater than 1×10 7 L mol−1 S−1;... Agent: Elmore Patent Law Group, PC

20100029545 - Boronic acid-containing block copolymers for controlled drug delivery: Polymeric nanoaggregate drug-delivery compositions including boron-containing copolymers are described. The drug-delivery compositions may further include a therapeutic agent comprising a nucleic acid, a polynucletide, a peptide, a polypeptide, a protein, a pharmaceutical or any combinations thereof. Methods for making the polymeric nanoaggregate compositions including at least one therapeutic agent (for... Agent: Baker Botts L.L.P.

20100029544 - Composition: Novel polyallylamine (PAA) based graft polymers are provided, including groups such as cholesteryl, cetyl, palmitoyl, which are adapted to deliver an entity that is normally of poor solubility in an aqueous medium, said entity being such as a drug, peptide, protein, or polynucleotide that is releasably contained within the said... Agent: Taft, Stettinius & Hollister LLP

20100029546 - Preparation method of galactosyl-has magnetic nanoparticles containing adriamycin: Preparation of galactose albumin adriamycin magnetic nanoparticles: in order to prepare galactose albumin magnetic nanoparticle, cottonseed oil and magnetic nano powder is needed. Mix galactose albumin, adriamycin and magnetic nanoparticle at a proportion, and get the particle through emulsification in cottonseed oil, heating for solidification, and diethyl ether washing. This... Agent: Knobbe Martens Olson & Bear LLP

20100029548 - Glycoproteins produced in plants and methods of their use: Methods of increasing the yield in plant expression of recombinant proteins comprising: engineering glycosylation sites into cloned genes or cDNAs for proteins using codons that drive post-translational modifications in plants; and engineering the cloned genes or cDNAs to contain a plant secretory signal sequence that targets the gene products (protein)... Agent: Dinsmore & Shohl LLP

20100029547 - Mvl, an antiviral protein from a cyanobacterium: The present invention relates, e.g., to an isolated polypeptide from a cyanobacterium, Microcystis viridis, which binds specifically to an oligosaccharide comprising the tetrasaccharide Man-alpha-(1→6)Man-beta (1→4) GlcNAc-beta(1→4)GlcNAc. The polypeptide can be obtained, for example, from a cell that expresses a recombinant nucleic acid that encodes a MVL-like polypeptide. The invention also... Agent: Edwards Angell Palmer & Dodge LLP

20100029549 - Situ self-setting mineral-polymer hybrid materials, composition and use thereof: The present invention relates to self-setting compositions consisting in admixed liquid and solid components enable the formation of hardened bio-materials having a broad range of properties and performances. The present invention proposes a) a thermo-sensitive self-gelling liquid component, being water-based, comprising at least a polycationic and a phosphate source, wherein... Agent: David S. Resnick

20100029550 - Organic compounds: A pharmaceutical composition for parenteral administration of a somatostatin analogue salt of aspartate, e.g. mono- or diaspartate, lactate, succinate, e.g. mono- or disuccinate, acetate, glutamate, e.g. mono- or diglutamate or citrate and water forming a gelling depot system after injection in contact with the body fluid.... Agent: Novartis Corporate Intellectual Property

20100029551 - Treatment of inflammatory lung conditions with aerosolized macrolide antibiotics: Provided herein are pharmaceutical compositions comprising an anti-inflammatory macrolide compound suitable for aerosolized administration to the lungs by inhalation, and methods of treating inflammatory lung conditions, particularly those characterized by chronic inflammation, by administering an aerosolized anti-inflammatory macrolide compound to the lungs by inhalation. Also provided are unit dose formulations... Agent: Fenwick & West LLP

20100029557 - Alpha-lactalbumin composition: The present invention relates to a pharmaceutical composition comprising monomeric alpha-lactalbumin complex, preferably LAC, which is an active complex of alpha-lactalbumin and a fatty acid or lipid with selective cytotoxic activity. The composition of the invention comprises insignificant amounts of oligomeric/multimeric alpha-lactalbumin complex, preferably LAC. Based on the selective cytotoxicity... Agent: Nixon & Vanderhye, PC

20100029558 - Alpha1 proteinase inhibitor peptides methods and use: The invention is directed to the use of peptides that can bind and block the interaction of α1 proteinase inhibitor (α1PI) and one or more molecules, for example antibodies to HIV-1 envelope proteins. The invention features methods of activating α1PI in a cell, methods of treating or preventing a disease... Agent: Peter C. Schechter Edwards Angell Palmer & Dodge LLP

20100029561 - Ameliorating agent for insulin resistance: The present invention provides an insulin sensitizer and a prophylactic/therapeutic agent for diseases involved by sugar metabolic abnormality, comprising a substance that inhibits the expression or activity of CPSF5 protein and/or a substance that inhibits the expression or activity of CPSF6 protein. Provided as the substances are (a) an antisense... Agent: Edwards Angell Palmer & Dodge LLP

20100029554 - Composition and methods for treatment of congestive heart failure: Provided herein is the use of GLP-1 molecules or agonists and analogs thereof, and the use of exendin molecules or agonists and analogs thereof, including their derivatives and active fragments, for the prevention or treatment of congestive heart failure. Pharmaceutical compositions for use in the methods described herein are also... Agent: Intellectual Property Department Amylin Pharmaceuticals, Inc.

20100029560 - Compositions and methods for diagnosing, treating, and preventing prostate conditions: Disclosed are compositions and methods for diagnosing, preventing, and treating prostate cancer and prostate intraepithelial neoplasia (PIN).... Agent: Morris Manning Martin LLP

20100029563 - Derivatives of growth hormone and related proteins, and methods of use thereof: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in... Agent: Sheridan Ross PC

20100029555 - G-csf site-specific mono-conjugates: Novel site-specific mono-conjugates of Granulocyte Colony Stimulating Factor (G-CSF) are hereby described, with analogues and derivatives thereof, which stimulate proliferation and differentiation of progenitor cells to mature neutrophiles. These conjugates have been obtained using transglutaminase to covalently and site-specifically bind a hydrophilic, non-immunogenic polymer to a single glutamine residue of... Agent: Darby & Darby P.C.

20100029562 - Hg31p expression system: Expression plasmids and expression systems for the expression of human G31P+2 are described.... Agent: Ade & Company Inc.

20100029559 - Method for achieving desired glial growth factor 2 plasma levels: The present invention relates to administering glial growth factor 2 (GGF2) to a patient in need thereof, to achieve serum levels of GGF2 within a desired therapeutic window determined based on the disease or disorder afflicting the patient. In a particular embodiment, the patient is suffering from a disease or... Agent: Klauber & Jackson

20100029567 - Method of correcting imbalance between bone resorption and bone formation and kits and compositions therefor: Compounds, methods, uses, compositions, kits and packages for the treatment of imbalance between bone resorption and bone formation, based on uses of 4-phenyl-2 propionamidotetralin (4-P-PDOT) and analogs, derivatives, prodrugs, precursors thereof, and salts thereof, are described.... Agent: Klarquist Sparkman, LLP

20100029553 - Microfluidic device for controlled aggregation of spider silk: The present invention is directed to a device and method of controlling the phase separation of one or a mixture of two or more spider silk proteins, leading to the defined and controllable assembly of the said silk protein(s) to defined morphologies, such as spheres, nano fibrils, threads, etc.... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20100029564 - Novel process of solubilizing protein from a proteinaceous material and compositions thereof: The process for solubilizing proteinaceous material of the present invention includes subjecting the proteinaceous material to a sufficient amount of a basic solution to obtain a supernatant that has a basic pH and exposing the supernatant to the basic solution for a sufficient length of time and temperature for hydrolysis... Agent: Mckee, Voorhees & Sease, P.L.C

20100029552 - Peptide inhibitors of c-jun dimerization and uses thereof: The present invention provides a method for the screening of nucleic acid fragment expression libraries and selecting encoded peptides based upon their ability to modulate the activity of a target protein or nucleic acid and assume conserved conformations compatible with albeit not reiterative of the target protein or nucleic acid.... Agent: Morrison & Foerster LLP

20100029569 - Pharmaceutical formulation: The invention relates to aqueous pharmaceutical formulations comprising human growth hormone, histidine, poloxamer, phenol, and mannitol.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100029565 - Recombinant b. pseudomallei adhesin protein and methods and uses thereof: Isolated and/or recombinant adhesin polypeptides from B. pseudomallei are provided, which are used as vaccines. Genetic constructs comprising nucleic acid sequences encoding such polypeptides are also provided. Vectors comprising such constructs have been prepared and used for transforming host cells for producing the polypeptides of the invention. Antibodies to such... Agent: Blake, Cassels & Graydon LLP

20100029556 - Stable composition comprising a bone anabolic protein, namely a pthrp analogue, and uses thereof: The present invention provides a storage-stable composition containing a parathyroid hormone-related protein (PTHrP) analogue and methods of using a PTHrP analogue and the PTHrP compositions described herein to treat osteoporosis, to increase bone mass or to increase bone quality. The composition is storage stable, in sterile form, and in general... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100029568 - Tighter-binding c-peptide inhibitors of hiv-1 entry: The invention provides compositions and methods for the treatment of HIV infection, inhibition against drug-resistant strains of HIV-1 and methods of enhancing the anti-HIV potency of peptide inhibitors against drug-resistant strains of HIV-1. In particular, oligomeric C-peptide inhibitors for inhibiting HIV entry into host cells are disclosed.... Agent: David S. Resnick

20100029566 - Use of at least one botulinum neurotoxin for treating the pain induced by therapeutic treatments for the aids virus: The present invention relates to the use of at least one botulinum neurotoxin for the production of a medicament for treating or preventing pain induced by a medicament used for treating the AIDS virus.... Agent: Hunton & Williams LLP Intellectual Property Department

20100029571 - Novel and powerful mhc-class ii peptides derived from survivin: The present invention relates to peptides, nucleic acids, and cells for use in the immunotherapy of cancer. The present invention furthermore relates to survivin-derived tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100029570 - Peptide and treatment for hiv-1 infection: A compound of the formula X1-M-SEQ ID NO:1, or a derivative thereof, is provided, wherein X1-M- represents an optional group comprising a protein transduction domain conjugated to the N-terminus of the amino acid sequence SEQ ID NO:1. Pharmaceutical compositions comprising and therapeutic methods using the compound are also provided.... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20100029572 - Neurotrophic peptides: The present invention relates to a neurotrophic peptide having an amino acid sequence selected from the group consisting of VG-DGGLFEKKL (SEQ ID No. 1), EDQQVHFTPTEG (SEQ ID No. 2) and IPENEADGMPATV (SEQ ID NO. 3).... Agent: Fulbright & Jaworski L.L.P.

20100029573 - Tumor-associated peptides that bind to mhc-molecules: The invention relates to a tumor-associated peptide with an amino acid sequence selected from the group consisting of SEQ ID NO. 1 to SEQ ID NO. 577 from the attached sequence protocol, the peptide being capable of binding to a molecule of the human major histocompatibility complex (MHC) class I.... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100029574 - Cosmetic compositions: The present invention generally features novel cosmetic skin and hair care compositions for enhancing the appearance of eyelashes and eyebrows. Specifically, the topical skin and hair care compositions of the invention contain a concentration of at least one of pentapeptide-17 tetrapeptide-12 that provide for thicker, longer and more voluminous appearing... Agent: Bozicevic, Field & Francis LLP

20100029575 - N-oxides of kappa receptor peptides: Certain peptides which exhibit high selectivity for the kappa opioid receptor (KOR) versus the mu opioid receptor and little or no CYP3A4 inhibitory activity including tetrapeptides of four D-isomer amino acid residues having a C-terminus which is an N-oxide-substituted amide such, as H-D-Phe-D-Phe-D-Nle-D-Arg-NH-4-picolyl-N-oxide. A preferred compound, which has an affinity... Agent: Cara Therapeutics, Inc. Intellectual Property Department

20100029576 - Diazoxide for the treatment of friedreich's ataxia: A pharmaceutical preparation treats Friedreich's ataxia and treats or prevents pathologies related thereto. In particular, the pharaceutical preparation concerns the use of diazoxide or 7-chloro-3-methyl-4H-1,2,4 benzothiadiazine 1,1-dioxide, in combination with glucose and/or leucine, for the treatment of Friedreich's ataxia (FRDA) and for the treatment or prevention of pathologies related thereto.... Agent: Hess Patent Law Firm, P.C.

20100029577 - Chiral separation, characterization and biological action of optically active isomers of digoxin: Disclosed herein is the method for separation of enantiomers or isomers of digoxin. These isomers are to be used-in the treatment of heart failure without adverse or unneeded cardiac actions in humans. Additionally what is claimed is an isolate with less or no cardiac contractile effect but with AV node... Agent: Office Of Laurence M. Dunlap, Ltd.

20100029578 - Methods of treating atrial fibrillation with p38 inhibitor compounds: The invention disclosed herein relates generally to compounds and methods useful in treating or preventing atrial fibrillation (AF).... Agent: Marshall, Gerstein & Borun LLP

20100029579 - Antiviral compounds: The invention provides a new class of compounds exhibiting an inhibitory effect on neuraminidase (NA), hemagglutinin (HA) and structural M2 protein bearing viruses. These compounds are also useful as inhibitors of the replication factors of hepatitis virus type C (HVC). The invention also describes pharmaceutical compositions containing the compounds of... Agent: Standley Law Group LLP

20100029748 - Metastasis promoting genes and proteins: Two sets of genes and their encoded proteins, one set of 17 genes/proteins and one set of 18 genes/proteins that can be used in predicting the risk of cancer metastasis to the brain, and as a screening assay to identify the suitable treatments for brain metastases. Genes/proteins within the sets... Agent: Larson & Anderson, LLC Re: Msk

20100029747 - Methods and compositions for inhibiting the function of polynucleotide sequences: A therapeutic composition for inhibiting the function of a target polynucleotide sequence in a mammalian cell includes an agent that provides to a mammalian cell an at least partially double-stranded RNA molecule comprising a polynucleotide sequence of at least about 200 nucleotides in length, said polynucleotide sequence being substantially homologous... Agent: David S. Resnick

20100029746 - Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes: The invention relates to one or more inhibitors, in particular siRNAs, which down-regulate the expression of human pro-apoptotic genes. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method... Agent: Cooper & Dunham, LLP

20100029749 - Chimeric nk receptor and methods for treating cancer: The present invention relates to chimeric immune receptor molecules for reducing or eliminating tumors. The chimeric receptors are composed a C-type lectin-like natural killer cell receptor, or a protein associated therewith, fused to an immune signaling receptor containing an immunoreceptor tyrosine-based activation motif. Methods for using the chimeric receptors are... Agent: Licata & Tyrrell P.C.

20100029751 - Compositions comprising a parvovirus vp1-variant and a parvovirus ns1 protein for induction of cytolysis: The present invention provides a composition comprising (a) a parvovirus NS1 protein and (b) a parvovirus VP1 protein. Furthermore, the present invention provides DNA sequences encoding said proteins. The composition of the invention is useful for the preparation of a toxin for treating tumoral diseases.... Agent: Intellectual Property / Technology Law

20100029750 - Novel crosslinked pei nanoparticle based transfection agents for delivery of biomolecules: The present invention relates to a novel crosslinked polyethylenimine (PEI) nanoparticle based nucleic acid transfection agent wherein the crosslinker is having carbon chain in the range of C2 to C8, ranging between 3.27-19.8%, having the size of nanoparticle ranging between 20-600 nm and zeta potential ranging from +5 to 50... Agent: Ladas & Parry LLP

20100029580 - Method for diagnosing non-small cell lung carcinoma: The present invention relates to the constitutive activity of the Hedgehog pathway in non-small cell lung carcinoma (NSCLC). A method for diagnosing NSCLC by detecting the level of a component of the Hedgehog pathway is provided, as is a method for identifying subjects that will respond positively to treatment with... Agent: Licata & Tyrrell P.C.

20100029581 - Nutritional supplement: A nutritional supplement comprises about 2 parts roasted, ground flaxseed, about 2 parts of chick pea flour, about 1.5-2 parts of whole wheat or brown rice flour, about 1 part of raw, ground almonds and optionally, about 0.5-1 part of whole wheat bran. The supplement may additionally contain one or... Agent: Hahn Loeser & Parks, LLP

20100029582 - Anticoagulant antithrombotic dual inhibitors comprising a biotin label: The present invention relates compounds of the formula: oligosaccharide-spacer-(GpIIb/IIIa antagonist), wherein the oligosaccharide is a negatively charged oligosaccharide residue comprising four to twenty five monosaccharide units, the charge being compensated by positively charged counterions, and wherein the oligosaccharide residue is derived from an oligosaccharide which has (AT-II mediated) anti-Xa activity... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20100029583 - Process for obtaining an active ingredient with an immediate tensor effect on the skin, active ingredient and compositions: The invention relates to a method for obtaining an active ingredient having an immediate anti-wrinkle and skin-tensioning effect, characterised in that it comprises extracting and purifying high molecular weight polysaccharides from oat bran and/or fibres and/or grains, and solutioning and stabilising the polysaccharides in water. The invention also relates to... Agent: Young & Thompson

20100029584 - Process for producing a cellulose-based film to be used for skin and tissue lesions: The process for producing a cellulose film, to be used for covering, regenerating, repairing and healing of skin and tissue lesions, such as sores, ulcers, burns, wounds etc. by means of cultivation, in a culture medium comprising nitrogen and carbon sources, of microorganisms comprising the Acetobacter xylinum species; the culture... Agent: Steinfl & Bruno

20100029585 - Toll-like receptor agonist formulations and their use: The present invention is directed generally to stable formulations of a TLR agonist preferably a TLR7 or a TLR8 agonist, for use in the treatment of cancer, preferably solid tumors and lymphomas. Specifically, the present invention is directed to stable formulations of up to 50 mg/ml of a TLR agonist... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20100029589 - 4,5-dihydro-oxazol-2yl derivatives: R1, R2, X, Y, and n are defined in the specification and to pharmaceutically acceptable acid addition salts thereof. The invention also provides pharmaceutical compositions and methods of manufacture of such compounds. The compounds are useful for the treatment of diseases related to the biological function of the trace amine... Agent: Hoffmann-la Roche Inc. Patent Law Department

20100029587 - Cyclic siloxanes and their use: The invention relates to cyclic siloxanes in which organically modifying groups are bonded to the silicon atom via an oxygen atom (SiOC linkage), and to their use in the production of polyesterpolyurethane and as additive for enhancing the activity of biocides and pesticides.... Agent: Frommer Lawrence & Haug

20100029586 - Packaging for a fabric softening composition: A packaged product comprising packaging in combination with a fabric softening composition incorporating a skin benefit agent as an ingredient to enable the fabric softening composition to render textile fabrics treated with the composition capable of delivering the skin benefit agent to the skin with which the fabrics come into... Agent: Unilever Patent Group

20100029588 - Substituted phenylamidines and the use thereof as fungicides: The present invention relates to oxime ether-, hydrazone- or azomethine-substituted phenylamidines of the general formula (I), to a process for their preparation, to the use of the amidines according to the invention for controlling unwanted microorganisms and also to a composition for this purpose, comprising the amidines according to the... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20100029590 - Methods for treating or preventing hemorrhagic cystitis using a glycerophosphate salt: Glycerophosphate salts have been found to mitigate the syndromes or conditions of discomfort associated with hem-orrhagic cystitis. Therefore, methods are provided for treating or preventing the syndromes or conditions of discomfort associated with hemorrhagic cystitis using a glycerophosphate salt, hi particular, methods are provided for treating or preventing the syndromes... Agent: Panitch Schwarze Belisario & Nadel LLP

20100029591 - Combinations of a pyrimidine containing nnrti with rt inhibitors: The present invention concerns combinations of a pyrimidine containing NNRTI with nucleoside reverse transcriptase inhibitors and/or nucleotide reverse transcriptase inhibitors useful for the treatment of HIV infected patients or for the prevention of HIV transmission or infection.... Agent: Philip S. Johnson Johnson & Johnson

20100029592 - Deuterium-enriched fosaprepitant: The present application describes deuterium-enriched fosaprepitant, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Vance Intellectual Property, PC

20100029593 - Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin: The present invention relates to mixed calcium/sodium salt of inositol tripyrophosphate, methods of preparing and methods of use. The mixed calcium/sodium salt may be a monocalcium tetrasodium salt of inositol tripyrophosphate. Methods of use include administering the above salts in an effective amount to treat diseases caused by hypoxia or... Agent: King & Spalding

20100029594 - Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin: The present invention relates to mixed calcium/sodium salt of inositol tripyrophosphate, methods of preparing and methods of use. The mixed calcium/sodium salt may be a monocalcium tetrasodium salt of inositol tripyrophosphate. Methods of use include administering the above salts in an effective amount to treat diseases caused by hypoxia or... Agent: King & Spalding

20100029595 - Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmaceutical composition comprising benzamidine derivatives or their salts, and alendronic acid or its salt: e

20100029596 - Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmacuetical composition comprising benzamidine derivative or it's salt, and bisphosphonate: The present invention provides a method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmaceutical composition comprising benzamidine derivative or its salt, and bisphosphonate for the purpose of using simultaneously, separately, or sequentially as active ingredients. As a prophylactic or therapeutic... Agent: Arent Fox LLP

20100029597 - Reca inhibitors with antibiotic activity, compositions and methods of use: The present invention is directed to the use of RecA inhibitors as antibiotic agents, and provides RecA inhibitors useful in treating infections. Also provided are various compositions and methods associated with RecA inhibition.... Agent: Choate, Hall & Stewart LLP

20100029598 - Extended benzamide derivatives as modulators of the ep2 receptor: The present invention relates to extended benzamide derivatives of the general formula I, to processes for preparation thereof and to use thereof for production of pharmaceutical compositions for treatment of disorders and indications associated with the EP2 receptor.... Agent: Millen, White, Zelano & Branigan, P.C.

20100029599 - Indolylamides as modulators of the ep2 receptor: The present invention relates to indolylamide derivatives of the general formula (I), to processes for preparation thereof and to use thereof for production of pharmaceutical compositions for treatment of disorders and indications associated with the EP2 receptor.... Agent: Millen, White, Zelano & Branigan, P.C.

20100029600 - Dihydro-triterpenes in the treatment of viral infections, cardiovascular disease, inflammation, hypersensitivity or pain: The present invention relates to compositions comprising the triterpenes, dihydrobutyrospermol, dihydrolupeol and/or dihydroparkeol, the composition being applicable as a pharmaceutical, a dietary supplement or as a cosmetic. Further, the invention relates to the use of such compositions for the preparation of a medicament, a dietary supplement or a cosmetic for... Agent: Birch Stewart Kolasch & Birch

20100029601 - Administration of fluocinolone acetonide, tretinoin and hydroquinone cream in melasma maintenance therapy: Topical application of a triple combination immixture of fluocinolone acetonide, tretinoin and hydroquinone is useful for the maintenance therapy of melasma to prevent hyperpigmentation recurrence or reduce the severity of the hyperpigmentation recurrence.... Agent: Buchanan, Ingersoll & Rooney PC

20100029602 - Low-dose mometasone formulations: Provided is a topical cream composition for the delivery of mometasone furoate comprising low dose mometasone furoate for the treatment of corticosteroid responsive dermatoses. The composition of the present invention can be safely applied over large surface areas of the skin (including areas with wrinkles and/or hair), and can be... Agent: Leydig Voit & Mayer, Ltd

20100029603 - 16alpha-methyl or ethyl substituted estrogens: wherein the dotted ring is a fully saturated, a fully aromatic or a saturated ring with a Δ5-10 double bond; R1 is (C1-C3)alkyl or (C2-C3)alkenyl, and each of these groups can be substituted with one or more halogens; R2 is (C1-C4)alkyl, (C2-C4)alkenyl or methylene, and each of these groups can... Agent: Organon Usa, Inc. C/o Schering-plough Corporation

20100029604 - Antibacterial combination and its use: The invention relates to a pharmaceutical composition comprising an ethylene derivatives of tricyclic carbapenems of the general Formula (I) in the form of pure diastereoisomers and in the form of pure geometric isomers or a salt, ester or amide derivate thereof and an antibiotic and the use of this composition... Agent: Manelii Denison & Selter PLLC

20100029607 - Substituted piperazines as cb1 antagonists: e

20100029609 - Biaryl sulfonamide derivatives:

20100029610 - Heteroaryl compounds and uses thereof: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.... Agent: Choate, Hall & Stewart LLP

20100029605 - Compounds and compositions as protein kinase inhibitors: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, ARG, BCR-Abl, BRK, EphB, Fms, Fyn,... Agent: Genomics Institute Of The Novartis Research Foundation

20100029608 - Histamine h3 receptor agents, preparation and therapeutic uses: The present invention provides a novel compound of Formula (I) or a pharmaceutically acceptable salt thereof, having histamine-113 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another, embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of... Agent: Eli Lilly & Company

20100029606 - Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof: The present invention provides compounds of formula (I) and compositions thereof, methods of making them, and methods of using them to modulate alpha7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory system.... Agent: Choate, Hall & Stewart LLP

20100029611 - S1p1 receptor agonists and use thereof: e

20100029612 - 2-aminoethyl substituted pyrimidin-2-ones cyclopropanes, pyrazolines, pyrimidines and benzothiazepines and their uses as urotensin ii and somatostatin 5 receptor ligands: The present invention provides a combinatorial approach to a library of novel compounds having four diversity points. The compounds provide for the mapping of urotensin II and somatostatin 5 receptors by differential binding of said receptors. The present invention further relates to a method of treating diseases for which modulation... Agent: Knobbe Martens Olson & Bear LLP

20100029613 - Treatment and prevention of epilepsy: The present invention is directed to a method of treating or preventing epileptic seizures in a subject and a method of inhibiting hypersynchronous burst activity of neurons by administering an agent which interferes with glutamate, aspartate, and/or ATP release from astrocytes. Also presented is a method of identifying agents suitable... Agent: Nixon Peabody LLP - Patent Group

20100029614 - Spirocyclic heterocyclic derivatives and methods of their use: Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other δ opioid receptor-mediated conditions.... Agent: Feldmangale, P.A.

20100029615 - Benzimidazole derivatives: The present invention relates to a compound of the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, A, X, n, and are as defined herein. Such novel benzamidazole derivatives are useful in trv treatment of abnormal cell growth, such as cancer, in mammals. This... Agent: Pfizer Inc

20100029616 - Urotensin ii receptor antagonists: e

20100029617 - 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulene derivatives as orexin receptor antagonists: The invention relates to 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulene derivatives and their use as orexin receptor antagonists.... Agent: Hoxie & Associates LLC

20100029618 - Alpha-2 receptor pan agonist and anticonvulsant compositions for treating chronic pain: Disclosed herein is a pharmaceutical composition comprising a pain-relieving anticonvulsant and an pan-alpha-2 adrenergic receptor agonist. The composition is effective for treating chronic pain, and methods of treating chronic pain using the composition and the compounds comprising it are also disclosed.... Agent: Allergan, Inc.

20100029619 - Fused heterocyclic compound: s

20100029621 - Hexafluoroisopropanol derivatives:

20100029620 - Substituted triazoline, tetrazolone and imidazolone derivatives for use as a medicine: a pharmaceutically acceptable acid or base addition salt thereof, a stereochemically isomeric form thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein the variables are defined in Claim 1, having selective α2C-adrenoceptor antagonist activity. It further relates to their preparation, compositions comprising them and their use as... Agent: Philip S. Johnson Johnson & Johnson

20100029622 - Microemulsions: p

20100029623 - 4-(1-amino-ethyl)-cyclohexylamine derivatives: The invention relates to compounds of formula (I) wherein R0 represents H or OH; R1 represents alkoxy; U and W represent N, V represents CH and R2 represents H or F, or U and V represent CH, W represents N and R2 represents H or F, or U and V... Agent: Hunton & Williams LLP Intellectual Property Department

20100029624 - Male contraceptive: e

20100029626 - Cyclic sulfones useful as mitochondrial sodium-calcium exchangers: The invention relates to novel compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula (I) and to the use of a compound of formula (I) for the preparation of pharmaceutical compositions for use in the... Agent: Novartis Institutes For Biomedical Research, Inc.

20100029625 - Therapeutic agent for restenosis: [wherein, n represents an integer of 1 to 3, R0 represents aryl, —NR1CONR2 (wherein R1 represents a hydrogen atom or the like, and R2 represents lower alkyl or the like) or the like, R3 represents lower alkyl, R4 represents a hydrogen atom or the like, and R5 represents aryl or... Agent: Greenblum & Bernstein, P.L.C

20100029627 - Mtki quinazoline derivatives: h

20100029628 - 2,4,5-substituted piperidines as renin inhibitors: SP-P2140 ATE-132—Abstract Novel substituted piperidines of the general formula (I) and (II) with the substituent definitions as explained in detail in the description are described. The compounds are suitable in particular as renin inhibitors and are highly potent.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100029629 - Acyclic compounds having 5-ht6 receptor affinity: -

20100029632 - Broadspectrum 2-amino-benzoxazole sulfonamide hiv protease inhibitors: N-oxides, salts, stereoisomeric forms, racemic mixtures, prodrugs, esters and metabolites thereof, wherein R1 and R8 each are H, optionally substituted C1-6alkyl, C2-6alkenyl, C3-7cycloalkyl, aryl, Het1, Het2; R1 may also be a radical of formula (R11aR11b)NC(R10aR10b)CR9—; t is 0, 1 or 2; R2 is H or C1-6alkyl; L is —C(═O)—, —O—C(═O)—,... Agent: Philip S. Johnson Johnson & Johnson

20100029631 - Carboxylic acid compounds and medicinal compositions containing the same as the active ingredient: wherein the symbols in the formula are the same meanings as those in specification, salts thereof, solvates thereof, or prodrugs thereof binds to DP receptor and shows antagonistic activity for DP receptor. Thus, it is useful for prevention and/or treatment of diseases such as allergic disease (e.g., allergic rhinitis, allergic... Agent: Sughrue-265550

20100029633 - Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors: Compounds of Formula I: in which A, B, R1, R1a, R2, R3, R4, R5 R6, R7 and R8 have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of diseases mediated by class 3 and class 5 receptor tyrosine kinases. Particular compounds of this invention... Agent: Viksnins Harris & Padys Pllp

20100029630 - Reverse-turn mimetics and method relating thereto: Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic and therapeutic agents. Libraries containing the reverse-turn mimetic structures of this invention are also disclosed... Agent: Seed Intellectual Property Law Group PLLC

20100029635 - 6,7,8,9-substituted 1-phenyl-1,5-dihydro-pyrido[3,2-b]indol-2-ones useful as anti-infective pharmaceutical agents: n

20100029634 - Chemokine receptor modulators:

20100029637 - Chymase inhibitors: Disclosed are small molecule inhibitors which are useful in treating various diseases and conditions involving chymase.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100029638 - Fused heterocyclyc inhibitor compounds: The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) and/or Cyclin-dependent kinase (CDK) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.... Agent: Harness, Dickey, & Pierce, P.l.c

20100029636 - Lck inhibitors: e

20100029639 - Ion channel modulating compounds and uses thereof: Ion channel modulating compounds are disclosed. The compounds of the present invention may be incorporated in compositions and kits. The present invention also discloses a variety of in vitro and in vivo uses for the compounds and compositions, including the treatment of arrhythmia and the production of analgesia and local... Agent: Seed Intellectual Property Law Group PLLC

20100029640 - Neuroprotective agents for the prevention and treatment of neurodegenerative diseases: n

20100029641 - Aryl sulfamide derivatives and methods of their use: or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, vasomotor symptoms, sexual dysfunction, gastrointestinal disorders and genitourinary disorder, depression disorders, endogenous behavioral disorders, cognitive disorders, diabetic... Agent: Wyeth Patent Law Group

20100029642 - Methods of using pyridodihydropyrazinones:

20100029643 - Heterocyclyc sulfonamides having edg-1 antagonistic activity: The invention relates to chemical compounds of formula (I), (Ia) and (Ib) or pharmaceutically acceptable salts thereof, which possess Edg-1 antagonistic activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the... Agent: Astrazeneca R&d Boston

20100029644 - Compounds which modulate the cb2 receptor: Compounds of formula (I) are disclosed. Compounds according to the invention are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20100029645 - Inhibitors of cytosolic phospholipase a2: m

20100029646 - Prodrugs of diphenyl ox-indol-2-one compounds: The present application discloses prodrugs of substituted 3,3-diphenyl-1,3-dihydro-indol-2-one compounds having the general formula (I). The 4-position of the phenyl moieties and the N-position of the indole represent useful handles for the introduction of particular prodrug groups, in particular those comprising an amino acid moiety. The prodrug compounds are believed to... Agent: Darby & Darby P.C.

20100029647 - 3,4,(5)-substituted tetrahydrophyridines: e

20100029648 - 11-beta hsd1 inhibitors: This invention relates to inhibiting 11βHSD1.... Agent: Wyeth LLC Patent Law Group

20100029649 - Phenyl-substituted pyrimidine compounds useful as kinase inhibitors: i

20100029650 - Bicyclic compounds and use as antidiabetics: The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20100029651 - Aryl-substituted heterocycles, and use thereof: The invention relates to aryl-substituted heterocycles, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of thromboembolic disorders.... Agent: Edwards Angell Palmer & Dodge LLP

20100029652 - Combination therapy for treating hepatitis c infections: The invention provides a method of treating hepatitis C, by providing compound of Formula I (shown below) in combination with a second active agent to a patient infected with the hepatitis C virus. Also provided herein are pharmaceutical combinations comprising a compound of Formula I and a second active agent.... Agent: Cantor Colburn, LLP

20100029653 - Pyrazolopyridine, indazole, imidazopyridine, imidazopyrimidine, pyrazolopyrazine and pyrazolopyridine derivatives as stimulators of guanylate cyclase for cardiovascular disorders: The present application relates to novel azabicyclic compounds, processes for their preparation, their use alone or in combinations for the treatment and/or prevention of diseases, and their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular disorders.... Agent: Edwards Angell Palmer & Dodge LLP

20100029656 - Azabicyclic heterocycles as cannabinoid receptor modulators: The present application describes CB-1 inverse agonists according to Formula (I) and (Ia), pharmaceutical compositions comprising at least one compound according to Formula (I) or (Ia), and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula (I) or (Ia), both alone and... Agent: Louis J. Wille Bristol-myers Squibb Company

20100029654 - Cardiovascular compositions and use of the same for the treatment of alzheimer's disease: Methods and compositions for the treatment of Alzheimer's Disease are described. More specifically, the invention demonstrates that administration of cardiovascular agents to a mammal suffering from the symptoms of Alzheimer's Disease causes an amelioration of those symptoms. The finding of the present invention can be used in treatment regimens designed... Agent: Marshall, Gerstein & Borun LLP

20100029655 - Processes for the preparation of anti-viral compounds and compositions containing them: t

20100029661 - Anesthetic compositions and methods of use: The invention generally relates to anesthetic compositions comprising low doses of a selective a-2 adrenergic receptor agonists in combination with anesthetic agents. The invention also relates to methods of using these compositions; in particular, the use of these compositions in humans to enhance the efficacy of a local peripheral anesthetic... Agent: Wood, Phillips, Katz, Clark & Mortimer

20100029657 - Bridged, bicyclic heterocyclic or spiro bicyclic heterocyclic derivatives of pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof: e

20100029663 - Compositions and methods for reducing activation of alpha-1 receptors: The invention generally relates to compositions and methods for reducing activation of a-1 adrenergic receptors. The compositions comprise highly selective a-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.... Agent: Wood, Phillips, Katz, Clark & Mortimer

20100029660 - Compositions and methods for reversing rebound hyperemia: The invention generally relates to compositions and methods for inducing vasoconstriction with low incidence of rebound hyperemia. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and... Agent: Wood, Phillips, Katz, Clark & Mortimer

20100029658 - Heterocyclic derivatives, pharmaceutical compositions and methods of use thereof: The present invention relates to novel quinoxaline, quinazoline and phthalazine derivatives as well as multimeric derivatives, methods for their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds for the treatment and prevention of brain damage resulting from brain injury, especially secondary brain damage due to traumatic... Agent: Winston & Strawn LLP Patent Department

20100029659 - Preferential vasoconstriction compositions and methods of use: The invention generally relates to compositions and methods for preferential vasoconstriction of smaller blood vessels relative to larger blood vessels. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between... Agent: Wood, Phillips, Katz, Clark & Mortimer

20100029664 - Pyrrolidin-3-ylmethyl-amine as orexin antagonists: e

20100029662 - Vasoconstriction compositions and methods of use: The invention generally relates to compositions for inducing vasoconstriction. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.... Agent: Wood, Phillips, Katz, Clark & Mortimer

20100029666 - Macrocyclic quinoxaline compounds as hcv ns3 protease inhibitors: The present invention relates to macrocyclic a compound of formula (I) and its use as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections.... Agent: Merck And Co., Inc

20100029665 - Methods and compositions for treating migraine pain: The present invention provides novel methods and compositions for the treatment and prevention of headaches, vascular headaches, migraine headaches, cluster headaches, and migraine. One of the headaches, vascular headaches, migraine headaches, cluster headaches, and migraine treated by the methods and compositions of the invention is migraine.... Agent: Adamas Pharmaceuticals, Inc.

20100029669 - 3-(substituted ethyl)-rifamycin derivatives useful as antimicrobial agents: The present invention is directed to novel 3-(substituted ethyl) rifamycin derivatives, pharmaceutical compositions containing them and the use of said derivatives and pharmaceutical compositions as antimicrobial agents against pathogenic microorganisms, particularly against resistant microbes.... Agent: Philip S. Johnson Johnson & Johnson

20100029668 - Novel pyridazine derivatives: The present invention relates to novel pyridazine derivatives of formula (I) as active ingredients which have microbiocidal activity, in particular fungicidal activity: wherein R1 is hydrogen, C1-C6alkyl, C1-C6haloalkyl or C3-C6cycloalkyl; R2 is an optionally substituted heteroaryl; R3 is an optionally substituted heteroaryl; and R4 is hydrogen, halogen, C1-C6alkyl, C1-C6haloalkyl, C1-C6alkoxy,... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20100029667 - Spray dried formulation: Pharmaceutical compositions comprising a poorly water soluble ionizable drug, a cationic species and a dispersion polymer are disclosed, together with a process for forming the compositions. The neutral form of the drug has (i) a solubility of less than 1 mg/ml, in aqueous solution at a pH between 6 and... Agent: Chernoff, Vilhauer, Mcclung & Stenzel, LLP

20100029670 - Organic compounds: a

20100029671 - Heterocyclic compounds and uses thereof in the treatment of sexual disorders: Novel heterocyclic compounds, which exhibit a dopamine receptor (preferably a D4 receptor) agonistic activity, and/or a PDE5 inhibitory activity, processes of preparing same, pharmaceutical compositions containing same and uses thereof in the treatment of sexual disorders such as decreased libido, orgasm disorder and erectile dysfunction are disclosed.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20100029672 - Method of treating liver disease: Treating diseased or damaged tissue, particularly the liver, using stem cells. The hepatic stem cell population of a subject suffering from disease or damaged tissue can be expanded by administering at least one regulator of the sympathetic nervous system. The regulator can be an adrenoceptor agonist or antagonist, adrenoceptor antagonists,... Agent: Stites & Harbison, PLLC

20100029673 - Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use: The invention relates to a method for the production of an anti-cancer effect or a method for the treatment of a sold tumour disease by administration of an anti-angiogenic agent selected from 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline and 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline and pharmaceutically-acceptable acid-addition salts thereof, in combination with a Src kinase inhibitor selected from 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline... Agent: Morgan Lewis & Bockius LLP

20100029674 - Methods of using phosphoantigen for the treatment of cancer: The present invention relates to compositions and methods useful for treating a cancer in mammals, including humans. The methods and compositions typically comprise use of a chemotherapeutic agent and a γδ T cell activator such that the composition is effective for treating a cancer. Preferably the composition enhances the effect... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20100029675 - Pyrimidine-2, 4-diamine jak2 kinase inhibiting anti-inflammation use: A method of treatment or prevention of Castleman's disease, atherosclerosis, coronary artery disease, peripheral edema, peripheral vascular disease, glaucoma, and wet or dry age-related macular degeneration (AMD), asthma; chronic bronchitis; chronic obstructive pulmonary disease; adult respiratory distress syndrome; infant respiratory distress syndrome; cough; chronic obstructive pulmonary disease in animals; adult... Agent: Supergen, Inc.

20100029676 - T315a and f317i mutations of bcr-abl kinase domain: The present invention relates to mutant BCR-ABL kinase proteins, and to diagnostic and therapeutic methods and compositions useful in the management of disorders, for example cancers, involving cells that express such mutant BCR-ABL kinase proteins.... Agent: Bristol - Myers Squibb Company Patent Department

20100029677 - 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml): e

20100029678 - Diuretics:

20100029679 - Antibacterial quinoline derivatives: a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof. The claimed compounds are useful for the treatment of a bacterial infection. Also claimed is a composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of the claimed compounds, the use of the... Agent: Philip S. Johnson Johnson & Johnson

20100029680 - Certain chemical entities, compositions and methods: Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100029681 - Heterocyclic compounds as calcium channel blockers: Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type calcium channel activity are disclosed. Specifically, a series of heterocyclic compounds are disclosed of the general formula (1) where X1 and X2 are linkers and W is an optionally substituted imidazolyl, oxazolyl, thiazolyl, benzimidazolyl,... Agent: Morrison & Foerster LLP

20100029682 - Novel chromene and thiochromene carboxamide derivatives, methods for preparing same and therapeutic applications of same: The present invention relates to novel chromene or thiochromene carboxamide derivatives, the preparation of same, pharmaceutical compositions of same and the use of same as dopamine D3 ligands as a medicament for central nervous system disorders.... Agent: Birch Stewart Kolasch & Birch

20100029683 - Methods for regulating cell mitosis by inhibiting serine/threonine phosphateses: Disclosed herein are methods of inhibiting proliferation of a cancer cell or inducing apoptosis of a cancer cell, which does not overexpress N—CoR. Also disclosed herein are methods of inhibiting proliferation or inducing apoptosis of a cancer cell that overexpresses TCTP and methods for determining whether a compound is effective... Agent: Cooper & Dunham, LLP

20100029688 - Bipiperidinyl compounds, compositions containing such compounds and methods of treatment: Bipiperidinyl compounds of the formula I, are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts and solvates are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119.... Agent: Merck And Co., Inc

20100029686 - Hcv protease inhibitors and uses thereof: This invention relates to: (a) compounds of formula I and salts thereof that, inter alia, are useful as hepatitis C virus (HCV) inhibitors; (b) intermediates useful for the preparation of such compounds and salts; (c) pharmaceutical compositions comprising such compounds and salts; and (d) methods of use of such compounds,... Agent: Paul D. Yasger Abbott Laboratories

20100029685 - Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators: This invention relates to oxadiazolyl and thiadiazolyl derivatives, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the... Agent: Birch Stewart Kolasch & Birch

20100029687 - Piperidine derivative or salt thereof: [Means for Resolution] It was found that a novel piperidine derivative which is characterized in that one of a 3-position and a 4-position is substituted with an aminomethyl group substituted with an arylalkyl group or the like and the other position is substituted with aryl, heteroaryl or the like, or... Agent: Sughrue-265550

20100029684 - Pyrazinone modulator of corticotropin-releasing factor receptor activity: The invention relates to the compound (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile, pharmaceutical compositions of the compound, and methods of using the compound for the treatment of psychiatric disorders and neurological diseases including depression, anxiety related disorders, irritable bowel syndrome, addiction and negative aspects of drug and alcohol withdrawal, and other conditions associated with CRF.... Agent: Louis J. Wille Bristol-myers Squibb Company

20100029690 - Nitrogen-containing heterocyclic compounds: Nitrogen-containing heterocyclic compounds represented by the following Formula (1) are provided. The compounds or salts thereof have a strong EP1 antagonistic activity when they are administered to a human or an animal, and they are useful as an effective component of a pharmaceutical agent for prophylaxis and/or treatment of an... Agent: Greenblum & Bernstein, P.L.C

20100029689 - Phosphodiesterase 4 inhibitors: t

20100029691 - Fast onset orodispersable tablets: The present invention provides orodispersable tablets and methods of using the same. The tablets and methods are useful, for example, for reducing first pass metabolism of orally administered active agents, enhancing bioavailability of active agents, and/or reducing the time it takes for an active agent to achieve maximal effect in... Agent: Morrison & Foerster LLP

20100029693 - Novel pi3k delta inhibitors and methods of use thereof: The present invention relates generally to phosphoinositide 3-kinases (PI3Ks), and more particularly to specific, selective, improved PI3Kδ inhibitors and methods of inhibiting undesirable levels of PI3Kδ activity using these PI3Kδ inhibitors to treat disorders mediated by PI3Kδ.... Agent: Morrison & Foerster LLP

20100029692 - Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders: The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having... Agent: Townsend And Townsend And Crew, LLP

20100029694 - Heterocyclic compounds and their use as aldosterone synthase inhibitors: e

20100029696 - Indolylamino quinazoline derivatives as antitumor agents: A quinazoline derivative of the Formula (I) wherein the substituents are as defined in the text for use in the production of an anti proliferative effect which effect is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm blooded animal such as man.... Agent: Morgan Lewis & Bockius LLP

20100029695 - Method of treating dermatitis comprising administering a chymase inhibitor: A medicament safe and free from side effects, for the prevention or treatment of dermatitis exhibiting a biphasic inflammation reaction or dermatitis induced by repeated exposure to an antigen, which suppresses the progress of the condition and improves the quality of life of the patient, which medicament treats dermatitis exhibiting... Agent: Drinker Biddle & Reath (dc)

20100029697 - Substituted pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine derivatives as cannabinoid-1 receptor modulators: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis,... Agent: Merck And Co., Inc

20100029698 - Pesticidal mixtures: The present invention relates to mixtures comprising, as active components, 1) an insecticidal compound I selected from fipronil and ethiprole; and 2) a fungicidal compound IIA selected from azoles, strobilurins, carboxamides, heterocylic compounds, carbamates, and other active compounds, and optionally 3) one or two fungicidal compounds IIB selected from List... Agent: Brinks, Hofer, Gilson & Lione

20100029699 - Matrix metalloproteinase inhibitors: e

20100029700 - 1-(2-aryl-2-oxoethyl)-3-phenyl-1, 4-diazaspiro [4.5]dec-3-en-2-one derivatives and their use as glycine transporter inhibitors:

20100029701 - Macrocyclic spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease: which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of... Agent: Merck And Co., Inc

20100029702 - Method for identification of compound having anti-anxiety effect: There are provided a method for identifying a compound having an anti-anxiety effect, an inhibitor of a function of a protein having a function as a G-protein coupled receptor, characterized by finding the protein and a gene encoding the protein and using at least one of a DNA represented by... Agent: Kilyk & Bowersox, P.l.l.c.

20100029703 - Anhydrous crystalline vinflunine salts, method of preparation and use thereof as a drug and means of vinflunine purification: The present invention relates to anhydrous crystalline vinflunine salts obtained with 1 or 2 equivalents of a pharmaceutically acceptable mineral or organic acid [Acid] 1 or 2 in which [Acid] represents hydrobromic, sulfuric, lactic and fumaric acids for the group of water-soluble crystalline salts, and para-toluene sulfonic, benzoic, mandelic and... Agent: Birch Stewart Kolasch & Birch

20100029704 - Salt of nonsteroidal anti-inflammatory drug and organic amine compound and use thereof: The invention provides a salt, particularly an ionic liquid, of a non-steroidal anti-inflammatory drug (NSAID) comprising a carboxylic acid and an organic amine compound, as well as a method of producing such a salt.... Agent: Leydig Voit & Mayer, Ltd

20100029705 - Beta-2-adrenoreceptor agonists: e

20100029706 - Hydrogenated pyrido[4,3-b]indoles for the treatment of oxidative stress: Methods of treating or suppressing oxidative stress diseases including mitochondrial diseases, impaired energy processing disorders, and diseases of aging such as diabetes and cancer with hydrogenated pyrido[4,3-b]indoles such as dimebolin, are disclosed.... Agent: Wilson, Sonsini, Goodrich & Rosati

20100029707 - Tricyclic compound and medical use thereof: wherein R1 is a hydrocarbon group optionally having substituent(s), amino optionally having substituent(s), hydroxy optionally having a substituent or a heterocyclic group optionally having substituent(s), R2 is a hydrogen atom or a hydrocarbon group optionally having substituent(s), R3 is a hydrogen atom, a halogen atom, a hydrocarbon group optionally having... Agent: Wenderoth, Lind & Ponack, L.L.P.

20100029708 - Compounds and compositions for treatment of cancer: Compounds and compositions for treating, preventing or managing cancer are disclosed. The compositions provided herein comprise SNS-595 and N-desmethyl-SNS-595. Also provided are pharmaceutical compositions comprising the compounds and methods of treatment using the compounds and compositions.... Agent: Jones Day

20100029710 - Compounds having both angiotensin ii receptor antagonism and ppary activating activities: Compounds of following formula (I) are provided that have both angiotensin II receptor antagonist activity and PPARy agonist activity. Also provided are pharmaceutical compositions comprising the compounds and methods of treatment of diseases with the compounds including type 2 diabetes, insulin resistance, hyperinsulinemia, hyperlipidemia, hypertriglyceridemia, metabolic syndrome, congestive heart failure,... Agent: Pfizer Inc. Patent Department

20100029709 - Novel compounds useful for the treatment of degenerative and inflammatory diseases: This compound may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, diseases involving cartilage degradation, bone and/or joint degradation, for example osteoarthritis; and/or conditions involving inflammation or immune... Agent: Klauber & Jackson

20100029711 - Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors: This invention relates to novel chromen-2-one derivatives of Formula (I) useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical compositions comprising the compounds of the invention.... Agent: Birch Stewart Kolasch & Birch

20100029712 - Irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis: A method and solution for perioperatively inhibiting a variety of pain, inflammation, spasm and restenosis processes resulting from cardiovascular or general surgical, therapeutic and diagnostic procedures. The solution preferably includes multiple pain and inflammation inhibitory agents, including at least one local anesthetic agent, and spasm inhibitory agents at dilute concentration... Agent: Omeros Medical Systems, Inc.

20100029713 - Quiniclidine derivatives of (hetero) arylcycloheptanecarboxylic acid as muscarinic receptor antagonists: The invention provides compounds of formula (I) wherein R4 is a group of formula (II) or (IIIa) or (IIIb) and R1, R2, R3, R5, a, b and X are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them, a process for preparing pharmaceutical compositions, their... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100029714 - Aqueous pharmaceutical suspensions containing rebamipide and manufacturing process thereof: The invention provides a rebamipide-containing aqueous pharmaceutical suspension which can be prepared by a simple process and keep the dispersed fine-particle state of rebamipide stable without having the fine particle agglutinated. The rebamipide-containing aqueous pharmaceutical suspension of the invention is prepared by mixing polyvinyl alcohol and additionally a sodium salt... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20100029715 - Polymorphic forms of a macrocyclic inhibitor of hcv: Provided are crystalline forms of the compound of formula (I), which is a macrocyclic inhibitor of HCV, processes for the preparation thereof, and pharmaceutical compositions comprising these crystalline forms.... Agent: Philip S. Johnson Johnson & Johnson

20100029717 - Alkylsulphonamide quinolines: o

20100029716 - Novel 1,2,3,4- tetrahydroquinoline derivatives: The present invention relates to a novel derivative of Compound 1 selectively substituted with fluorine and/or deuterium and optionally further substituted with deuterium and 13C elsewhere in the molecule. The compounds of this invention are cholesterol esterase transfer protein inhibitors and possess unique biopharmaceutical and pharmacokinetic properties compared to Compound... Agent: Edwards Angell Palmer & Dodge LLP

20100029718 - Organic compounds: The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100029719 - Arylsulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors: e

20100029720 - Carboxamide derivatives as muscarinic receptor antagonists:

20100029721 - Pharmaceutical formulation comprising metformin and repaglinide: The invention is related to a pharmaceutical composition comprising repaglinide in combination with metformin or a salt thereof in unit dosage form wherein a pre-formulation of the repaglinide has a pH independent dissolution profile and a relative humidity of less than about 25% prior to mixing with the metformin or... Agent: Novo Nordisk, Inc. Intellectual Property Department

20100029722 - Organic compounds: The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.... Agent: Novartis Institutes For Biomedical Research, Inc.

20100029723 - Methods and compositions for reduction of side effects of therapeutic treatments: The invention provides compositions and methods utilizing a nicotinic receptor modulator, e.g., to reduce or eliminate a side effect associated with dopaminergic agent treatment. In some embodiments, the invention provides compositions and methods utilizing a combination of a dopaminergic agent and a nicotinic receptor modulator that reduces or eliminates a... Agent: Wilson, Sonsini, Goodrich & Rosati

20100029726 - Cyclohexanesulfonyl derivatives as glyt1 inhibitors to treat schizophrenia: e

20100029725 - Resistance management strategies: Insect refuge strategies are described for the management of insect resistance development. The present invention relates generally to the control of pests that cause damage to crop plants, and in particular to corn plants, by their feeding activities directed to root damage, and more particularly to the control of such... Agent: Mckee, Voorhees & Sease, P.L.C Attn: Pioneer Hi-bred

20100029724 - Screening method: s

20100029727 - 1, 3, 4 -oxadiazole derivatives as dgat1 inhibitors:

20100029729 - Compounds: The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100029728 - Phosphodiesterase inhibitors: The present invention relates to phosphodiesterase (PDE) type IV selective inhibitors. Compounds disclosed herein can be useful in the treatment of CNS diseases, AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis,... Agent: Ranbaxy Inc.

20100029730 - Thiazolyl biphenyl amides: e

20100029731 - Method for preparing largazole analogs and uses thereof: Analogs of largazole are described herein. Methods of treating cancer and blood disorders using largazole and largazole analogs and pharmaceutical compositions comprising the same are additionally described herein. Methods for preparing largazole analogs are likewise described.... Agent: Swanson & Bratschun, L.L.C.

20100029732 - Combinations of beta-2-adrenoceptor agonistic benzothiazolone: The invention provides a pharmaceutical product comprising a first active ingredient which is N-[2-(Diethylamino)ethyl]-N-(2-{[2-(4-hydroxy-2-oxo-2,3-dihydro-1,3-benzothiazol-7-yl)ethyl]amino}ethyl)-3-[2-(1-naphthyl)ethoxy]propan amide or a salt thereof, and a second active ingredient selected from: a non-steroidal Glucocorticoid Receptor (GR Receptor)=Agonist; an antioxidant; a CCR1 antagonist; a chemokine antagonist (not CCR1); a corticosteroid; a CRTh2 antagonist; a DP1 antagonist;... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20100029733 - Bicyclic nitrogen-containing heterocyclic compounds: A nitrogen-containing bicyclic heterocyclic compound represented by the following formula (1) is provided. When the compound or a salt thereof is administered to a human being or an animal, the compound has a strong antagonistic action against EP1 receptors, and is useful, for example, as an active ingredient of a... Agent: Greenblum & Bernstein, P.L.C

20100029734 - Methods for breast cancer screening and treatment: A method for selecting a breast cancer patient for therapy with an agent that reduces production of angiotensin II, for example an ACE inhibitor or renin inhibitor, comprises (a) determining whether the cancer comprises a tumor that is estrogen receptor positive (ER+) and (b) selecting the patient for such therapy... Agent: Harness, Dickey, & Pierce, P.l.c

20100029735 - Therapeutic compounds: Disclosed herein is a compound of the formula. Therapeutic methods, compositions, and medicaments for the treatment of glaucoma or ocular hypertension related thereto are also disclosed.... Agent: Allergan, Inc.

20100029736 - 2-substituted proline bis-amide orexin receptor antagonists: The present invention is directed to 2-substituted proline bis-amide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and... Agent: Merck And Co., Inc

20100029737 - Inhibitors of d-amino acid oxidase: The present invention provides novel inhibitors of the enzyme D-amino acid oxidase. The compounds of the invention are useful for treating or preventing diseases and/or condition, wherein modulation of D-serine levels, and/or its oxidative products, is effective in ameliorating symptoms. The invention further provides methods of enhancing learning, memory and/or... Agent: Morgan, Lewis & Bockius LLP (sf)

20100029740 - Azabicyclic compounds as serotonin, dopamine and norepinephrine re-uptake inhibitors: e

20100029738 - Bicyclic tetrahydropyrrole compounds: The present invention relates to substituted bicyclic tetrahydropyrrole compounds of general formula (I), methods for their preparation, medicaments comprising these compounds as well their use in the manufacture of a medicament for the treatment of humans and animals.... Agent: Cooper & Dunham LLP

20100029741 - Fused heterocycles: e

20100029739 - Use of a combination of hypothermia inducing drugs: The present invention relates to the induction of hypothermia in humans in a predictable and dose responsive fashion by use of a pharmaceutical composition comprising a combination of (1) vanilloid receptor agonists, capsaicinoids or capsaicinoid-like agonists reaching and binding to vanilloid receptors, and (2) cannabinoids or cannabimimetic agonists reaching and... Agent: Nixon & Vanderhye, PC

20100029742 - Crystalline forms of the mono-sodium salt of d-isoglutamyl-d-tryptophan: The present invention relates to crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan, pharmaceutical compositions comprising them, their use in the treatment of various diseases and conditions, and processes for their preparation. In particular, the present invention relates the crystal modification 1 (polymorphic form F), the crystal modification 2 (polymorphic... Agent: Apotex, Inc.

20100029743 - Atorvastatin pharmaceutical compositions: The present invention relates to pharmaceutical formulations of atorvastatin or its pharmaceutically acceptable salts, solvates, hydrates, enantiomers, polymorphs or their mixtures; and processes for preparing the same, and their methods of use, treatment and administration. Further, the present invention relates to pharmaceutical compositions comprising an acid-solubility-enhanced form of atorvastatin or... Agent: Dr. Reddy''s Laboratories, Inc.

20100029744 - Methods for alzheimer's disease treatment and cognitive enhancement: The present invention relates to compositions comprising a combination of PKC activators and PKC inhibitors and methods to modulate α-secretase activity; improve or enhance cognitive ability; and/or reduce neurodegeneration in individuals suffering from diseases that impair cognitive ability, particularly Alzheimer's Disease. The invention also relates to methods for improving or... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20100029745 - Derivatives of substituted 3-phenyl-1-(phenylthienyl)propan-1-ones and of 3-phenyl-1-(phenylfuranyl) propan-1-ones, preparation and use: The present invention relates to compounds derived from substituted 3-phenyl-1-(thien-2-yl)propan-1-ones, pharmaceutical compositions comprising them as well as their therapeutic applications, notably in the field of human and animal health.... Agent: Nixon & Vanderhye, PC

20100029752 - Novel compounds, pharmaceutical compositions containing same, and methods of use for same: A pharmaceutical composition containing a pharmaceutical diluent and a compound of formula II: wherein: R8═H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, —C(O)R4, where R4 is H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, optionally containing halogen atoms, or —OH, —OR7 or —NR7, where R7 is H, C1-C20... Agent: Fox Rothschild LLP

20100029753 - Modulators of ccr9 receptor and methods of use thereof: Provided are compounds that are modulators of CCR9 receptor activity, compositions containing the compounds and methods of use of the compounds and compositions. In certain embodiments, provided are methods for treating or ameliorating diseases associated with modulation of CCR9 receptor activity.... Agent: Pfizer Inc. Patent Department

20100029754 - Thiophene-carboxamide derivatives and their use as inhibitors of the enzyme ikk-2: o

20100029755 - P-glycoprotein inhibitor comprising octilonium bromide as an effective ingredient: The present invention relates to a new use of octylonium bromide as p-glycoprotein inhibitor to increase cellular uptake of drugs. More particularly, the present invention provides octylonium bromide as a p-glycoprotein inhibitor to increase cellular uptake of drugs such as anticancer drugs by taking octylonium bromide simultaneously with or proceeding... Agent: Birch Stewart Kolasch & Birch

20100029756 - Novel compositions containing isolated tetrameric type a proanthocyanadin and methods of use and manufacture: The present invention relates to compositions containing an isolated novel tetrameric type A proanthocyanidin isomer having a formula of C60H48O24. The isomer is most preferably isolated from cinnamon (Cinnamomum spp.) and may be used in pharmaceutical compositions as anti-inflammatories, bactericides, antimicrobial formulations, or supplements for general or specific uses.... Agent: Hogan & Hartson LLP

20100029758 - Derivatives of isoflavones: The present invention discloses novel isoflavone conjugates and their use for affinity targeting of drugs, imaging and detection agents to cells having estrogen receptors, particularly estrogen receptors subtype β.... Agent: Winston & Strawn LLP Patent Department

20100029757 - Use of xanthohumol and/or isoxanthohumol as an agent for preventing and/or combating liver diseases: The present invention relates to the use of xanthohumol with formula (I) as an agent for the production of a preparations for preventing and/or combating liver diseases.... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20100029759 - Composition useful for the treatment of type 2 diabetes: It is described the use of L-canitine and/or an alkanoyl L-canitine, or a pharmaceutically acceptable salt thereof, in combination with a statin, for the preparation of a medicament for the treatment of type 2 diabetes.... Agent: Lucas & Mercanti, LLP

20100029760 - Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity: The present invention relates to a composition for preventing and treating metabolic syndrome, containing tanshinone derivatives as an effective ingredient. More specifically, the present invention relates to a composition for preventing and treating metabolic syndrome, containing tanshinone derivatives that exhibit superior activity in enhancing metabolic activity, as an effective ingredient.... Agent: Cantor Colburn, LLP

20100029761 - Novel compounds, pharmaceutical compositions containing same, and methods of use for same: A pharmaceutical diluent and a compound of formula VI: wherein: R10=H, or C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, optionally containing halogen atoms; R11=H3 or C]-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, optionally containing halogen atoms; R12=H, or C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, optionally containing... Agent: Fox Rothschild LLP

20100029762 - Administration of adapalene and benzoyl peroxide for the long-term treatment of acne vulgaris: A regimen for the safe and effective long-term treatment of acne vulgaris entails topically applying onto the affected skin area of a subject afflicted therewith, for a period of time of at least four (4) months, e.g., for at least twelve (12) months and advantageously on a daily basis and... Agent: Buchanan, Ingersoll & Rooney PC

20100029763 - Methods to prepare penta-1,4-dien-3-ones and substituted cyclohexanones and derivatives with antitumoral and antiparasitic properties, the compounds and their uses: The present invention refers to new derivatives of the penta-1,4-dien-3-ones, as well as their processes of preparation. These compounds present strong antitumoral activity and promising antiparasitic action, behaving as almost atoxic by laboratory assays and also by hystopathologic studies. The present invention refers also to a pharmaceutical composition including the... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20100029764 - Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction: Provided are electrokinetically-altered fluids (e.g., gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity. Particular aspects of the present invention provide... Agent: Davis Wright Tremaine, LLP/seattle

20100029765 - Topical aqueous composition comprising tretinoin: Topical aqueous compositions for the treatment of a skin disorder particularly acne. Topical aqueous composition comprising tretinoin and a hydrophilic cellulose derivative as a gelling agent, wherein the composition has a pH of about 4 to about 6.5 and viscosity of less than about 20,000 cP or provided. The composition... Agent: Ranbaxy Inc.

20100029766 - Blends comprising a substituted fatty acid or a derivative thereof: p

20100029767 - Anthranilic acid derivatives: Compounds of formula (I) are provided, wherein X is CH═CH, CH2O wherein the oxygen atom is bound to ring B, or OCH2 wherein the oxygen atom is bound to ring A; Y is hydrogen, straight or branched C1-C6 alkyl or a pharmaceutically acceptable inorganic cation; R1 is ethyl or cyclopropyl;... Agent: Alston & Bird LLP

20100029768 - Compositions and methods for promoting fat loss: This invention provides diets useful for promoting fat loss in animals having a total lysine to metabolizable energy ratio of from about 6 to about 10 g/Mcal. This invention also provides compositions for promoting fat loss in animals, methods for preparing the compositions, methods for using the diets and compositions,... Agent: Colgate-palmolive Company

20100029770 - Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism: Subjects having at least one condition selected from the group consisting of mental retardation, Down's syndrome, fragile X syndrome and autism are treated with a composition that includes gamma-aminobutyric acid agonists and/or M1 muscarinic receptor antagonists. The gamma-aminobutyric acid agonist (GABA) can be a GABA(B) agonist, such as baclofen. GABA(B)... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20100029769 - Topical formulation: There is described a topical formulation. The topical formulation comprises: (i) diclofenac or a pharmaceutically acceptable salt thereof, (ii) a first compound, and (iii) a second compound. The first compound and second compound are different, and each is selected from the group consisting essentially of N-lauroyl sarcosine, sodium octyl sulfate,... Agent: Katten Muchin Rosenman LLP (c/o Patent Administrator)

20100029771 - Treatment of addictive disorders: The present invention is directed to the treatment of addiction, and particularly to addictions with a chemical dependency component, with gamma-hydroxybutyrate (GHB) and at least one gamma-aminobutyric acid (B) receptor agonist (GABAB receptor agonist), for example, baclofen. Pharmaceutical compositions therefor are also provided.... Agent: WilsonIPLaw

20100029772 - Dicarboxylic acid derivatives and their use: The present application relates to novel dicarboxylic acid derivatives, process for their preparation, their use for the treatment and/or prophylaxis of diseases, and their use for producing medicaments for the treatment and/or prophylaxis of diseases, especially for the treatment and/or prevention of cardiovascular disorders.... Agent: Barbara A. Shimei Director, Patents & Licensing

20100029773 - Systematic identification of new anti-prion drugs by high-throughput screening based on scanning for intensely fluorescent targets (sift): The present invention relates to a method of identifying a compound for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases, comprising the steps of: (a) bringing into contact a labeled monomeric protein and a differently labeled aggregate of said protein in the (1) presence... Agent: Pillsbury Winthrop Shaw Pittman LLP

20100029774 - Aliskiren monofumarate and processes for preparation thereof: The present invention provides a novel fumarate compound of aliskiren monofumarate, and process for preparation thereof. The present invention also provides pharmaceutical compositions comprising aliskiren monofumarate, and methods of using aliskiren monofumarate for treating hypertension.... Agent: Kenyon & Kenyon LLP

20100029775 - Renin inhibitors for the prevention and treatment of hypertension in obese patients: The present invention relates to methods for the prevention of, delay progression to or treatment of hypertension in obese patients, comprising administering to a warm-blooded animal a therapeutically effective amount of a renin inhibitor or a pharmaceutically acceptable salt thereof.... Agent: Novartis Corporate Intellectual Property

20100029777 - 4-[(e)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-napthalenyl)-1-propenyl]benzoic acid analogs and method of manufacture and use thereof: Analogs of 4-[(E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-napthalenyl)-1-propenyl]benzoic acid and methods of manufacture and use thereof, such as for use in cancer prevention and treatment.... Agent: Intellectual Property Dept./dewitt Ross & Stevens Wisconsin Alumni Research Foundation

20100029776 - Pesticidal composition comprising fenamidone and an insecticide compound: a

20100029778 - Hair and/or scalp treatment compositions: Hair and/or scalp treatment compositions comprise an antidandruff agent, an effective amount of a cannabinoid receptor (CBR) activating agent and a cosmetically acceptable diluent or carrier. Alternatively, the compositions may be shampoo compositions comprising from 3 to 50 wt % surfactant, a CB receptor activating agent and a cosmetically acceptable... Agent: Unilever Patent Group

20100029779 - Composition and method for treatment of mrsa: The present invention provides a photosensitizing composition for treatment of MRSA comprising a photosensitizer and chlorhexidine and a pharmaceutically acceptable carrier. The present invention also provides a method for reducing disease causing microbes comprising: applying the composition comprising a photosensitizer, chlorhexidine at a concentration of more than about 0.01% and... Agent: Dobrusin & Thennisch PC

20100029780 - Topical composition: A topical composition comprising at least one C1 to C4 alcohol, at least one anti-microbial and at least one emollient.... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20100029781 - Methods for preparation of anti-acne formulation and compositions prepared thereby: The present invention provides methods to make solvent-microparticle (SMP) topical formulations for bioactive drugs. The formulations, which are aqueous gels containing undissolved solid drug, include a drug in a solution which can permeate the stratum corneum layer of the epidermis and the drug in an undissolved microparticulate solid form that... Agent: Allergan, Inc.

20100029782 - Calcilytic compounds: Novel calcilytic compounds of Formula (I), pharmaceutical compositions, methods of synthesis, and methods of using them are provided.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20100029783 - Stabilized compositions of alkylating agents and methods of using same: A composition and method for treatment of cancer. The composition for treating a skin disorder, comprising: an alkylating agent such as, for example, a Nitrogen Mustard or an HX salt of the Nitrogen Mustard, wherein the alkylating agent is in a non-aqueous vehicle or carrier that does not include petrolatum... Agent: Gfd Patents, LLC

20100029784 - Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties: The present invention relates to methods and compositions comprising naphthoquinones such as 2,3-dimethylnaphthalene-1,4-dione, for the use of treating, regulating or preventing a skin condition characterized by oxidative stress or a degenerative process. Methods of preventing, lightening or reducing the appearance of visible and/or tactile discontinuities of the skin resulting from... Agent: Morrison & Foerster LLP

20100029786 - Flavor improving agent, and food and drink containing the same: The present invention provides a novel flavor improving agent capable of sufficiently enhancing or alleviating the flavor sensed in oral cavity; for example, enhancing and improving the thickness in taste or the like to provide depth and profoundness to the flavor, and also improving the sense of volume or the... Agent: Foley And Lardner LLP Suite 500

20100029785 - Particle compositions with a pre-selected cell internalization mode: A method of formulating a particle composition having a pre-selected cell internalization mode involves selecting a target cell having surface receptors and obtaining particles that have i) surface moieties, that have an affinity for or are capable of binding to the surface receptors of the cell and ii) a preselected... Agent: Foley And Lardner LLP Suite 500

20100029787 - Thickener, cosmetic preparation containing the same, and process for producing the same: Also, the present invention is a method of manufacturing a water-swelling polymer in a radical polymerization system consisting of a composition having an organic solvent or oil component as the dispersion medium and an aqueous solution of a water soluble ethylene type unsaturated monomer as the dispersion phase wherein said... Agent: Townsend & Banta C/o Portfolio Ip

20100029788 - Wet edible pearlescent film coatings: Provided herein are wet powder compositions which include a pearlescent pigment, a film-forming edible polymer and from about 1% to about 30% by weight water. The wet powder compositions may be used to make pearlescent film coating suspensions which include a pearlescent pigment, a film-forming polymer, a plasticizer and from... Agent: Michael Best & Friedrich LLP

20100029789 - Load bearing hydrogel implants: The present invention features dual network hydrogels that possess the structural, mechanical, and biological properties required of load bearing three-dimensional support structures.... Agent: Fish & Richardson PC

20100029790 - Solid film, rapidly dissolvable in liquids: A solid film rapidly dissolvable in liquids, in particular biological liquids, to release pharmaceutical, cosmetic and nutrient substances. The solid film is also soluble in biological organic liquids to protect wounds of the human body by releasing cicatrizing, disinfectant and cosmetic substances. The film can also be used to release... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, L.L.P.

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20141002: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 6.03452 seconds

PATENT INFO